



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

09 July 2021
EMA/CHMP/350170/2021
Human Medicines Division

Committee for medicinal products for human use (CHMP)

Minutes for the meeting on 17-20 May 2021

Chair: Harald Enzmann – Vice-Chair: Bruno Sepodes

Disclaimers

Some of the information contained in this set of minutes is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the [CHMP meeting highlights](#) once the procedures are finalised and start of referrals will also be available.

Of note, the minutes is a working document primarily designed for CHMP members and the work the Committee undertakes.

Note on access to documents

Some documents mentioned in the minutes cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on-going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).



Table of contents

1.	Introduction	8
1.1.	Welcome and declarations of interest of members, alternates and experts.....	8
1.2.	Adoption of agenda	8
1.3.	Adoption of the minutes	8
2.	Oral Explanations	9
2.1.	Pre-authorisation procedure oral explanations.....	9
2.1.1.	eflornithine / sulindac - Orphan - EMEA/H/C/005043.....	9
2.1.2.	Ozawade - pitolisant - EMEA/H/C/005117.....	9
2.1.3.	tanezumab - EMEA/H/C/005189	9
2.2.	Re-examination procedure oral explanations	10
2.3.	Post-authorisation procedure oral explanations	10
2.3.1.	Keytruda - pembrolizumab - EMEA/H/C/003820/II/0097	10
2.3.2.	Veklury – remdesivir - EMEA/H/C/005622/R/0015	10
2.4.	Referral procedure oral explanations	10
3.	Initial applications	11
3.1.	Initial applications; Opinions	11
3.1.1.	Bylvay - odevixibat - Orphan - EMEA/H/C/004691	11
3.1.2.	Icatibant Accord - icatibant - EMEA/H/C/005083	11
3.1.3.	Imcivree - setmelanotide - Orphan - EMEA/H/C/005089	12
3.1.4.	Klisyri - tirbanibulin mesilate - EMEA/H/C/005183	12
3.1.5.	Ozawade - pitolisant - EMEA/H/C/005117.....	13
3.1.6.	Ryeqo - relugolix / estradiol / norethisterone acetate - EMEA/H/C/005267	13
3.1.7.	Skysona - elivaldogene autotemcel - Orphan - ATMP - EMEA/H/C/003690.....	14
3.1.8.	Verquvo - vericiguat - EMEA/H/C/005319.....	14
3.2.	Initial applications; List of outstanding issues (Day 180; Day 120 for procedures with accelerated assessment timetable)	15
3.2.1.	ranibizumab - EMEA/H/C/005545	15
3.2.2.	roxadustat - EMEA/H/C/004871	15
3.2.3.	bevacizumab - EMEA/H/C/005433	16
3.2.4.	avalglucosidase alfa - Orphan - EMEA/H/C/005501	16
3.2.5.	tanezumab - EMEA/H/C/005189	16
3.2.6.	sitagliptin - EMEA/H/C/005598	16
3.2.7.	sugammadex - EMEA/H/C/005403	17
3.2.8.	tafasitamab - Orphan - EMEA/H/C/005436	17
3.3.	Initial applications; List of questions (Day 120; Day 90 for procedures with accelerated assessment timetable)	17

3.3.1.	sotorasib - EMEA/H/C/005522	17
3.3.2.	voxelotor - Orphan - EMEA/H/C/004869	18
3.3.3.	amivantamab - EMEA/H/C/005454	18
3.3.4.	sapropterin - EMEA/H/C/005646	18
3.3.5.	teriparatide - EMEA/H/C/005793	18
3.3.6.	semaglutide - EMEA/H/C/005422	19
3.4.	Update on on-going initial applications for Centralised procedure.....	19
3.4.1.	betaine anhydrous - EMEA/H/C/005637	19
3.4.2.	dabigatran etexilate - EMEA/H/C/005639	19
3.4.3.	pralsetinib - EMEA/H/C/005413	19
3.4.4.	insulin human (rDNA) - EMEA/H/C/005331	20
3.4.5.	lenadogene nolparvovec - Orphan - ATMP - EMEA/H/C/005047	20
3.4.6.	metformin hydrochloride / sitagliptin hydrochloride monohydrate - EMEA/H/C/005678.....	20
3.5.	Re-examination of initial application procedures under Article 9(2) of Regulation no 726/2004	20
3.6.	Initial applications in the decision-making phase.....	21
3.7.	Withdrawals of initial marketing authorisation application	21

4.	Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008	21
4.1.	Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Opinion	21
4.1.1.	Bortezomib Accord - bortezomib - EMEA/H/C/003984/X/0023	21
4.1.2.	Cosentyx - secukinumab - EMEA/H/C/003729/X/0067	21
4.2.	Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Day 180 list of outstanding issues	22
4.2.1.	Deltyba - delamanid - Orphan - EMEA/H/C/002552/X/0046/G	22
4.2.2.	Rinvoq - upadacitinib - EMEA/H/C/004760/X/0006/G	22
4.2.3.	Volibris - ambrisentan - EMEA/H/C/000839/X/0061/G	23
4.2.4.	Vosevi - sofosbuvir / velpatasvir / voxilaprevir - EMEA/H/C/004350/X/0045/G	23
4.3.	Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Day 120 List of question	24
4.3.1.	Ozempic - semaglutide - EMEA/H/C/004174/X/0021	24
4.4.	Update on on-going extension application according to Annex I of Commission Regulation (EC) No 1234/2008	24
4.5.	Re-examination procedure of extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008	24

5. Type II variations - variation of therapeutic indication procedure according to Annex I of Commission Regulation (EC) No 1234/2008 24

5.1.	Type II variations - variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008; Opinions or Requests for supplementary information.....	24
5.1.1.	Blincyto - blinatumomab - Orphan - EMEA/H/C/003731/II/0038	24
5.1.2.	Cervarix - human papillomavirus vaccine [types 16, 18] (recombinant, adjuvanted, adsorbed) - EMEA/H/C/000721/II/0110	25
5.1.3.	Darzalex - daratumumab - Orphan - EMEA/H/C/004077/II/0043	25
5.1.4.	Darzalex - daratumumab - Orphan - EMEA/H/C/004077/II/0044	26
5.1.5.	Dengvaxia - dengue tetravalent vaccine (live, attenuated) - EMEA/H/C/004171/II/0011 ..	26
5.1.6.	Dengvaxia - dengue tetravalent vaccine (live, attenuated) - EMEA/H/C/004171/II/0012 ..	27
5.1.7.	Evotaz - atazanavir / cobicistat - EMEA/H/C/003904/II/0038	27
5.1.8.	Jardiance - empagliflozin - EMEA/H/C/002677/II/0055	28
5.1.9.	Jyseleca - filgotinib - EMEA/H/C/005113/II/0001	28
5.1.10.	Keytruda - pembrolizumab - EMEA/H/C/003820/II/0097	29
5.1.11.	Libtayo - cemiplimab - EMEA/H/C/004844/II/0011	29
5.1.12.	Libtayo - cemiplimab - EMEA/H/C/004844/II/0012	30
5.1.13.	Lorviqua - lorlatinib - EMEA/H/C/004646/II/0015	30
5.1.14.	Siklos - hydroxycarbamide - EMEA/H/C/000689/II/0047	31
5.1.15.	Spherox - spheroids of human autologous matrix-associated chondrocytes - ATMP - EMEA/H/C/002736/II/0020	31
5.1.16.	Tookad - padeliporfin - EMEA/H/C/004182/II/0013	32
5.1.17.	Veklury - remdesivir - EMEA/H/C/005622/II/0016	32
5.1.18.	Vyxeos liposomal - daunorubicin / cytarabine - Orphan - EMEA/H/C/004282/II/0018/G ...	33
5.1.19.	Xeljanz - tofacitinib - EMEA/H/C/004214/II/0035	33
5.1.20.	WS1840 Opdivo - nivolumab - EMEA/H/C/003985/WS1840/0089 Yervoy - ipilimumab - EMEA/H/C/002213/WS1840/0084	33
5.1.21.	WS1937/G Eucras - vildagliptin / metformin hydrochloride - EMEA/H/C/000807/WS1937/0080/G Icandra - vildagliptin / metformin hydrochloride - EMEA/H/C/001050/WS1937/0083/G Zomarist - vildagliptin / metformin hydrochloride - EMEA/H/C/001049/WS1937/0082/G.....	34
5.1.22.	WS1938/G Galvus - vildagliptin - EMEA/H/C/000771/WS1938/0066/G Jalra - vildagliptin - EMEA/H/C/001048/WS1938/0068/G Xiliarx - vildagliptin - EMEA/H/C/001051/WS1938/0066/G.....	34
5.1.23.	WS1941 Edistride - dapagliflozin - EMEA/H/C/004161/WS1941/0043 Forxiga - dapagliflozin - EMEA/H/C/002322/WS1941/0062	35
5.2.	Update on on-going Type II variation; variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008	36
5.3.	Re-examination of Type II variation; variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008	36

6.	Ancillary medicinal substances in medical devices	36
6.1.	Ancillary medicinal substances in medical devices; Opinions/ Day 180 list of outstanding issues / Day 120 list of questions	36
6.2.	Update of Ancillary medicinal substances in medical devices	36
7.	Procedure under Article 83(1) of Regulation (EC) 726/2004 (Compassionate Use)	36
7.1.	Procedure under Article 83(1) of Regulation (EC) 726/2004 (Compassionate Use)	36
8.	Pre-submission issues	36
8.1.	Pre-submission issue.....	36
8.1.1.	valoctocogene roxaparvovec - Orphan - ATMP - H0005830	36
8.2.	Priority Medicines (PRIME).....	37
8.2.1.	List of applications received.....	37
8.2.2.	Recommendation for PRIME eligibility	37
9.	Post-authorisation issues	37
9.1.	Post-authorisation issues	37
9.1.1.	Comirnaty - COVID-19 mRNA vaccine (nucleoside-modified) - EMEA/H/C/005735/II/0030	37
9.1.2.	Dengvaxia - dengue tetravalent vaccine (live, attenuated) - EMEA/H/C/004171/II/0013 ..	38
9.1.3.	Kengrexal – cangrelor - EMEA/H/C/003773/P46/003.....	38
9.1.4.	Ledaga - chlormethine – Orphan - EMEA/H/C/002826/II/0027	38
9.1.5.	Ondexxya - andexanet alfa - EMEA/H/C/004108/II/0003	39
9.1.6.	Ondexxya - andexanet alfa - EMEA/H/C/004108/II/0009/G	39
9.1.7.	Vaxzevria - COVID 19 Vaccine (ChAdOx1 S [recombinant]) - EMEA/H/C/005675/II/0014 .	39
9.1.8.	Vaxzevria - COVID 19 Vaccine (ChAdOx1 S [recombinant]) - EMEA/H/C/005675/II/0015 .	40
9.1.9.	Vaxzevria - COVID 19 Vaccine (ChAdOx1 S [recombinant]) - EMEA/H/C/005675/II/0017/G40	
9.1.10.	Esbriet - pirfenidone - EMEA/H/C/002154/II/0069	41
9.1.11.	Veklury – remdesivir - EMEA/H/C/005622/R/0015	41
10.	Referral procedures	42
10.1.	Procedure for Centrally Authorised products under Article 20 of Regulation (EC) No 726/2004	42
10.2.	Requests for CHMP Opinion under Article 5(3) of Regulation (EC) No 726/2004 .	42
10.2.1.	Sotrovimab (VIR-7831/GSK4182136) for the treatment of COVID-19 - EMEA/H/A-5(3)/150842	
10.3.	Procedure under Articles 5(2) and 10 of Regulation (EC) No 726/2004	42
10.4.	Disagreement between Member States on application for medicinal product (potential serious risk to public health) –under Article 29(4) of Directive 2001/83/EC	42
10.5.	Harmonisation - Referral procedure under Article 30 of Directive 2001/83/EC....	43
10.6.	Community Interests - Referral under Article 31 of Directive 2001/83/EC	43
10.7.	Re-examination Procedure under Article 32(4) of Directive 2001/83/EC.....	43

10.8.	Procedure under Article 107(2) of Directive 2001/83/EC	43
10.9.	Disagreement between Member States on Type II variation– Arbitration procedure initiated by MAH under Article 6(13) of Commission Regulation (EC) No 1084/2003	43
10.10.	Procedure under Article 29 of Regulation (EC) 1901/2006.....	43
10.11.	Referral under Article 13 Disagreement between Member States on Type II variation– Arbitration procedure initiated by Member State under Article 13 (EC) of Commission Regulation No 1234/2008	43
11.	Pharmacovigilance issue	43
11.1.	Early Notification System	43
12.	Inspections	44
12.1.	GMP inspections	44
12.2.	GCP inspections	44
12.3.	Pharmacovigilance inspections.....	44
12.4.	GLP inspections	44
13.	Innovation Task Force	44
13.1.	Minutes of Innovation Task Force.....	44
13.2.	Innovation Task Force briefing meetings.....	44
13.3.	Requests for CHMP Opinion under Article 57(1)J and (1)P of Regulation (EC) No 726/2004	44
13.4.	Nanomedicines activities	44
14.	Organisational, regulatory and methodological matters	45
14.1.	Mandate and organisation of the CHMP	45
14.2.	Coordination with EMA Scientific Committees.....	45
14.2.1.	Pharmacovigilance Risk Assessment Committee (PRAC)	45
14.3.	Coordination with EMA Working Parties/Working Groups/Drafting Groups	45
14.3.1.	Biologics Working Party (BWP).....	45
14.3.2.	Modelling and Simulation Working Party (MSWP).....	45
14.3.3.	Scientific Advice Working Party (SAWP)	46
14.3.4.	Quality Working Party (QWP).....	46
14.4.	Cooperation within the EU regulatory network.....	46
14.5.	Cooperation with International Regulators.....	46
14.6.	Contacts of the CHMP with external parties and interaction with the Interested Parties to the Committee	46
14.7.	CHMP work plan	46
14.8.	Planning and reporting	46
14.8.1.	Marketing Authorisation Applications 3-year forecast report	46
14.9.	Others	47

15.	Any other business	47
15.1.	AOB topic.....	47
15.1.1.	Diabetes Indication	47
15.1.2.	Update on COVID-19.....	47
15.1.3.	ECDC recommendations on adverse reactions to COVID-19 vaccination and the safety of substances of human origin.....	47
15.1.4.	Scientific Advice Group (SAG) re-nominations.....	47
15.1.5.	COVID-19 vaccine (NVX-CoV2373) – EMEA/H/C/005808	48
	Lists of participants	49
	Explanatory notes	58

1. Introduction

1.1. Welcome and declarations of interest of members, alternates and experts

The Chairperson opened the meeting by welcoming all participants. Due to the current coronavirus (COVID-19) outbreak, and the associated EMA Business Continuity Plan (BCP), the meeting was held remotely.

In accordance with the Agency's policy on handling of declarations of interests of scientific Committees' members and experts, based on the declarations of interest submitted by the Committee members, alternates and experts and based on the topics in the agenda of the current meeting, the Committee Secretariat announced the restricted involvement of some meeting participants in upcoming discussions as included in the pre-meeting list of participants and restrictions. See May 2021 CHMP minutes for the list of participants and restrictions in relation to declarations of interests applicable to the items of the agenda for the CHMP plenary session held 17–20 May 2021.

Participants in this meeting were asked to declare any changes, omissions or errors to their declared interests and/or additional restrictions concerning the matters for discussion. No new or additional interests or restrictions were declared.

Discussions, deliberations and voting took place in full respect of the restricted involvement of Committee members and experts in line with the relevant provisions of the Rules of Procedure and as included in the list of participants. All decisions taken at this meeting were made in the presence of a quorum of members (i.e. 17 or more members were present remotely). All decisions, recommendations and advice were agreed by consensus, unless otherwise specified.

1.2. Adoption of agenda

CHMP agenda for 17-20 May 2021

The CHMP adopted the agenda.

1.3. Adoption of the minutes

CHMP minutes for 19-22 April 2021

Minutes from PROcedural and Organisational Matters (PROM) meeting held on 10 May 2021

The CHMP adopted the CHMP minutes for 19-22 April 2021.

The CHMP adopted the minutes from the PROM meeting held on 10 May 2021.

2. Oral Explanations

2.1. Pre-authorisation procedure oral explanations

2.1.1. eflornithine / sulindac - Orphan - EMEA/H/C/005043

Cancer Prevention Pharma (Ireland) Limited; treatment of adults patients with familial adenomatous polyposis (FAP)

Scope: Oral explanation

Action: Oral explanation to be held on 19 May 2021 at 15:30

List of Outstanding Issues adopted on 25.03.2021. List of Questions adopted on 15.10.2020.

An oral explanation was held on Wednesday 19 May 2021. The presentation by the applicant focused on the clinical data in support of the application.

2.1.2. Ozawade - pitolisant - EMEA/H/C/005117

BIOPROJET PHARMA; Treatment of Excessive Daytime Sleepiness (EDS) in patients with Obstructive Sleep Apnoea (OSA)

Scope: Possible oral explanation

Action: Possible oral explanation to be held on 18 May 2021 at 11:00

New active substance (Article 8(3) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 22.04.2021, 25.03.2021, 10.12.2020. List of Questions adopted on 25.06.2020.

The CHMP agreed that an oral explanation was not needed this time.

See 3.1

2.1.3. tanezumab - EMEA/H/C/005189

treatment of moderate to severe chronic pain associated with osteoarthritis (OA) in adult patients for whom treatment with non-steroidal anti-inflammatory drugs (NSAIDs) and/or an opioid is ineffective, not tolerated or inappropriate

Scope: Oral explanation

Action: Oral explanation to be held on 18 May 2021 at 16:00

List of Outstanding Issues adopted on 28.01.2021. List of Questions adopted on 23.07.2020.

An oral explanation was held on Tuesday, 18 May 2021. The presentation by the applicant focused on the clinical data in support of the application.

See 3.2

2.2. Re-examination procedure oral explanations

No items

2.3. Post-authorisation procedure oral explanations

2.3.1. Keytruda - pembrolizumab - EMEA/H/C/003820/II/0097

Merck Sharp & Dohme B.V.

Rapporteur: Armando Genazzani, Co-Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Menno van der Elst

Scope: "Extension of indication to include in combination with chemotherapy, first-line treatment of locally advanced unresectable or metastatic carcinoma of the oesophagus or HER-2 negative gastroesophageal junction adenocarcinoma in adults whose tumours express PD-L1 with a CPS \geq 10, based on the results from the pivotal KEYNOTE-590 (KN590) trial. As a consequence, sections 4.1, 4.2, 4.8, 5.1, 5.2 and 5.3 of the SmPC are updated. The Package Leaflet is updated in accordance. Minor updates are also included in Annex II of the Product Information. Version of the RMP (Version 31.0) has also been submitted."

Action: Possible oral explanation to be held on 18 May 2021 at 14:00

Request for Supplementary Information adopted on 22.04.2021, 25.02.2021.

Participation of a patient representative.

An oral explanation was held on Tuesday 18 May 2021. The presentation by the applicant focused on the clinical data in support of the application.

See 5.1

2.3.2. Veklury – remdesivir - EMEA/H/C/005622/R/0015

Gilead Sciences Ireland UC

Rapporteur: Janet Koenig, Co-Rapporteur: Filip Josephson

Scope: Renewal of conditional marketing authorisation, possible oral explanation

Action: Possible oral explanation to be held on 17 May 2021 at 16:00

The RSI adopted in March was revised at the April plenary following conclusion of the LEG/31 procedure. Request for Supplementary Information adopted on 25.03.2021.

The CHMP agreed that an oral explanation was not needed this time.

See 9.1

2.4. Referral procedure oral explanations

No items

3. Initial applications

3.1. Initial applications; Opinions

3.1.1. Bylvay - odeixibat - Orphan - EMEA/H/C/004691

Albireo; treatment of progressive familial intrahepatic cholestasis (PFIC)

Scope: Opinion

Action: For adoption

New active substance (Article 8(3) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 20.04.2021. List of Questions adopted on 23.02.2021.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation under exceptional circumstances by consensus together with the CHMP assessment report and translation timetable.

Furthermore, the CHMP considered that odeixibat is a new active substance, as claimed by the applicant.

The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.

The legal status was agreed as medicinal product subject to restricted medical prescription.

The CHMP noted the letter of recommendation dated 20 May 2021.

The summary of opinion was circulated for information.

3.1.2. Icatibant Accord - icatibant - EMEA/H/C/005083

Accord Healthcare S.L.U.; treatment of hereditary angioedema

Scope: Opinion

Action: For adoption

Generic application (Article 10(1) of Directive No 2001/83/EC), Generic of Firazyr

List of Questions adopted on 10.12.2020.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.

The legal status was agreed as medicinal product subject to medical prescription.

The summary of opinion was circulated for information.

The CHMP adopted the similarity assessment report.

3.1.3. [Imcivree - setmelanotide - Orphan - EMEA/H/C/005089](#)

Rhythm Pharmaceuticals Limited; Treatment of obesity and the control of hunger associated with deficiencies in the leptin-melanocortin pathway

Scope: Opinion

Action: For adoption

New active substance (Article 8(3) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 25.03.2021. List of Questions adopted on 13.10.2020.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

Furthermore, the CHMP considered that setmelanotide is a new active substance, as claimed by the applicant.

The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.

The legal status was agreed as medicinal product subject to restricted medical prescription.

The CHMP noted the letter of recommendation dated 17 May 2021.

The summary of opinion was circulated for information.

3.1.4. [Klisyri - tirbanibulin mesilate - EMEA/H/C/005183](#)

Almirall, S.A.; topical field treatment of non-hyperkeratotic, non-hypertrophic actinic keratosis

Scope: Opinion

Action: For adoption

New active substance (Article 8(3) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 22.04.2021, 25.02.2021. List of Questions adopted on 25.06.2020.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by majority (24 out of 29 votes) together with the CHMP assessment report and translation timetable.

Furthermore, the CHMP considered that tirbanibulin is a new active substance, as claimed by the applicant.

The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.

The divergent position (Alexandre Moreau, Andrea Laslop, Christian Gartner, Simona Badoi, Sinan B. Sarac) was appended to the opinion.

The legal status was agreed as medicinal product subject to medical prescription.

The summary of opinion was circulated for information.

3.1.5. Ozawade - pitolisant - EMEA/H/C/005117

BIOPROJET PHARMA; Treatment of Excessive Daytime Sleepiness (EDS) in patients with Obstructive Sleep Apnoea (OSA)

Scope: Opinion

Action: For adoption

New active substance (Article 8(3) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 22.04.2021, 25.03.2021, 10.12.2020. List of Questions adopted on 25.06.2020.

See 2.1

The CHMP agreed that an oral explanation was not needed this time.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable. In addition, the CHMP agreed on an additional year of market/data exclusivity.

Furthermore, the CHMP considered that pitolisant is a new active substance, as claimed by the applicant.

The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.

The legal status was agreed as medicinal product subject to restricted medical prescription.

The summary of opinion was circulated for information.

3.1.6. Ryego - relugolix / estradiol / norethisterone acetate - EMEA/H/C/005267

Gedeon Richter Plc.; treatment of uterine fibroids

Scope: Opinion

Action: For adoption

New active substance (Article 8(3) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 25.03.2021, 28.01.2021. List of Questions adopted on 23.07.2020.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

Furthermore, the CHMP considered that relugolix is a new active substance, as claimed by the applicant.

The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.

The legal status was agreed as medicinal product subject to medical prescription.

The CHMP noted the letter of recommendation dated 19 May 2021.

The summary of opinion was circulated for information.

3.1.7. Skysona - elivaldogene autotemcel - Orphan - ATMP - EMEA/H/C/003690

bluebird bio (Netherlands) B.V; treatment of early cerebral adrenoleukodystrophy

Scope: Opinion

Action: For adoption

New active substance (Article 8(3) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 16.04.2021. List of Questions adopted on 22.01.2021.

The Committee confirmed that all issues previously identified in this application had been addressed.

Based on the draft opinion prepared by the CAT, the CHMP adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

Furthermore, the CHMP considered that elivaldogene autotemcel is a new active substance, as claimed by the applicant.

The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.

The legal status was agreed as medicinal product subject to restricted medical prescription.

The CHMP noted the letter of recommendation dated 12 May 2021.

The summary of opinion was circulated for information.

3.1.8. Verquvo - vericiguat - EMEA/H/C/005319

Bayer AG; treatment of symptomatic chronic heart failure

Scope: Opinion

Action: For adoption

New active substance (Article 8(3) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 25.03.2021. List of Questions adopted on 15.10.2020.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

Furthermore, the CHMP considered that vericiguat is a new active substance, as claimed by the applicant.

The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.

The legal status was agreed as medicinal product subject to medical prescription.

The CHMP noted the letter of recommendation dated 20 May 2021.

The summary of opinion was circulated for information.

3.2. Initial applications; List of outstanding issues (Day 180; Day 120 for procedures with accelerated assessment timetable)

3.2.1. ranibizumab - EMEA/H/C/005545

treatment of neovascular age-related macular degeneration (AMD)

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 28.01.2021.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

3.2.2. roxadustat - EMEA/H/C/004871

treatment of anaemia

Scope: List of outstanding issues

Action: For adoption

List of Outstanding Issues adopted on 25.02.2021. List of Questions adopted on 17.09.2020.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a 2nd list of outstanding issues with a specific timetable.

3.2.3. bevacizumab - EMEA/H/C/005433

indicated in adults for the treatment of neovascular macular degeneration associated with aging and diabetes.

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 17.09.2020.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

3.2.4. avalglucosidase alfa - Orphan - EMEA/H/C/005501

Genzyme Europe BV; for long-term enzyme replacement therapy for the treatment of patients with Pompe disease.

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 28.01.2021.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

3.2.5. tanezumab - EMEA/H/C/005189

treatment of moderate to severe chronic pain associated with osteoarthritis (OA) in adult patients for whom treatment with non-steroidal anti-inflammatory drugs (NSAIDs) and/or an opioid is ineffective, not tolerated or inappropriate

Scope: List of outstanding issues

Action: For adoption

List of Outstanding Issues adopted on 28.01.2021. List of Questions adopted on 23.07.2020.

See 2.1

An oral explanation was held on Tuesday, 18 May 2021. The presentation by the applicant focused on the clinical data in support of the application.

The Committee adopted a 2nd list of outstanding issues with a specific timetable:

3.2.6. sitagliptin - EMEA/H/C/005598

treatment of type 2 diabetes mellitus

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 17.09.2020.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

3.2.7. [sugammadex - EMEA/H/C/005403](#)

treatment of neuromuscular blockade induced by rocuronium or vecuronium

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 17.09.2020.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues.

The CHMP agreed to the request by the applicant for an extension to the clock stop to respond to the list of outstanding issues with a specific timetable.

3.2.8. [tafasitamab - Orphan - EMEA/H/C/005436](#)

Incyte Biosciences Distribution B.V.; is indicated in combination with lenalidomide followed by Tafasimab monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), including DLBCL arising from low grade lymphoma, who are not eligible for, or refuse, autologous stem cell transplant (ASCT).

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 17.09.2020.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

3.3. **Initial applications; List of questions (Day 120; Day 90 for procedures with accelerated assessment timetable)**

3.3.1. [sotorasib - EMEA/H/C/005522](#)

treatment of locally advanced or metastatic non-small cell lung cancer

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.3.2. voxelotor - Orphan - EMEA/H/C/004869

Global Blood Therapeutics Netherlands B.V.; Indicated for the treatment of haemolytic anaemia in adults and paediatric patients 12 years of age and older with sickle cell disease (SCD).

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.3.3. amivantamab - EMEA/H/C/005454

for treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) Exon 20 insertion mutations, after failure of platinum-based chemotherapy.

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.3.4. sapropterin - EMEA/H/C/005646

treatment of hyperphenylalaninemia (HPA)

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.3.5. teriparatide - EMEA/H/C/005793

treatment of osteoporosis

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.3.6. [semaglutide - EMEA/H/C/005422](#)

treatment for weight loss and weight maintenance

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.4. **Update on on-going initial applications for Centralised procedure**

3.4.1. [betaine anhydrous - EMEA/H/C/005637](#)

treatment of homocystinuria

Scope: Letter from the applicant dated 17 May 2021 requesting an extension of clock-stop to respond to the list of questions adopted in April 2021.

Action: For adoption

List of Questions adopted on 22.04.2021.

The CHMP agreed to the request by the applicant for an extension of clock-stop to respond to the list of questions adopted in April 2021.

3.4.2. [dabigatran etexilate - EMEA/H/C/005639](#)

prevention of venous thromboembolic events

Scope: Letter from the applicant dated 06 May 2021 requesting an extension of clock-stop to respond to the list of questions adopted in November 2020.

Action: For adoption

List of Questions adopted on 12.11.2020.

The CHMP did not agree with the request by the applicant for an extension of clock-stop to respond to the list of questions adopted in November 2020, but agreed to a shorter extension.

3.4.3. [pralsetinib - EMEA/H/C/005413](#)

treatment of non-small cell lung cancer (NSCLC)

Scope: Need for SAG consultation

Action: For discussion

List of Outstanding Issues adopted on 28.01.2021. List of Questions adopted on 17.09.2020.

The CHMP confirmed the need for a SAG.

3.4.4. insulin human (rDNA) - EMEA/H/C/005331

treatment of patients with diabetes mellitus who require intravenous insulin

Scope: Letter from the applicant dated 07 May 2021 requesting an extension of clock-stop to respond to the list of outstanding issues adopted in March 2021.

Action: For adoption

List of outstanding issues adopted on 25.03.2021. List of Questions adopted on 23.07.2020.

The CHMP agreed to the request by the applicant for an extension of clock-stop to respond to the list of outstanding issues adopted in March 2021.

3.4.5. lenadogene nolparvovec - Orphan - ATMP - EMEA/H/C/005047

GenSight Biologics S.A.; treatment of vision loss due to Leber Hereditary Optic Neuropathy (LHON)

Scope: Letter from the applicant dated 22 April 2021 requesting an extension of clock-stop to respond to the list of questions adopted in February 2021.

Action: For information

List of Questions adopted on 25.02.2021.

The CHMP endorsed the request by the applicant for an extension of clock-stop to respond to the list of questions adopted in February 2021, as adopted by CAT.

3.4.6. metformin hydrochloride / sitagliptin hydrochloride monohydrate - EMEA/H/C/005678

treatment of type 2 diabetes mellitus

Scope: Letter from the applicant dated 07 May 2021 requesting an extension of clock-stop to respond to the list of questions adopted in March 2021.

Action: For adoption

List of Questions adopted on 25.03.2021.

The CHMP agreed to the request by the applicant for an extension of clock-stop to respond to the list of questions adopted in March 2021.

3.5. Re-examination of initial application procedures under Article 9(2) of Regulation no 726/2004

No items

3.6. Initial applications in the decision-making phase

No items

3.7. Withdrawals of initial marketing authorisation application

No items

4. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008

4.1. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Opinion

4.1.1. Bortezomib Accord - bortezomib - EMEA/H/C/003984/X/0023

Accord Healthcare S.L.U.

Rapporteur: Daniela Philadelphy, PRAC Rapporteur: Amelia Cupelli

Scope: "Extension application to introduce a new pharmaceutical form associated with new strength (2.5 mg/ml solution for injection)."

Action: For adoption

List of Outstanding Issues adopted on 25.02.2021. List of Questions adopted on 17.09.2020.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The Icelandic and Norwegian CHMP members were in agreement with the CHMP recommendations.

The CHMP adopted the similarity assessment report.

4.1.2. Cosentyx - secukinumab - EMEA/H/C/003729/X/0067

Novartis Europharm Limited

Rapporteur: Outi Mäki-Ikola, PRAC Rapporteur: Eva A. Segovia

Scope: "Extension application to introduce a new strength of 75 mg solution for injection."

Action: For adoption

List of Questions adopted on 25.02.2021.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The Icelandic and Norwegian CHMP members were in agreement with the CHMP recommendations.

4.2. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Day 180 list of outstanding issues

4.2.1. Deltyba - delamanid - Orphan - EMEA/H/C/002552/X/0046/G

Otsuka Novel Products GmbH

Rapporteur: Christophe Focke, PRAC Rapporteur: Laurence de Fays

Scope: "Extension application to introduce a new pharmaceutical form (dispersible tablets) associated with a new strength (25 mg), grouped with a type II extension of indication variation (C.I.6.a) to include the treatment of children of at least 10 kg of body weight for the approved Deltyba 50 mg film-coated tablets; as a consequence, sections 3, 4.1, 4.2, 4.8, 5.1, 5.2 and 5.3 of the SmPC are updated. The Package Leaflet and Labelling are updated accordingly. Version 3.3 of the RMP has also been submitted and Annex II is updated to remove the specific obligation related to an in vitro study using the HFS-TB model."

Action: For adoption

List of Questions adopted on 10.12.2020.

The Committee discussed the issues identified in this application, mainly relating to quality and clinical aspects as well as the RMP.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of outstanding issues and a specific timetable.

4.2.2. Rinvoq - upadacitinib - EMEA/H/C/004760/X/0006/G

AbbVie Deutschland GmbH & Co. KG

Rapporteur: Kristina Dunder, PRAC Rapporteur: Nikica Mirošević Skvrce

Scope: "Extension application to introduce a new strength (30 mg prolonged-release tablet), grouped with a type II variation (C.I.6.a) to add a new indication (treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy for Rinvoq).

As a consequence, sections 4.1, 4.2, 4.5, 4.8, 5.1, 5.2 and 5.3 of the SmPC as well as the Package Leaflet are updated. The RMP (version 4.0) is updated in accordance.

In addition, the marketing authorisation holder (MAH) took the opportunity to include a minor update in the Annex II."

Action: For adoption

List of Questions adopted on 25.02.2021.

The Committee discussed the issues identified in this application, mainly relating to non-clinical and clinical aspects as well as the RMP.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of outstanding issues and a specific timetable.

4.2.3. Volibris - ambrisentan - EMEA/H/C/000839/X/0061/G

GlaxoSmithKline (Ireland) Limited

Rapporteur: Maria Concepcion Prieto Yerro, Co-Rapporteur: Tomas Radimersky, PRAC

Rapporteur: Eva A. Segovia

Scope: "Extension application to introduce a new strength (2.5 mg film-coated tablet), grouped with an extension of indication to include paediatric use (8 to less than 18 years). Version 9.0 of the RMP has been submitted.

Type IA category A.7."

Action: For adoption

List of Questions adopted on 17.09.2020.

The Committee discussed the issues identified in this application, mainly relating to quality and non-clinical aspects.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of outstanding issues and a specific timetable.

4.2.4. Vosevi - sofosbuvir / velpatasvir / voxilaprevir - EMEA/H/C/004350/X/0045/G

Gilead Sciences Ireland UC

Rapporteur: Filip Josephson, PRAC Rapporteur: Ana Sofia Diniz Martins

Scope: "Extension application to introduce a new strength (200 mg /50 mg /50 mg film-coated tablets). The extension application is grouped with a type II variation (C.I.6.a) to include paediatric use in patients aged 12 years and older and weighing at least 30 kg. Sections 4.2, 4.8, 5.1 and 5.2 of the SmPC and the Package Leaflet are updated to support the extended indication. The RMP (version 5.0) is updated in accordance. Furthermore, the MAH took the opportunity to implement minor editorial updates throughout the Product Information, and to update the list of local representatives in the Package Leaflet."

Action: For adoption

List of Questions adopted on 25.02.2021.

The Committee discussed the issues identified in this application, mainly relating to quality aspects.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of outstanding issues and a specific timetable.

The CHMP agreed to consult the QWP and PKWP and adopted lists of questions to these groups.

4.3. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Day 120 List of question

4.3.1. Ozempic - semaglutide - EMEA/H/C/004174/X/0021

Novo Nordisk A/S

Rapporteur: Johann Lodewijk Hillege, Co-Rapporteur: Kirstine Moll Harboe, PRAC

Rapporteur: Annika Folin

Scope: "Extension application to add a new strength of 2 mg solution for injection."

Action: For adoption

The Committee discussed the issues identified in this application, mainly relating to quality and clinical aspects as well as the RMP.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

4.4. Update on on-going extension application according to Annex I of Commission Regulation (EC) No 1234/2008

4.5. Re-examination procedure of extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008

No items

5. Type II variations - variation of therapeutic indication procedure according to Annex I of Commission Regulation (EC) No 1234/2008

5.1. Type II variations - variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008; Opinions or Requests for supplementary information

5.1.1. Blincyto - blinatumomab - Orphan - EMEA/H/C/003731/II/0038

Amgen Europe B.V.

Rapporteur: Alexandre Moreau, PRAC Rapporteur: Eva Jirsová

Scope: "Extension of indication to include the use of blinatumomab as monotherapy for the treatment of paediatric patients aged 1 year or older with high-risk first relapsed Philadelphia chromosome negative CD19 positive B-precursor ALL as consolidation therapy; as a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 13 of the RMP has also been submitted."

Action: For adoption

Request for Supplementary Information adopted on 28.01.2021.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The Icelandic and Norwegian CHMP members were in agreement with the CHMP recommendations.

The CHMP noted the letter of recommendation dated 20 May 2021.

The summary of opinion was circulated for information.

The CHMP adopted the similarity assessment report.

5.1.2. [Cervarix - human papillomavirus vaccine \[types 16, 18\] \(recombinant, adjuvanted, adsorbed\) - EMEA/H/C/000721/II/0110](#)

GlaxoSmithkline Biologicals SA

Rapporteur: Christophe Focke, Co-Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Jean-Michel Dogné

Scope: "Extension of indication to include the prevention of head and neck cancers causally related to certain oncogenic human papillomavirus types for Cervarix; as a consequence, sections 4.1 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 23.0 of the RMP has also been submitted to mainly reflect the updated indication.

In addition, the Marketing authorisation holder (MAH) took the opportunity to update the list of local representatives in the Package Leaflet. Furthermore, the PI is brought in line with the latest QRD template version 10.1."

Action: For adoption

Request for Supplementary Information adopted on 17.09.2020.

The Committee discussed the issues identified in this application, mainly relating to clinical aspects.

The Committee adopted a 2nd request for supplementary information with a specific timetable.

5.1.3. [Darzalex - daratumumab - Orphan - EMEA/H/C/004077/II/0043](#)

Janssen-Cilag International NV

Rapporteur: Sinan B. Sarac, Co-Rapporteur: Blanca Garcia-Ochoa, PRAC Rapporteur: Marcia Sofia Sanches de Castro Lopes Silva

Scope: "Extension of indication to include treatment of adult patients with newly diagnosed systemic light chain (AL) amyloidosis in combination with cyclophosphamide, bortezomib and dexamethasone; The variation leads to amendments to the Summary of Product

Characteristics, Annex II, Package Leaflet and to the Risk Management Plan (RMP).”

Action: For adoption

Request for Supplementary Information adopted on 25.02.2021.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The Icelandic and Norwegian CHMP members were in agreement with the CHMP recommendations.

The summary of opinion was circulated for information.

5.1.4. Darzalex - daratumumab - Orphan - EMEA/H/C/004077/II/0044

Janssen-Cilag International NV

Rapporteur: Sinan B. Sarac, Co-Rapporteur: Blanca Garcia-Ochoa, PRAC Rapporteur: Marcia Sofia Sanches de Castro Lopes Silva

Scope: “Extension of indication for Darzalex subcutaneous formulation to include combination with pomalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received one prior therapy containing a proteasome inhibitor and lenalidomide and were lenalidomide-refractory, or who have received at least two prior therapies that included lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or after the last therapy; The variation leads to amendments to the Summary of Product Characteristics and Package Leaflet and to the Risk Management Plan (RMP).”

Action: For adoption

Request for Supplementary Information adopted on 25.02.2021.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The Icelandic and Norwegian CHMP members were in agreement with the CHMP recommendations.

The summary of opinion was circulated for information.

The CHMP adopted the similarity assessment report.

5.1.5. Dengvaxia - dengue tetravalent vaccine (live, attenuated) - EMEA/H/C/004171/II/0011

Sanofi Pasteur

Rapporteur: Christophe Focke

Scope: "To modify the approved therapeutic indication to include conditions for the eligibility to pre-vaccination serostatus screening. As a consequence, sections 4.1, 4.2 and 4.4 of the SmPC and sections 1, 2 and 3 of the Package Leaflet are updated accordingly."

Action: For adoption

Request for Supplementary Information adopted on 10.12.2020.

The Committee discussed the issues identified in this application, mainly relating to clinical aspects.

The Committee adopted a 2nd request for supplementary information with a specific timetable.

5.1.6. [Dengvaxia - dengue tetravalent vaccine \(live, attenuated\) - EMEA/H/C/004171/II/0012](#)

Sanofi Pasteur

Rapporteur: Christophe Focke

Scope: "Extension of indication to include paediatric population from 6 years of age for Dengvaxia; as a consequence, sections 4.1, 4.2, 4.8 and 5.1 of the SmPC and sections 1, 2 and 4 of the Package Leaflet are updated. Furthermore, the MAH takes the opportunity to add an instruction for the installation of the needle in the SmPC and the Package Leaflet of the single-dose presentation."

Action: For adoption

Request for Supplementary Information adopted on 10.12.2020.

The Committee discussed the issues identified in this application, mainly relating to clinical aspects.

The Committee adopted a 2nd request for supplementary information with a specific timetable.

5.1.7. [Evotaz - atazanavir / cobicistat - EMEA/H/C/003904/II/0038](#)

Bristol-Myers Squibb Pharma EEIG

Rapporteur: Bruno Sepodes, PRAC Rapporteur: Adrien Inoubli

Scope: "Extension of indication to include the use of Evotaz in combination with other antiretroviral agents in the treatment of HIV-1 infection in adolescent patients aged ≥ 12 to < 18 years, weighing ≥ 35 kg without known mutations associated with resistance to atazanavir; as a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 8.0 of the RMP has also been submitted. In addition, the Marketing authorisation holder (MAH) took the opportunity to make minor editorial corrections."

Action: For adoption

Request for Supplementary Information adopted on 10.12.2020.

The Committee confirmed that all issues previously identified in this application had been

addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The Icelandic and Norwegian CHMP members were in agreement with the CHMP recommendations.

The summary of opinion was circulated for information.

5.1.8. [Jardiance - empagliflozin - EMEA/H/C/002677/II/0055](#)

Boehringer Ingelheim International GmbH

Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Eva A. Segovia

Scope: "Extension of indication to include treatment of adult patients with heart failure and reduced ejection fraction for Jardiance; as a consequence, sections 4.1, 4.2, 4.4, 4.8, 4.9 and 5.1 of the SmPC are updated. This is based on final results from the EMPEROR HFrEF study, a phase III randomised, double-blind trial to evaluate efficacy and safety of once daily empagliflozin 10 mg compared to placebo. The Package Leaflet and Labelling are updated in accordance. Version 15.0 of the RMP has also been submitted. In addition, the Marketing authorisation holder (MAH) took the opportunity to update the list of local representatives in the Package Leaflet."

Action: For adoption

Request for Supplementary Information adopted on 22.04.2021, 28.01.2021.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The Icelandic and Norwegian CHMP members were in agreement with the CHMP recommendations.

The summary of opinion was circulated for information.

5.1.9. [Jyseleca - filgotinib - EMEA/H/C/005113/II/0001](#)

Gilead Sciences Ireland UC

Rapporteur: Kristina Dunder, Co-Rapporteur: Jean-Michel Race, PRAC Rapporteur: Nikica Mirošević Skvrce

Scope: "C.I.6 (Extension of indication) C.I.6a (Extension of indication). Extension of indication to include the treatment of active ulcerative colitis in adults patients for Jyseleca. As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC and the Package Leaflet are updated accordingly. Version 1.1 of the RMP has also been submitted. In addition, the Marketing authorisation holder (MAH) took the opportunity to do minor updates to the Annex II and to implement minor editorial changes in the SmPC and Package Leaflet."

Action: For adoption

Request for Supplementary Information adopted on 28.01.2021.

The Committee discussed the issues identified in this application, mainly relating to non-clinical and clinical aspects.

The Committee adopted a 2nd request for supplementary information with a specific timetable.

5.1.10. Keytruda - pembrolizumab - EMEA/H/C/003820/II/0097

Merck Sharp & Dohme B.V.

Rapporteur: Armando Genazzani, Co-Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Menno van der Elst

Scope: "Extension of indication to include in combination with chemotherapy, first-line treatment of locally advanced unresectable or metastatic carcinoma of the oesophagus or HER-2 negative gastroesophageal junction adenocarcinoma in adults whose tumours express PD-L1 with a CPS ≥ 10 , based on the results from the pivotal KEYNOTE-590 (KN590) trial. As a consequence, sections 4.1, 4.2, 4.8, 5.1, 5.2 and 5.3 of the SmPC are updated. The Package Leaflet is updated in accordance. Minor updates are also included in Annex II of the Product Information. Version of the RMP (Version 31.0) has also been submitted."

Action: Possible oral explanation to be held on 18 May 2021 at 14:00

Request for Supplementary Information adopted on 22.04.2021, 25.02.2021.

See 2.3

Participation of a patient representative.

An oral explanation was held on Tuesday 18 May 2021. The presentation by the applicant focused on the clinical data in support of the application.

The Committee adopted a positive opinion by majority (28 out of 31 votes) together with the CHMP Assessment Report and translation timetable.

The Icelandic and Norwegian CHMP members were in agreement with the CHMP recommendations.

The divergent position (Kristina Dunder, Concepcion Prieto Yerro, Johann Lodewijk Hillege) was appended to the opinion.

The summary of opinion was circulated for information.

5.1.11. Libtayo - cemiplimab - EMEA/H/C/004844/II/0011

Regeneron Ireland Designated Activity Company (DAC)

Rapporteur: Sinan B. Sarac, Co-Rapporteur: Johanna Lähtenvuo, PRAC Rapporteur: Menno van der Elst

Scope: "Extension of indication for Libtayo as monotherapy indicated for the first-line treatment of adult patients with non-small cell lung cancer (NSCLC) expressing PD-L1 (in \geq

50% tumor cells), with no EGFR, ALK or ROS1 aberrations, who have:

- locally advanced NSCLC and who are not candidates for surgical resection or definitive chemoradiation, or have progressed after treatment with definitive chemoradiation, or
- metastatic NSCLC.

The PL is revised accordingly. A revised RMP is submitted.”, Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

Action: For adoption

Request for Supplementary Information adopted on 25.03.2021, 10.12.2020.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The Icelandic and Norwegian CHMP members were in agreement with the CHMP recommendations.

The summary of opinion was circulated for information.

5.1.12. Libtayo - cemiplimab - EMEA/H/C/004844/II/0012

Regeneron Ireland Designated Activity Company (DAC)

Rapporteur: Sinan B. Sarac, Co-Rapporteur: Johanna Lähteenvuo, PRAC Rapporteur: Menno van der Elst

Scope: “Extension of indication to include: Libtayo as monotherapy is indicated for the treatment of adult patients with locally advanced basal cell carcinoma (BCC) previously treated with a hedgehog pathway inhibitor.

SmPC sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 have been revised. The PL has been updated accordingly. A revised RMP has been submitted.”, Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

Action: For adoption

Request for Supplementary Information adopted on 25.03.2021, 10.12.2020.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The Icelandic and Norwegian CHMP members were in agreement with the CHMP recommendations.

The summary of opinion was circulated for information.

5.1.13. Lorviqua - lorlatinib - EMEA/H/C/004646/II/0015

Pfizer Europe MA EEIG

Rapporteur: Sinan B. Sarac, Co-Rapporteur: Armando Genazzani, PRAC Rapporteur: Nikica

Mirošević Skvrce

Scope: "Extension of indication to include the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) previously not treated with an ALK inhibitor based on results from the phase III randomised CROWN (1006) study listed as a specific obligation (SOB) in the Annex II; as a consequence, sections 4.1, 4.2 and 5.1 of the SmPC are updated. The Package leaflet is updated accordingly. Version 3.0 of the RMP has also been submitted. In addition the applicant proposes to downgrade the specific obligation to conduct a single arm study in patients who progressed after alectinib or ceritinib to a recommendation and convert the conditional MA to a full MA."

Action: For adoption

The Committee discussed the issues identified in this application, mainly relating to clinical aspects and the RMP.

The Committee adopted a request for supplementary information with a specific timetable.

5.1.14. Siklos - hydroxycarbamide - EMEA/H/C/000689/II/0047

Addmedica S.A.S.

Rapporteur: Karin Janssen van Doorn

Scope: "Extension of indication to include treatment of severe chronic anemia (haemoglobin level < 6 g/dL or < 7 g/dL with poor clinical or functional tolerance) in adults, adolescents and children older than 2 years suffering from sickle cell syndrome for Siklos; as a consequence, sections 4.1, 4.2 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance."

Action: For adoption

Request for Supplementary Information adopted on 28.01.2021, 15.10.2020.

The Committee discussed the issues identified in this application, mainly relating to non-clinical and clinical aspects.

The Committee adopted a 3rd request for supplementary information with a specific timetable.

5.1.15. Spherox - spheroids of human autologous matrix-associated chondrocytes - ATMP - EMEA/H/C/002736/II/0020

CO.DON AG

Rapporteur: Lisbeth Barkholt, CHMP Coordinator: Kristina Dunder

Scope: "Extension of the indication to include treatment of adolescents with closed epiphyseal growth plate in the affected joint; consequently, sections 4.1, 4.2, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated accordingly.

The variation leads to amendments to the Summary of Product Characteristics and Package Leaflet."

Action: For adoption

Request for Supplementary Information adopted on 19.03.2021.

The Committee confirmed that all issues previously identified in this application had been addressed.

Based on the draft opinion prepared by the CAT, the Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The Icelandic and Norwegian CHMP members were in agreement with the CHMP recommendations.

The summary of opinion was circulated for information.

5.1.16. Tookad - padeliporfin - EMEA/H/C/004182/II/0013

STEBa Biotech S.A

Rapporteur: Bruno Sepodes, PRAC Rapporteur: Maia Uusküla

Scope: "Modification of the wording of the existing indication. The new wording will be the treatment of adult patients with previously untreated, unilateral, low-risk, adenocarcinoma of the prostate with a life expectancy ≥ 10 years and Clinical stage T1c or T2a, ISUP Grade Group ≤ 2 , based on high-resolution biopsy strategies, PSA ≤ 10 ng/mL, Low core positivity for Tookad; as a consequence, section 4.1 of the SmPC is updated. Version 6.0 of the RMP has also been submitted."

Action: For adoption

The Committee discussed the issues identified in this application, mainly relating to clinical aspects and the RMP.

The Committee adopted a request for supplementary information with a specific timetable.

5.1.17. Veklury - remdesivir - EMEA/H/C/005622/II/0016

Gilead Sciences Ireland UC

Rapporteur: Janet Koenig, PRAC Rapporteur: Eva Jirsová

Scope: "Extension of indication to include treatment of adults with pneumonia not requiring supplemental oxygen (moderate COVID-19), based on Part A of study GS-US-540-5774, a Phase 3, randomized, open-label, multicenter study comparing 2 RDV regimens (5 days and 10 days) versus standard of care in 584 participants with moderate COVID 19, and study CO US 540 5776 [Adaptive COVID-19 Treatment Trial (ACTT) 1, a National Institute of Allergy and Infectious Diseases (NIAID)-sponsored Phase 3, randomized, double blind, placebo controlled, multicenter study]. As a consequence, sections 4.1 and 5.1 of the SmPC are being updated, and the Package Leaflet is updated in accordance. A revised version 1.2 of the RMP has also been submitted."

Action: For adoption

The Committee discussed the issues identified in this application, mainly relating to clinical aspects and the RMP.

The Committee adopted a request for supplementary information with a specific timetable.

5.1.18. Vyxeos liposomal - daunorubicin / cytarabine - Orphan - EMEA/H/C/004282/II/0018/G

Jazz Pharmaceuticals Ireland Limited

Rapporteur: Johanna Lähtenvuo, Co-Rapporteur: Janet Koenig, PRAC Rapporteur: Marcia Sofia Sanches de Castro Lopes Silva

Scope: "Extension of indication to add treatment of relapsed/refractory AML in paediatric patients with subsequent updates to sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC based on the new safety and efficacy data from the paediatric clinical study AAML1421. The Package leaflet is updated accordingly. The RMP version 1.1 has also been submitted. In addition, the PI is updated in line with the latest QRD template 10.2.

Submission of the final data from paediatric clinical study CPX-MA-1201 in support of the extension of indication.", Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

Action: For adoption

The Committee discussed the issues identified in this application, mainly relating to clinical aspects and the request for 1 year of market protection.

The Committee adopted a request for supplementary information with a specific timetable.

5.1.19. Xeljanz - tofacitinib - EMEA/H/C/004214/II/0035

Pfizer Europe MA EEIG

Rapporteur: Armando Genazzani, Co-Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Liana Gross-Martirosyan

Scope: "Extension of indication to include treatment of adult patients with active ankylosing spondylitis (AS) who have responded inadequately to conventional therapy for Xeljanz film-coated tablets; as a consequence, sections 4.1, 4.2, 4.4, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 17.1 of the RMP has also been submitted."

Action: For adoption

The Committee discussed the issues identified in this application, mainly relating to non-clinical and clinical aspects.

The Committee adopted a request for supplementary information with a specific timetable.

5.1.20. WS1840 Opdivo - nivolumab - EMEA/H/C/003985/WS1840/0089 Yervoy - ipilimumab - EMEA/H/C/002213/WS1840/0084

Bristol-Myers Squibb Pharma EEIG

Lead Rapporteur: Blanca Garcia-Ochoa, PRAC Rapporteur: Brigitte Keller-Stanislowski

Scope: "Extension of indication to include the combination of nivolumab with ipilimumab in the treatment of adult patients with mismatch repair deficient (dMMR) or microsatellite instability high (MSI-H) metastatic colorectal cancer (CRC) after prior fluoropyrimidine

based combination chemotherapy; as a consequence, sections 4.1, 4.2 ,4.4, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 20.2 for Opdivo and version 30.2 for Yervoy of the RMP have also been submitted.”

Action: For adoption

Request for Supplementary Information adopted on 25.03.2021, 12.11.2020.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The Icelandic and Norwegian CHMP members were in agreement with the CHMP recommendations.

The summary of opinion was circulated for information.

- 5.1.21. [WS1937/G](#)
[Eucreas - vildagliptin / metformin hydrochloride - EMEA/H/C/000807/WS1937/0080/G](#)
[Icandra - vildagliptin / metformin hydrochloride - EMEA/H/C/001050/WS1937/0083/G](#)
[Zomarist - vildagliptin / metformin hydrochloride - EMEA/H/C/001049/WS1937/0082/G](#)
-

Novartis Europharm Limited

Lead Rapporteur: Kristina Dunder, PRAC Rapporteur: Annika Folin

Scope: “Modification of approved therapeutic indication to simplify wording. Update of SmPC section 5.1 to add VERIFY study data (new study). Existing warning on drugs that may affect renal function or metformin disposition was expanded to include drugs that inhibit renal transporter (OCT2/MATE inhibitors) and corresponding update in drug interaction (section 4.4 and 4.5). PI update to QRD v10.1.”

Action: For adoption

Request for Supplementary Information adopted on 25.03.2021, 28.01.2021.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The Icelandic and Norwegian CHMP members were in agreement with the CHMP recommendations.

The summary of opinion was circulated for information.

- 5.1.22. [WS1938/G](#)
[Galvus - vildagliptin - EMEA/H/C/000771/WS1938/0066/G](#)

Novartis Europharm Limited

Lead Rapporteur: Kristina Dunder

Scope: "Modification of approved therapeutic indication to simplify wording. Update of SmPC section 5.1 to add VERIFY study data (new study)."

Action: For adoption

Request for Supplementary Information adopted on 25.03.2021, 28.01.2021.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The Icelandic and Norwegian CHMP members were in agreement with the CHMP recommendations.

The summary of opinion was circulated for information.

5.1.23. [WS1941](#) [Edistride - dapagliflozin - EMEA/H/C/004161/WS1941/0043](#) [Forxiga - dapagliflozin - EMEA/H/C/002322/WS1941/0062](#)

AstraZeneca AB

Lead Rapporteur: Kristina Dunder, PRAC Rapporteur: Annika Folin

Scope: "Update of sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC for Forxiga and Edistride based on the results from the renal outcomes study D169AC00001 (DAPA-CKD). The Annex II.B and Package Leaflet of these products are updated accordingly. The DAPA-CKD study is a category 3, Post-Authorisation Safety Study (PASS) listed in the dapagliflozin RMP to evaluate the potential risk of lower limb amputation; it is a multicentre, event-driven, randomized, double-blind, parallel group, placebo-controlled study, evaluating the effect of dapagliflozin versus placebo, given once daily in addition to standard of care, to prevent the progression of chronic kidney disease (CKD) or cardiovascular (CV)/renal death. In addition, the Risk Management Plan for dapagliflozin (version 22) has been updated."

Action: For adoption

Request for Supplementary Information adopted on 25.02.2021.

The Committee discussed the issues identified in this application, mainly relating to clinical aspects and the RMP.

The Committee adopted a 2nd request for supplementary information with a specific timetable.

5.2. Update on on-going Type II variation; variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008

5.3. Re-examination of Type II variation; variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008

No items

6. Ancillary medicinal substances in medical devices

6.1. Ancillary medicinal substances in medical devices; Opinions/ Day 180 list of outstanding issues / Day 120 list of questions

No items

6.2. Update of Ancillary medicinal substances in medical devices

No items

7. Procedure under Article 83(1) of Regulation (EC) 726/2004 (Compassionate Use)

7.1. Procedure under Article 83(1) of Regulation (EC) 726/2004 (Compassionate Use)

No items

8. Pre-submission issues

8.1. Pre-submission issue

8.1.1. valoctocogene roxaparvovec - Orphan - ATMP - H0005830

BioMarin International Limited; indicated for the treatment of adults with severe haemophilia A (congenital factor VIII deficiency) without a history of factor VIII inhibitors and without detectable antibodies to adeno-associated virus serotype 5 (AAV5). is not indicated for use in women of childbearing potential.

Scope: Briefing note and the Rapporteurs' recommendation on the request for accelerated assessment.

Action: For adoption

The CHMP agreed to the request for accelerated assessment and adopted the briefing note and Rapporteurs' recommendation on the Request for Accelerated Assessment.

8.2. Priority Medicines (PRIME)

Information related to priority medicines cannot be released at present time as these contain commercially confidential information

8.2.1. List of applications received

Action: For information

The CHMP noted the information.

8.2.2. Recommendation for PRIME eligibility

Action: For adoption

The CHMP adopted the recommendation for PRIME eligibility. The CHMP reviewed 2 recommendations for eligibility to PRIME: 1 was accepted and 1 was denied.

The individual outcomes are listed in the PRIME Monthly Report on the EMA website.

9. Post-authorisation issues

9.1. Post-authorisation issues

9.1.1. Comirnaty - COVID-19 mRNA vaccine (nucleoside-modified) - EMEA/H/C/005735/II/0030

BioNTech Manufacturing GmbH

Rapporteur: Filip Josephson, Co-Rapporteur: Jean Michel Race, PRAC Rapporteur: Menno van der Elst

Scope: "Extension of the existing indication from "individuals 16 years of age and older" to "individuals 12 years of age and older" for Comirnaty; as a consequence, sections 4.1, 4.2, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 2.0 of the RMP has also been submitted."

Action: For information

The members were reminded of the adopted timetable. The members were informed that an extraordinary CHMP will be scheduled on Friday, 28 May 2021.

9.1.2. Dengvaxia - dengue tetravalent vaccine (live, attenuated) - EMEA/H/C/004171/II/0013

Sanofi Pasteur

Rapporteur: Christophe Focke

Scope: "To update sections 4.2, 4.8 and 5.1 of the SmPC in order to introduce a new posology regimen from 3 doses to 2 doses for individuals from 9 years of age based on interim results from study CYD65 listed as a category 3 study in the RMP; this is a Phase II, observer-blind, placebo-controlled trial in order to assess Immunogenicity and Safety of Tetravalent Dengue Vaccine Given in 1-, 2-, or 3-Dose Schedules Followed by a Single Booster; section 3 of the Package Leaflet is updated accordingly"

Action: For adoption

Request for Supplementary Information adopted on 10.12.2020.

The Committee discussed the issues identified in this application, mainly relating to clinical aspects.

The Committee adopted a 2nd request for supplementary information with a specific timetable.

9.1.3. Kengrexal – cangrelor - EMEA/H/C/003773/P46/003

Chiesi Farmaceutici S.p.A.

Rapporteur: Johann Lodewijk Hillege, Co-Rapporteur: Alar Irs

Scope: "The MAH submitted a completed paediatric study (MDCO-CAN-15-01-CSR-01830) for Kengrexal 50 mg Powder for concentrate for solution for injection / infusion, in accordance with Article 46 of Regulation (EC) No1901/2006, as amended."

Action: For information

The CHMP noted the update.

9.1.4. Ledaga - chlormethine – Orphan - EMEA/H/C/002826/II/0027

Helsinn Birex Pharmaceuticals Limited

Rapporteur: Sinan B. Sarac

Scope: "Update of section 4.2 of the SmPC in order to allow flexibility in the starting frequency of the treatment based on current clinical practice; the Package Leaflet is updated accordingly."

Action: For adoption

The Committee discussed the issues identified in this application, mainly relating to clinical aspects.

The Committee adopted a request for supplementary information with a specific timetable.

9.1.5. Ondexxya - andexanet alfa - EMEA/H/C/004108/II/0003

Alexion Europe SAS

Rapporteur: Jan Mueller-Berghaus

Scope: "Submission of the final report from Population PK and PK/PD Modelling Report (POR-PKPD-ADEX-321) listed as a category 2 study in the RMP/Specific Obligation 004 in Annex II."

Scope: List of outstanding issues

Action: For adoption

Request for Supplementary Information adopted on 25.02.2021, 28.05.2020, 12.12.2019.

The Committee discussed the issues identified in this application, mainly relating to clinical aspects.

The Committee adopted a 4th request for supplementary information with a specific timetable.

9.1.6. Ondexxya - andexanet alfa - EMEA/H/C/004108/II/0009/G

Alexion Europe SAS

Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Menno van der Elst

Scope: "C.I.4, C.I.3, C.I.6 (non-EoI)

Update of section 5.2 of the SmPC in order to update pharmacokinetic information based on results from study CSR 19-514 (PK Comparability) and CSR 16-508 (Japanese Ethnicity Study) listed as a specific obligation in the Annex II. Annex II was proposed to be updated accordingly. The RMP version 2.1 has also been submitted."

Action: For adoption

Request for Supplementary Information adopted on 25.03.2021, 10.12.2020, 30.04.2020.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The Icelandic and Norwegian CHMP members were in agreement with the CHMP recommendations.

9.1.7. Vaxzevria - COVID 19 Vaccine (ChAdOx1 S [recombinant]) - EMEA/H/C/005675/II/0014

AstraZeneca AB

Rapporteur: Sol Ruiz, PRAC Rapporteur: Jean-Michel Dogné

Scope: "Update of sections 4.3, 4.4 and 4.8 of the SmPC, following an update to the Company Core Data Sheet in relation to thromboembolism with thrombocytopenia, to

contraindicate the vaccine to patients who have experienced major venous and/or arterial thrombosis in combination with thrombocytopenia following vaccination with any COVID-19 vaccine, update the warnings on thrombocytopenia and coagulation disorders and include the frequency thrombosis with thrombocytopenia of "less than 1/100,000". The package leaflet is updated accordingly."

Action: For discussion

The CHMP was updated on discussions at the PRAC.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The Icelandic and Norwegian CHMP members were in agreement with the CHMP recommendations.

The summary of opinion was circulated for information.

9.1.8. [Vaxzevria - COVID 19 Vaccine \(ChAdOx1 S \[recombinant\]\) - EMEA/H/C/005675/II/0015](#)

AstraZeneca AB

Rapporteur: Sol Ruiz, PRAC Rapporteur: Jean-Michel Dogné

Scope: "Submission of an updated RMP version 3.1 in order to update the safety concerns to add 'Thrombosis in combination with thrombocytopenia' as an important identified risk and 'Thrombosis' as an important potential risk, with consequential changes in the RMP. Updates to the Pharmacovigilance Plan have also been implemented. These changes were requested by PRAC in the outcome of Signal Assessment Procedure on Embolic and Thrombotic Events with Vaxzevria EPITT no: 196833. The MAH has taken the opportunity to further update the RMP to reclassify "anaphylaxis" as an important identified risk, already reflected in the product information as an adverse reaction."

Action: For discussion

The CHMP was updated on discussions at the PRAC. The Committee discussed the issues identified in this application, mainly relating to the RMP.

The Committee adopted a request for supplementary information with a specific timetable.

9.1.9. [Vaxzevria - COVID 19 Vaccine \(ChAdOx1 S \[recombinant\]\) - EMEA/H/C/005675/II/0017/G](#)

AstraZeneca AB

Rapporteur: Sol Ruiz, PRAC Rapporteur: Jean-Michel Dogné

Scope: "C.I.4 (type II) - Update of section 4.6 of the SmPC in order to add the high-level results from the development and reproductive toxicity (DART) study (study number 490843).

C.I.4 (type II) - Update of section 5.3 of the SmPC in order to add the high-level results from the biodistribution study (study number 514559), listed as an imposed study in Annex II.

The MAH is taking the opportunity to update the wording of section 5.3 of the SmPC to add the results from the already assessed repeat-dose toxicity study. Moreover, the MAH is taking the opportunity to address the nonclinical recommendations adopted during the initial CMA application.”

Action: For discussion

The Committee discussed the issues identified in this application, mainly relating to non-clinical aspects.

The Committee adopted a request for supplementary information with a specific timetable.

9.1.10. Esbriet - pirfenidone - EMEA/H/C/002154/II/0069

Roche Registration GmbH

Rapporteur: Peter Kiely, Co-Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Rhea Fitzgerald

Scope: “Extension of indication to include the treatment of unclassifiable interstitial lung disease (UIILD) for Esbriet; as a consequence, sections 4.1, 4.2, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 11.0 of the RMP has also been submitted.”

Request for Supplementary Information adopted on 22.04.2021

Withdrawal of extension of indication application

Action: For information

The CHMP noted the withdrawal of the extension of indication application.

9.1.11. Veklury – remdesivir - EMEA/H/C/005622/R/0015

Gilead Sciences Ireland UC

Rapporteur: Janet Koenig, Co-Rapporteur: Filip Josephson

Scope: Renewal of conditional marketing authorisation, possible oral explanation

Action: Possible oral explanation to be held on 17 May 2021 at 16:00

The RSI adopted in March was revised at the April plenary following conclusion of the LEG/31 procedure. Request for Supplementary Information adopted on 25.03.2021.

See also 2.3

The CHMP agreed that an oral explanation was not needed this time.

The CHMP adopted a positive opinion by consensus together with the CHMP assessment report and translation timetable.

The CHMP was of the opinion that the renewal for this conditional Marketing Authorisation can be granted. The Marketing Authorisation remains conditional.

The Icelandic and Norwegian CHMP Members were in agreement with the CHMP opinion.

10. Referral procedures

10.1. Procedure for Centrally Authorised products under Article 20 of Regulation (EC) No 726/2004

No items

10.2. Requests for CHMP Opinion under Article 5(3) of Regulation (EC) No 726/2004

10.2.1. Sotrovimab (VIR-7831/GSK4182136) for the treatment of COVID-19 - EMEA/H/A-5(3)/1508

GlaxoSmithKline

Referral Rapporteur: Kirstine Moll Harboe, Referral Co-Rapporteur: Jayne Crowe

Scope: Opinion

Rapporteurs were appointed via written procedures on 14.04.2021

Action: For adoption

The Committee for Medicinal Products for Human Use (CHMP) has been asked by the EMA to give a scientific opinion under Article 5(3) of Regulation (EC) No 726/2004 on the currently available quality, preclinical and clinical data on the potential use of GSK4182136 (VIR-7831) for the treatment of patients with coronavirus disease 2019 (COVID-19) who do not require oxygen supplementation and who are at high risk of progressing to severe COVID-19.

The CHMP adopted an opinion by consensus, concluding that based on currently available data, sotrovimab (VIR-7831/GSK4182136) could be used for the treatment of adults and adolescents (aged 12 years and over and weighing at least 40 kg) with coronavirus disease 2019 (COVID-19) who do not require oxygen supplementation and who are at risk of progressing to severe COVID-19.

The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.

The EMA press release was circulated for information.

10.3. Procedure under Articles 5(2) and 10 of Regulation (EC) No 726/2004

No items

10.4. Disagreement between Member States on application for medicinal product (potential serious risk to public health) –under Article 29(4) of Directive 2001/83/EC

No items

10.5. Harmonisation - Referral procedure under Article 30 of Directive 2001/83/EC

No items

10.6. Community Interests - Referral under Article 31 of Directive 2001/83/EC

No items

10.7. Re-examination Procedure under Article 32(4) of Directive 2001/83/EC

No items

10.8. Procedure under Article 107(2) of Directive 2001/83/EC

No items

10.9. Disagreement between Member States on Type II variation– Arbitration procedure initiated by MAH under Article 6(13) of Commission Regulation (EC) No 1084/2003

No items

10.10. Procedure under Article 29 of Regulation (EC) 1901/2006

No items

10.11. Referral under Article 13 Disagreement between Member States on Type II variation– Arbitration procedure initiated by Member State under Article 13 (EC) of Commission Regulation No 1234/2008

No items

11. Pharmacovigilance issue

11.1. Early Notification System

May 2021 Early Notification System on envisaged CHMP/CMDh outcome accompanied by communication to the general public.

Action: For information

The CHMP noted the information.

12. Inspections

12.1. GMP inspections

Information related to GMP inspections will not be published as it undermines the purpose of such inspections

12.2. GCP inspections

Information related to GCP inspections will not be published as it undermines the purpose of such inspections

12.3. Pharmacovigilance inspections

Information related to Pharmacovigilance inspections will not be published as it undermines the purpose of such inspections

12.4. GLP inspections

Information related to GLP inspections will not be published as it undermines the purpose of such inspections

13. Innovation Task Force

13.1. Minutes of Innovation Task Force

No items

13.2. Innovation Task Force briefing meetings

No items

13.3. Requests for CHMP Opinion under Article 57(1)J and (1)P of Regulation (EC) No 726/2004

No items

13.4. Nanomedicines activities

No items

14. Organisational, regulatory and methodological matters

14.1. Mandate and organisation of the CHMP

No items

14.2. Coordination with EMA Scientific Committees

14.2.1. Pharmacovigilance Risk Assessment Committee (PRAC)

List of Union Reference Dates and frequency of submission of Periodic Safety Update Reports (EURD list) for May 2021

Action: For adoption

The CHMP adopted the EURD list.

14.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups

14.3.1. Biologics Working Party (BWP)

Chair: Sol Ruiz/Nanna Aaby Kruse

Reports from BWP May 2021 meeting to CHMP for adoption

- 9 reports on products in scientific advice and protocol assistance
- 8 reports on products in pre-authorisation procedures

Action: For adoption

The CHMP adopted the BWP reports.

14.3.2. Modelling and Simulation Working Party (MSWP)

Chairs: Kristin Karlsson/Flora Musuamba Tshinanu

Election of MSWP Chair and Vice-Chair. The mandate of MSWP chair Kristin Karlsson and MSWP vice-chair Flora Musuamba Tshinanu will expire on 28 June 2021.

Nomination(s) received

Action: For election

The CHMP re-elected Kristin Karlsson as MSWP chair and Flora Musuamba Tshinanu as MSWP vice-chair.

14.3.3. Scientific Advice Working Party (SAWP)

Chair: Anja Schiel

Report from the SAWP meeting held on 03-06 May 2021. Table of conclusions

Action: For information

The CHMP noted the report.

Scientific advice letters

Information related to scientific advice letters cannot be released at present time as these contain commercially confidential information.

14.3.4. Quality Working Party (QWP)

Chair: Blanka Hirschlerova

Letter from EC (DG SANTE) requesting further information on EFSA opinion on TiO₂, which was published on the 6th of May.

Action: For information

Follow-up from May PROM. EC (DG SANTE) requesting an analysis on aspects in relation to the EFSA opinion on TiO₂. CHMP agreed at the PROM to consult the QWP.

14.4. Cooperation within the EU regulatory network

No items

14.5. Cooperation with International Regulators

No items

14.6. Contacts of the CHMP with external parties and interaction with the Interested Parties to the Committee

No items

14.7. CHMP work plan

No items

14.8. Planning and reporting

14.8.1. Marketing Authorisation Applications 3-year forecast report

Action: For information

The CHMP noted the information.

14.9. Others

No items

15. Any other business

15.1. AOB topic

15.1.1. Diabetes Indication

Action: For discussion

Overall the CHMP supported further discussions possibly resulting in an update of the diabetes guideline. The CHMP agreed on an update at the next PROM to discuss further steps.

15.1.2. Update on COVID-19

Action: For information

The CHMP noted the information.

15.1.3. ECDC recommendations on adverse reactions to COVID-19 vaccination and the safety of substances of human origin

Action: For discussion

The CHMP endorsed the ECDC recommendation.

15.1.4. Scientific Advice Group (SAG) re-nominations

Follow up on the public call for expression of interests for renewal of mandate of all therapeutic SAGs

Action: For information

The members were informed that more nominations are needed for the 6 therapeutic SAGs.

For further information about the SAGs you can also refer to the public call published on EMA website:

<https://www.ema.europa.eu/en/news/becoming-member-one-emas-scientific-advisory-groups>

15.1.5. COVID-19 vaccine (NVX-CoV2373) – EMEA/H/C/005808

prevention of COVID-19

Scope: Rolling review timetable adopted via written procedure on 29 April 2021

Action: For information

The CHMP noted the RR timetable, which was adopted via written procedure.

Lists of participants

List of participants including any restrictions with respect to involvement of members/alternates/experts following evaluation of declared interests for the 17-20 May 2021 CHMP meeting.

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Harald Enzmann	Chair	Germany	No interests declared	
Andrea Laslop	Member	Austria	No interests declared	
Daniela Philadelphia	Alternate	Austria	No interests declared	
Christophe Focke	Member	Belgium	No restrictions applicable to this meeting	
Karin Janssen van Doorn	Alternate	Belgium	No interests declared	
Ilko Getov	Member	Bulgaria	No interests declared	
Margareta Bego	Member	Croatia	No interests declared	
Selma Arapovic Dzakula	Alternate	Croatia	No interests declared	
Helena Panayiotopoulou	Member	Cyprus	No interests declared	
Ondřej Slanař	Member	Czechia	No restrictions applicable to this meeting	
Tomas Radimersky	Alternate	Czechia	No interests declared	
Sinan B. Sarac	Member	Denmark	No interests declared	
Kirstine Moll Harboe	Alternate	Denmark	No interests declared	
Alar Irs	Member	Estonia	No restrictions applicable to this meeting	
Edward Laane	Alternate	Estonia	No restrictions applicable to this meeting	
Outi Mäki-Ikola	Member	Finland	No restrictions applicable to this meeting	
Johanna Lähteenvu	Alternate	Finland	No interests declared	
Alexandre Moreau	Member	France	No interests declared	
Jean-Michel Race	Alternate	France	No interests declared	
Martina Weise	Member	Germany	No restrictions applicable to this meeting	
Janet Koenig	Alternate	Germany	No interests declared	

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Konstantinos Markopoulos	Member	Greece	No interests declared	
Eleftheria Nikolaidi	Alternate	Greece	No interests declared	
Agnes Gyurasics	Alternate	Hungary	No interests declared	
Hrefna Gudmundsdottir	Alternate	Iceland	No interests declared	
Jayne Crowe	Member	Ireland	No interests declared	
Peter Kiely	Alternate	Ireland	No interests declared	
Armando Genazzani	Member	Italy	No interests declared	
Elita Poplavska	Member	Latvia	No interests declared	
Romaldas Mačiulaitis	Member	Lithuania	No participation in final deliberations and voting on	COVID vaccines
Martine Trauffer	Member	Luxembourg	No interests declared	
Carola de Beaufort	Alternate	Luxembourg	No interests declared	
John Joseph Borg	Member	Malta	No interests declared	
Helen Vella	Alternate	Malta	No interests declared	
Johann Lodewijk Hillege	Member	Netherlands	No interests declared	
Paula Boudewina van Hennik	Alternate	Netherlands	No interests declared	
Bjorg Bolstad	Member	Norway	No restrictions applicable to this meeting	
Ingrid Wang	Alternate	Norway	No interests declared	
Ewa Balkowiec Iskra	Member	Poland	No interests declared	
Bruno Sepodes	Member (Vice-Chair)	Portugal	No interests declared	
Fatima Ventura	Alternate	Portugal	No participation in final deliberations and voting on	COVID vaccines
Simona Badoi	Member	Romania	No interests declared	
Dana Gabriela Marin	Alternate	Romania	No interests declared	
Francisek Drafi	Member	Slovakia	No interests declared	

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Dorota Distlerova	Alternate	Slovakia	No restrictions applicable to this meeting	
Nevenka Trsinar Brodt	Alternate	Slovenia	No interests declared	
Maria Concepcion Prieto Yerro	Member	Spain	No interests declared	
Blanca Garcia-Ochoa	Alternate	Spain	No interests declared	
Kristina Dunder	Member	Sweden	No interests declared	
Filip Josephson	Alternate	Sweden	No interests declared	
Christian Gartner	Co-opted member	Austria	No restrictions applicable to this meeting	
Carla Torre	Co-opted member	Portugal	No interests declared	
Jan Mueller-Berghaus	Co-opted member	Germany	No interests declared	
Blanka Hirschlerova	Co-opted member	Czechia	No interests declared	
Sol Ruiz	Co-opted member	Spain	No interests declared	
Nina Hessvik	Expert - via Webex*	Norway	No interests declared	
Ingrid Lund	Expert - via Webex*	Norway	No interests declared	
Irene Bachmann	Expert - via Webex*	Germany	No interests declared	
Jana Klimasová	Expert - via Webex*	Slovakia	No restrictions applicable to this meeting	
Eva Malikova	Expert - via Webex*	Slovakia	No interests declared	
Anna Kubandová	Expert - via Webex*	Slovakia	No interests declared	
Jana Schweigertova	Expert - via Webex*	Slovakia	No interests declared	
Sargi Caizergues Lama	Expert - via Webex*	France	No interests declared	
Stephanie Hueber	Expert - via Webex*	France	No interests declared	
Nathalie Dumarcet	Expert - via Webex*	France	No interests declared	

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Bruno Delafont	Expert - via Webex*	France	No part in discussions, final deliberations and voting on	<p>WS1941</p> <p>Edistride - dapagliflozin - EMEA/H/C/004161/WS1941/0043</p> <p>Forxiga - dapagliflozin - EMEA/H/C/002322/WS1941/0062</p> <p>Vaxzevria - COVID 19 Vaccine (ChAdOx1 S [recombinant])</p> <p>Volibris - ambrisentan - EMEA/H/C/000839/X/0061/G</p> <p>Cervarix - human papillomavirus vaccine [types 16, 18] (recombinant, adjuvanted, adsorbed) - EMEA/H/C/000721/II/0110</p> <p>Sotrovimab - EMEA/H/A-5(3)/1508</p>
Kairi Rooma	Expert - via Webex*	Estonia	No interests declared	
Jana Lukacisinova	Expert - via Webex*	Czechia	No interests declared	
Petra Vacková	Expert - via Webex*	Czechia	No interests declared	
Sabine Mayrhofer	Expert - via Webex*	Germany	No interests declared	
Nora Cascante Estepa	Expert - via Webex*	Germany	No interests declared	
Susanne Mueller-Egert	Expert - via Webex*	Germany	No interests declared	
Hilke Zander	Expert - via Webex*	Germany	No interests declared	
Bettina Kartmann	Expert - via Webex*	Germany	No interests declared	
Loes den Otter	Expert - via Webex*	Netherlands	No interests declared	
Janneke van Leeuwen	Expert - via Webex*	Netherlands	No interests declared	
Frank Holtkamp	Expert - via Webex*	Netherlands	No interests declared	
Hanja de Kooter	Expert - via Webex*	Netherlands	No restrictions applicable to this meeting	
Chantal van de Schootbrugge	Expert - via Webex*	Netherlands	No interests declared	

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Patrick Vrijlandt	Expert - via Webex*	Netherlands	No interests declared	
Richard IJzerman	Expert - via Webex*	Netherlands	No part in discussions, final deliberations and voting on	WS1941 Edistrade - dapagliflozin - EMEA/H/C/004161/WS1941/0043 Forxiga - dapagliflozin - EMEA/H/C/002322/WS1941/0062
Jaap Fransen	Expert - via Webex*	Netherlands	No interests declared	
Lieke Sandberg Smits	Expert - via Webex*	Netherlands	No interests declared	
Hanneke Mulder	Expert - via Webex*	Netherlands	No interests declared	
Anissa Benlazar	Expert - via Webex*	France	No restrictions applicable to this meeting	
Valerie Lescrainier	Expert - via Webex*	Belgium	No interests declared	
Diederica Claeys	Expert - via Webex*	Belgium	No interests declared	
Flora Musuamba Tshinanu	Expert - via Webex*	Belgium	No restrictions applicable to this meeting	
Tim Leest	Expert - via Webex*	Belgium	No interests declared	
Tomas Lams	Expert - via Webex*	Belgium	No interests declared	
Violette Dirix	Expert - via Webex*	Belgium	No interests declared	
Ingrid Bourges	Expert - via Webex*	Belgium	No interests declared	
Cristina Migali	Expert - via Webex*	Italy	No interests declared	
Gabriella Passacquale	Expert - via Webex*	Italy	No interests declared	
Esther Brandon	Expert - via Webex*	Netherlands	No interests declared	
Anna Wallinder Marklund	Expert - via Webex*	Sweden	No interests declared	
Michal Radik	Expert - via Webex*	Slovakia	No interests declared	
Elina Asikanius	Expert - via Webex*	Finland	No restrictions applicable to this meeting	
Liisa Pylkkanen	Expert - via Webex*	Finland	No interests declared	
Juha Kolehmainen	Expert - via Webex*	Finland	No interests declared	
Karri Penttilä	Expert - via Webex*	Finland	No interests declared	
Paula Grönroos	Expert - via Webex*	Finland	No interests declared	

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Kirsi Maija Kaukonen	Expert - via Webex*	Finland	No interests declared	
Elisabeth Wischnitzki	Expert - via Webex*	Austria	No interests declared	
Johanna Wernsperger	Expert - via Webex*	Austria	No interests declared	
Mirjam Hinterleitner	Expert - via Webex*	Austria	No interests declared	
Tanja Zahlner	Expert - via Webex*	Austria	No interests declared	
Martina Schuessler-Lenz	Expert - via Webex*	Germany	No interests declared	
Jean-Michel Dogné	Expert - via Webex*	Belgium	No interests declared	
Sabine Straus	Expert - via Webex*	Netherlands	No interests declared	
Anja Schiel	Expert - via Webex*	Norway	No interests declared	
Larisa Higgins	Expert - via Webex*	Ireland	No interests declared	
Aaron Emmanuel Sosa Mejia	Expert - via Webex*	Denmark	No restrictions applicable to this meeting	
Adriana Andrić	Expert - via Webex*	Croatia	No interests declared	
Kristina Bech Jensen	Expert - via Webex*	Denmark	No interests declared	
Mette Toftegaard Madsen	Expert - via Webex*	Denmark	No interests declared	
Lene Weber Vestermark	Expert - via Webex*	Denmark	No interests declared	
Trine Jensen	Expert - via Webex*	Denmark	No restrictions applicable to this meeting	
Anne Hasle Buur	Expert - via Webex*	Denmark	No interests declared	
Susanne Høpner Rasmussen	Expert - via Webex*	Denmark	No restrictions applicable to this meeting	
Andreas James Schaeffer Senders	Expert - via Webex*	Denmark	No interests declared	
Mette Linnert Jensen	Expert - via Webex*	Denmark	No interests declared	
Mogens Westergaard	Expert - via Webex*	Denmark	No interests declared	
Anne-Marie Dalseg	Expert - via Webex*	Denmark	No interests declared	
Doris Johanna Hovgaard	Expert - via Webex*	Denmark	No interests declared	
Theis Moeslund Jensen	Expert - via Webex*	Denmark	No restrictions applicable to this meeting	

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Alfredo García-Arieta	Expert - via Webex*	Spain	No interests declared	
Maria Victoria Tudanca Pacios	Expert - via Webex*	Spain	No restrictions applicable to this meeting	
Concepcion Gimenez Rebollo	Expert - via Webex*	Spain	No part in final deliberations and voting on	Ozempic - semaglutide - EMEA/H/C/004174/X/0021 WS1941 Edistrade - dapagliflozin - EMEA/H/C/004161/WS1941/0043 Forxiga - dapagliflozin - EMEA/H/C/002322/WS1941/0062 Jardiance - empagliflozin - EMEA/H/C/002677/II/0055
Carolina Prieto Fernandez	Expert - via Webex*	Spain	No interests declared	
Lucia Lopez-Anglada Fernandez	Expert - via Webex*	Spain	No interests declared	
Macarena Gajardo	Expert - via Webex*	Spain	No interests declared	
Ana Sagredo	Expert - via Webex*	Spain	No interests declared	
Maria Chamorro Somoza Diaz-Sarmiento	Expert - via Webex*	Spain	No interests declared	
Stephanie Buchholz	Expert - via Webex*	Germany	No interests declared	
Andreas Brandt	Expert - via Webex*	Germany	No interests declared	
Martin Mengel	Expert - via Webex*	Germany	No interests declared	
Jutta Dedorath	Expert - via Webex*	Germany	No interests declared	
Melanie Diane Klok	Expert - via Webex*	Netherlands	No part in discussions, final deliberations and voting on	roxadustat - EMEA/H/C/004871
Paolo Foggi	Expert - via Webex*	Italy	No interests declared	
Antonella Isgrò	Expert - via Webex*	Italy	No interests declared	
Jorn Mulder	Expert - via Webex*	Netherlands	No interests declared	
Peter Sisovsky	Expert - via Webex*	Slovakia	No interests declared	
Fernando Mendez Hermida	Expert - via Webex*	Spain	No interests declared	
Leire Aguado	Expert - via Webex*	Spain	No interests declared	

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Gloria Maria Palomo Carrasco	Expert - via Webex*	Spain	No interests declared	
Consuelo Mejías Pavón	Expert - via Webex*	Spain	No interests declared	
Marion Haberkamp	Expert - via Webex*	Germany	No interests declared	
Andre Elferink	Expert - via Webex*	Netherlands	No interests declared	
Simona Russo	Expert - via Webex*	Italy	No restrictions applicable to this meeting	
Nanna Borup Johansen	Expert - via Webex*	Denmark	No interests declared	
Michel Kooijman	Expert - via Webex*	Netherlands	No interests declared	
Katrien Oude Rengerink	Expert - via Webex*	Netherlands	No part in discussions, final deliberations and voting on:	Keytruda - pembrolizumab - EMEA/H/C/003820/II/0097
Marian Mitroiu	Expert - via Webex*	Netherlands	No interests declared	
Ineke Havinga	Expert - via Webex*	Netherlands	No interests declared	
Adrianus Van Gompel	Expert - via Webex*	Netherlands	No interests declared	
Viktoriia Starokozhko	Expert - via Webex*	Netherlands	No restrictions applicable to this meeting	
Inne Crèvecoeur	Expert - via Webex*	Belgium	No restrictions applicable to this meeting	
Elisabeth Penninga	Expert - via Webex*	Denmark	No interests declared	
Adam Przybylowski	Expert - via Webex*	Poland	No interests declared	
Katarzyna Ziolkowska	Expert - via Webex*	Poland	No interests declared	
Kristin Skougaard	Expert - via Webex*	Denmark	No interests declared	
Peter Twomey	Expert - via Webex*	Ireland	No restrictions applicable to this meeting	
Dong Ho Kim Pietsch	Expert - via Webex*	Germany	No interests declared	
Jeroen Koomen	Expert - via Webex*	Netherlands	No interests declared	
Sabine Engel	Expert - via Webex*	Germany	No interests declared	
Shane Gormley	Expert - via Webex*	Ireland	No interests declared	

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Elma O'Reilly	Expert - via Webex*	Ireland	No interests declared	
Finbarr Leacy	Expert - via Webex*	Ireland	No interests declared	
Jorg Engelbergs	Expert - via Webex*	Germany	No interests declared	
Filip Kukulski	Expert - via Webex*	Health Canada	No interests declared	
Violetta Skalski	Expert - via Webex*	Health Canada	No interests declared	
Charlotte Geluk	Expert - via Webex*	Swissmedic	No interests declared	
Rolando Barbaro Dominguez Morales	Expert - via Webex*	WHO	No interests declared	
Kenichi Tamiya	Expert - via Webex*	PMDA	No interests declared	
Meeting run with the help of EMA staff				

*Experts were only evaluated against the product(s) they have been invited to talk about

Experts from international organisations or regulatory authorities in third countries cannot participate in the adoption of any procedural decision, scientific opinion or recommendation by the Committee at any step of the procedure.

Explanatory notes

The notes below give a brief explanation of the main sections and headings in the CHMP agenda and should be read in conjunction with the agenda or the minutes.

Oral explanations (section 2)

The items listed in this section are those for which marketing authorisation holders (MAHs) or applicants have been invited to the CHMP plenary meeting to address questions raised by the Committee. Oral explanations normally relate to on-going applications (section 3, 4 and 5) or referral procedures (section 10) but can relate to any other issue for which the CHMP would like to discuss with company representatives in person.

Initial applications (section 3)

This section lists applications for marketing authorisations of new medicines that are to be discussed by the Committee.

Section 3.1 is for medicinal products nearing the end of the evaluation and for which the CHMP is expected to adopt an **opinion** at this meeting on whether marketing authorisation should be granted. Once adopted, the CHMP opinion will be forwarded to the European Commission for a final legally binding decision valid throughout the EU.

The other items in the section are listed depending on the stage of the evaluation, which is shown graphically below:



The assessment of an application for a new medicine takes up to 210 'active' days. This active evaluation time is interrupted by at least one 'clock-stop' during which time the applicant prepares the answers to questions from the CHMP. The clock stop happens after day 120 and may also happen after day 180, when the CHMP has adopted a list of questions or outstanding issues to be addressed by the company. Related discussions are listed in the agenda under sections 3.2 (**Day 180 List of outstanding issues**) and 3.3 (**Day 120 list of questions**).

CHMP discussions may also occur at any other stage of the evaluation, and these are listed under section 3.4, **update on ongoing new applications for centralised procedures**.

The assessment leads to an opinion from the CHMP by day 210. Following a CHMP opinion the European Commission takes usually 67 days to issue a legally binding decision (i.e. by day 277 of the procedure). CHMP discussions on products that have received a CHMP opinion and are awaiting a decision are listed under section 3.6, **products in the decision making phase**.

Extension of marketing authorisations according to Annex I of Reg. 1234/2008 (section 4)

Extensions of marketing authorisations are applications for the change or addition of new strengths,

formulations or routes of administration to existing marketing authorisations. Extension applications follow a 210-day evaluation process, similarly to applications for new medicines (see figure above).

Type II variations - Extension of indication procedures *(section 5)*

Type II variations are applications for a change to the marketing authorisation which requires an update of the product information and which is not covered in section 4. Type II variations include applications for a new use of the medicine (extension of indication), for which the assessment takes up to 90 days. For the applications listed in this section, the CHMP may adopt an opinion or request supplementary information from the applicant.

Ancillary medicinal substances in medical devices *(section 6)*

Although the EMA does not regulate medical devices it can be asked by the relevant authorities (the so-called Notified Bodies) that are responsible for regulating these devices to give a scientific opinion on a medicinal substance contained in a medical device.

Re-examination procedures (new applications) under article 9(2) of regulation no 726/2004 *(section 3.5)*

This section lists applications for new marketing authorisation for which the applicant has requested a re-examination of the opinion previously issued by the CHMP.

Re-examination procedures *(section 5.3)*

This section lists applications for type II variations (including extension of indication applications) for which the applicant has requested re-examination of the opinion previously issued by the CHMP.

Withdrawal of application *(section 3.7)*

Applicants may decide to withdraw applications at any stage during the assessment and a CHMP opinion will therefore not be issued. Withdrawals are included in the agenda for information or discussion, as necessary.

Procedure under article 83(1) of regulation (EC) 726/2004 (compassionate use) *(section 7)*

Compassionate use is a way of making available to patients with an unmet medical need a promising medicine which has not yet been authorised (licensed) for their condition. Upon request, the CHMP provides recommendations to all EU Member States on how to administer, distribute and use certain medicines for compassionate use.

Pre-submission issues *(section 8)*

In some cases the CHMP may discuss a medicine before a formal application for marketing authorisation is submitted. These cases generally refer to requests for an accelerated assessment for medicines that are of major interest for public health or can be considered a therapeutic innovation. In case of an accelerated assessment the assessment timetable is reduced from 210 to 150 days.

Post-authorisation issues *(section 9)*

This section lists other issues concerning authorised medicines that are not covered elsewhere in the agenda. Issues include supply shortages, quality defects, some annual reassessments or renewals or type II variations to marketing authorisations that would require specific discussion at the plenary.

Referral procedures *(section 10)*

This section lists referrals that are ongoing or due to be started at the plenary meeting. A referral is a procedure used to resolve issues such as concerns over the safety or benefit-risk balance of a medicine or a class of medicines. In a referral, the EMA is requested to conduct a scientific assessment of a

particular medicine or class of medicines on behalf of the EU. Further information on such procedures can be found [here](#).

Pharmacovigilance issues (section 11)

This section lists issues that have been discussed at the previous meeting of the PRAC, the EMA's committee responsible for evaluating and monitoring safety issues for medicines. Feedback is provided by the PRAC. This section also refers to the early notification system, a system used to notify the European regulatory network on proposed EMA communication on safety of medicines.

Inspections Issues (section 12)

This section lists inspections that are undertaken for some medicinal products. Inspections are carried out by regulatory agencies to ensure that marketing authorisation holders comply with their obligations. Inspection can relate to good manufacturing practice (GMP), good clinical practice (GCP), good laboratory practice (GLP) or good pharmacovigilance practice (GVP).

Innovation task force (section 13)

The Innovation Task Force (ITF) is a body set up to encourage early dialogue with applicants developing innovative medicines. Minutes from the last ITF meeting as well as any related issue that requires discussion with the CHMP are listed in this section of the agenda. Further information on the ITF can be found [here](#).

Scientific advice working party (SAWP) (section 14.3.1)

This section refers to the monthly report from the CHMP's Scientific Advice Working Party (SAWP) on scientific advice given to companies during the development of medicines. Further general information on SAWP can be found [here](#).

Satellite groups / other committees (section 14.2)

This section refers to the reports from groups and committees making decisions relating to human medicines: the Coordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh), the Committee for Orphan Medicinal Products (COMP), the Committee for Herbal Medicinal Products (HMPC), Paediatric Committee (PDCO), the Committee for Advanced Therapies (CAT) and the Pharmacovigilance Risk Assessment Committee (PRAC).

Invented name issues (section 14.3)

This section lists issues related to invented names proposed by applicants for new medicines. The CHMP has established the Name Review Group (NRG) to perform reviews of the invented names. The group's main role is to consider whether the proposed names could create a public-health concern or potential safety risk. Further information can be found [here](#).

More detailed information on the above terms can be found on the EMA website: www.ema.europa.eu/



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

09 July 2021
EMA/CHMP/342381/2021

Annex to 17-20 May 2021 CHMP Minutes

Pre-submission and post-authorisations issues

A. PRE-SUBMISSION ISSUES	3
A.1. ELIGIBILITY REQUESTS.....	3
A.2. Appointment of Rapporteur / Co-Rapporteur Full Applications	3
A.3. PRE-SUBMISSION ISSUES FOR INFORMATION	3
B. POST-AUTHORISATION PROCEDURES OUTCOMES	3
B.1. Annual re-assessment outcomes.....	3
B.1.1. Annual reassessment for products authorised under exceptional circumstances	3
B.2. RENEWALS OF MARKETING AUTHORISATIONS OUTCOMES	3
B.2.1. Renewals of Marketing Authorisations requiring 2nd Renewal.....	3
B.2.2. Renewals of Marketing Authorisations for unlimited validity	3
B.2.3. Renewals of Conditional Marketing Authorisations	5
B.3. POST-AUTHORISATION PHARMACOVIGILANCE OUTCOMES	6
B.4. EPARs / WPARs	10
B.5. TYPE II VARIATION, WORKSHARING PROCEDURE OUTCOMES	11
B.5.1. CHMP assessed procedures scope: Pharmaceutical aspects	11
B.5.2. CHMP assessed procedures scope: Non-Clinical and Clinical aspects	15
B.5.3. CHMP-PRAC assessed procedures.....	27
B.5.4. PRAC assessed procedures.....	33
B.5.5. CHMP-CAT assessed procedures	40
B.5.6. CHMP-PRAC-CAT assessed procedures.....	40
B.5.7. PRAC assessed ATMP procedures	40
B.5.8. Unclassified procedures and worksharing procedures of type I variations	41
B.5.9. Information on withdrawn type II variation / WS procedure	42
B.5.10. Information on type II variation / WS procedure with revised timetable	43
B.6. START OF THE PROCEDURES TIMETABLES FOR INFORMATION	44
B.6.1. Start of procedure for New Applications: timetables for information	44
B.6.2. Start of procedure for Extension application according to Annex I of Reg. 1234/2008): timetables for information	45
B.6.3. Restart of procedure - responses received to Day 120 List of Questions timetables: for information	46



B.6.4. Annual Re-assessments: timetables for adoption.....	47
B.6.5. Renewals of Marketing Authorisations: timetables for adoption provided only if the validation has been completed	47
B.6.6. VARIATIONS – START OF THE PROCEDURE	48
B.6.7. Type II Variations scope of the Variations: Extension of indication	48
B.6.8. CHMP assessed procedures scope: Pharmaceutical aspects	51
B.6.9. CHMP assessed procedures scope: Non-Clinical and Clinical aspects	55
B.6.10. CHMP-PRAC assessed procedures.....	62
B.6.11. PRAC assessed procedures	67
B.6.12. CHMP-CAT assessed procedures.....	70
B.6.13. CHMP-PRAC-CAT assessed procedures	70
B.6.14. PRAC assessed ATMP procedures.....	70
B.6.15. Unclassified procedures and worksharing procedures of type I variations	70
B.7. DOCUMENTS TABLED IN MMD AFTER THE CHMP PLENARY	72
B.7.1. Yearly Line listing for Type I and II variations	72
B.7.2. Monthly Line listing for Type I variations	72
B.7.3. Opinion on Marketing Authorisation transfer (MMD only)	72
B.7.4. Notifications in accordance with Article 61(3) of Council Directive 2001/83/EC (MMD only)	72
B.7.5. Request for supplementary information relating to Notification of Type I variation (MMD only)	72
B.7.6. Notifications of Type I Variations (MMD only).....	72
C. Annex C - Post-Authorisation Measures (PAMs), (Line listing of Post authorisation measures with a description of the PAM. Procedures starting in that given month with assessment timetabled)	72
D. Annex D - Post-Authorisation Measures (PAMs), (Details on PAMs including description and conclusion, for adoption by CHMP in that given month, or finalised ones with PRAC recommendation and no adoption by CHMP needed)	72
E. Annex E - EMA CERTIFICATION OF PLASMA MASTER FILES	72
E.1. PMF Certification Dossiers:.....	73
E.1.1. Annual Update	73
E.1.2. Variations:.....	73
E.1.3. Initial PMF Certification:.....	73
E.2. Timetables – starting & ongoing procedures: For information	73
F. ANNEX F - Decision of the Granting of a Fee Reduction/Fee Waiver	73
G. ANNEX G.....	73
G.1. Final Scientific Advice (Reports and Scientific Advice letters):	73
G.2. PRIME	73
G.2.1. List of procedures concluding at 17-20 May 2021 CHMP plenary:.....	73
G.2.2. List of procedures starting in May 2021 for June 2021 CHMP adoption of outcomes	73
H. ANNEX H - Product Shared Mailboxes – e-mail address	73

A. PRE-SUBMISSION ISSUES

A.1. ELIGIBILITY REQUESTS

Report on Eligibility to Centralised Procedure for May 2021: For adoption	Adopted
----------------------------------------------------------------------------------	---------

A.2. Appointment of Rapporteur / Co-Rapporteur Full Applications

Final Outcome of Rapporteurship allocation for May 2021: For adoption	Adopted
------------------------------------------------------------------------------	---------

A.3. PRE-SUBMISSION ISSUES FOR INFORMATION

Information related to pre-submission of initial applications cannot be released at the present time as these contain commercially confidential information.

B. POST-AUTHORISATION PROCEDURES OUTCOMES

B.1. Annual re-assessment outcomes

B.1.1. Annual reassessment for products authorised under exceptional circumstances

SCENESSE - afamelanotide - EMEA/H/C/002548/S/0035, Orphan Clinuvel Europe Limited, Rapporteur: Janet Koenig, PRAC Rapporteur: Martin Huber	Positive Opinion adopted by consensus together with the CHMP assessment report. The Marketing Authorisation remains under exceptional circumstances. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP opinion.
------------------------------------------------------------------------------------------------------------------------------------------------------	------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

B.2. RENEWALS OF MARKETING AUTHORISATIONS OUTCOMES

B.2.1. Renewals of Marketing Authorisations requiring 2nd Renewal

B.2.2. Renewals of Marketing Authorisations for unlimited validity

Emtricitabine/Tenofovir disoproxil Zentiva - emtricitabine / tenofovir disoproxil - EMEA/H/C/004137/R/0019 Zentiva k.s., Generic, Generic of Truvada, Rapporteur: Alar Irs, PRAC Rapporteur: Ana Sofia Diniz Martins	Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable. Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP Opinion.
--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

<p>Glyxambi - empagliflozin / linagliptin - EMEA/H/C/003833/R/0039 Boehringer Ingelheim International GmbH, Rapporteur: Johann Lodewijk Hillege, Co- Rapporteur: Karin Janssen van Doorn, PRAC Rapporteur: Eva A. Segovia</p>	<p>Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable.</p> <p>Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity.</p> <p>The Icelandic and Norwegian CHMP Members were in agreement with the CHMP Opinion.</p>
<p>IBRANCE - palbociclib - EMEA/H/C/003853/R/0034 Pfizer Europe MA EEIG, Rapporteur: Filip Josephson, Co-Rapporteur: Alexandre Moreau, PRAC Rapporteur: Anette Kirstine Stark</p>	<p>Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable.</p> <p>Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity.</p> <p>The Icelandic and Norwegian CHMP Members were in agreement with the CHMP Opinion.</p>
<p>Ivabradine Zentiva - ivabradine - EMEA/H/C/004117/R/0008 Zentiva k.s., Generic, Generic of Procoralan, Rapporteur: Tomas Radimersky, PRAC Rapporteur: Menno van der Elst Request for Supplementary Information adopted on 20.05.2021.</p>	<p>Request for supplementary information adopted with a specific timetable.</p>
<p>Mysildecard - sildenafil - EMEA/H/C/004186/R/0009 Mylan S.A.S, Generic, Generic of Revatio, Rapporteur: Ondřej Slanař, PRAC Rapporteur: Menno van der Elst Request for Supplementary Information adopted on 22.04.2021.</p>	<p>Positive Opinion adopted by consensus together with the CHMP assessment report.</p> <p>Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity.</p> <p>The Icelandic and Norwegian CHMP Members were in agreement with the CHMP Opinion.</p>
<p>Onivyde pegylated liposomal - irinotecan hydrochloride trihydrate - EMEA/H/C/004125/R/0025, Orphan Les Laboratoires Servier, Rapporteur: Filip Josephson, Co-Rapporteur: Armando Genazzani, PRAC Rapporteur: David Olsen</p>	<p>Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable.</p> <p>Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity.</p> <p>The Icelandic and Norwegian CHMP Members were in agreement with the CHMP Opinion.</p>
<p>Rekovellev - follitropin delta - EMEA/H/C/003994/R/0028</p>	<p>Positive Opinion adopted by consensus together with the CHMP assessment report and</p>

<p>Ferring Pharmaceuticals A/S, Rapporteur: Jean-Michel Race, PRAC Rapporteur: Menno van der Elst</p>	<p>translation timetable.</p> <p>Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity.</p> <p>The Icelandic and Norwegian CHMP Members were in agreement with the CHMP Opinion.</p>
<p>Tenofovir disoproxil Zentiva - tenofovir disoproxil - EMEA/H/C/004120/R/0023 Zentiva k.s., Generic, Generic of Viread, Rapporteur: John Joseph Borg, PRAC Rapporteur: Adrien Inoubli Request for Supplementary Information adopted on 25.03.2021.</p>	<p>Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable.</p> <p>Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity.</p> <p>The Icelandic and Norwegian CHMP Members were in agreement with the CHMP Opinion.</p>
<p>XALKORI - crizotinib - EMEA/H/C/002489/R/0071 Pfizer Europe MA EEIG, Rapporteur: Alexandre Moreau, Co-Rapporteur: Armando Genazzani, PRAC Rapporteur: Tiphaine Vaillant</p>	<p>Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable.</p> <p>Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity.</p> <p>The Icelandic and Norwegian CHMP Members were in agreement with the CHMP Opinion.</p>

B.2.3. Renewals of Conditional Marketing Authorisations

<p>AYVAKYT - avapritinib - EMEA/H/C/005208/R/0007, Orphan Blueprint Medicines (Netherlands) B.V., Rapporteur: Blanca Garcia-Ochoa, Co-Rapporteur: Ingrid Wang, PRAC Rapporteur: Menno van der Elst</p>	<p>Positive Opinion adopted by consensus together with the CHMP assessment report.</p> <p>The CHMP was of the opinion that the renewal for this conditional Marketing Authorisation can be granted.</p> <p>The Marketing Authorisation remains conditional.</p> <p>The Icelandic and Norwegian CHMP Members were in agreement with the CHMP Opinion.</p>
<p>Idefirix - imlifidase - EMEA/H/C/004849/R/0003, Orphan Hansa Biopharma AB, Rapporteur: Martina Weise, PRAC Rapporteur: Menno van der Elst Request for Supplementary Information adopted</p>	<p>Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable.</p> <p>The CHMP was of the opinion that the renewal for this conditional Marketing Authorisation can</p>

on 22.04.2021.	<p>be granted.</p> <p>The Marketing Authorisation remains conditional.</p> <p>The Icelandic and Norwegian CHMP Members were in agreement with the CHMP Opinion.</p>
<p>Veklury - remdesivir - EMEA/H/C/005622/R/0015</p> <p>Gilead Sciences Ireland UC, Rapporteur: Janet Koenig, Co-Rapporteur: Filip Josephson, PRAC Rapporteur: Eva Jirsová</p> <p>Request for Supplementary Information adopted on 25.03.2021.</p>	<p>Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable.</p> <p>The CHMP was of the opinion that the renewal for this conditional Marketing Authorisation can be granted.</p> <p>The Marketing Authorisation remains conditional.</p> <p>The Icelandic and Norwegian CHMP Members were in agreement with the CHMP Opinion.</p>
<p>VITRAKVI - larotrectinib - EMEA/H/C/004919/R/0014</p> <p>Bayer AG, Rapporteur: Filip Josephson, PRAC Rapporteur: Rugile Pilviniene</p> <p>Request for Supplementary Information adopted on 20.05.2021.</p>	<p>Request for supplementary information adopted with a specific timetable.</p>

B.3. POST-AUTHORISATION PHARMACOVIGILANCE OUTCOMES

Signal detection

PRAC recommendations on signals adopted at the PRAC meeting held on 03-06 May 2021
PRAC:

Signal of Sarcoidosis	Adopted
<p>Lemtrada - alemtuzumab</p> <p>Rapporteur: Kirstine Moll Harboe, Co-Rapporteur: Filip Josephson, PRAC Rapporteur: Anette Kirstine Stark</p> <p>PRAC recommendation on a variation</p> <p>Action: For adoption</p>	

Signal of localised swelling in persons with history of dermal filler injections	Adopted
<p>Comirnaty – tozinameran Rapporteur: Filip Josephson, Co-Rapporteur: Jean-Michel Race, PRAC Rapporteur: Menno van der Elst</p>	
<p>PRAC recommendation on a variation Action: For adoption</p>	
Signal of Cardiac arrhythmia	Adopted
<p>Evenity – romosozumab Rapporteur: Kristina Dunder, Co-Rapporteur: Andrea Laslop, PRAC Rapporteur: Tiphaine Vaillant</p>	
<p>PRAC recommendation on a variation Action: For adoption</p>	
Signal of Henoch-Schoenlein purpura	Adopted
<p>Cosentyx – secukinumab Rapporteur: Outi Mäki-Ikola, Co-Rapporteur: Kristina Dunder, PRAC Rapporteur: Eva A. Segovia</p>	
<p>PRAC recommendation on a variation Action: For adoption</p>	
<p>PSUR procedures for which PRAC adopted a recommendation for variation of the terms of the MA at its May 2021 meeting:</p>	
<p>EMA/H/C/PSUSA/00002283/202009 (panitumumab) CAPS: Vectibix (EMA/H/C/000741) (panitumumab), Amgen Europe B.V., Rapporteur: Bjorg Bolstad, PRAC Rapporteur: David Olsen, "29/09/2019 To: 29/09/2020"</p>	<p>The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus, the variation to the terms of the marketing authorisation(s) for the above mentioned medicinal product(s), concerning the following change(s): Update of section 6.6 of the Summary of Product Characteristics in order to add the following statement: Vectibix must be administered using a low protein binding 0.2 or 0.22 micrometre in-line filter, through a peripheral line or indwelling catheter. The Icelandic and the Norwegian CHMP members agree with the above-mentioned recommendation of the CHMP.</p>
EMA/H/C/PSUSA/00002710/202009	The CHMP, having considered in accordance with

<p>(sirolimus) CAPS: Rapamune (EMA/H/C/000273) (sirolimus), Pfizer Europe MA EEIG, Rapporteur: Kristina Dunder, PRAC Rapporteur: Ulla Wändel Liminga, "15/09/2017 To: 14/09/2020"</p>	<p>Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended recommends by consensus the variation to the terms of the marketing authorisation for the above mentioned medicinal product, concerning the following change: Update of 'Other possible interactions' of section 4.5 of the SmPC to add the interaction between sirolimus and letermovir. The Package leaflet is updated accordingly. The Icelandic and the Norwegian CHMP members agree with the above-mentioned recommendation of the CHMP.</p>
<p>EMA/H/C/PSUSA/00002919/202010 (thalidomide) CAPS: Thalidomide Celgene (EMA/H/C/000823) (thalidomide), Celgene Europe BV, Rapporteur: Alexandre Moreau NAPS: NAPs - EU PRAC Rapporteur: Tiphaine Vaillant, "10/10/2019 To 09/10/2020"</p>	<p>The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 and Article 107g(3) of Directive 2001/83/EC the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus, the variation to the terms of the marketing authorisation(s) for the medicinal products containing the above referred active substance(s), concerning the following change(s): Update of section 4.4 of the SmPC to add a warning on thyroid disorders. The Package leaflet is updated accordingly. The Icelandic and the Norwegian CHMP members agree with the above-mentioned recommendation of the CHMP.</p>
<p>EMA/H/C/PSUSA/00010052/202009 (vortioxetine) CAPS: Brintellix (EMA/H/C/002717) (vortioxetine), H. Lundbeck A/S, Rapporteur: Karin Janssen van Doorn, PRAC Rapporteur: Laurence de Fays, "30/09/2019 to 29/09/2020"</p>	<p>The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus, the variation to the terms of the marketing authorisation(s) for the above mentioned medicinal product(s), concerning the following change(s): Update of section 4.8 of the SmPC to add the adverse reactions headache and hyperprolactinaemia with a frequency not known, and hyperhidrosis with a frequency common. The Package leaflet is updated accordingly. The Icelandic and the Norwegian CHMP members agree with the above-mentioned recommendation of the CHMP.</p>
<p>EMA/H/C/PSUSA/00010135/202009 (teriflunomide)</p>	<p>The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the</p>

CAPS:

AUBAGIO (EMA/H/C/002514) (teriflunomide),
sanofi-aventis groupe, Rapporteur: Martina
Weise, PRAC Rapporteur: Martin Huber,
"12/09/2017 To: 12/09/2020"

PSUR on the basis of the PRAC recommendation
and the PRAC assessment report as appended,
recommends by consensus, the variation to the
terms of the marketing authorisation(s) for the
above mentioned medicinal product(s),
concerning the following change(s):

Update of sections 4.4 and 4.8 of the SmPC to
add information on pulmonary hypertension
cases and the adverse reaction pulmonary
hypertension with a frequency not known.
Update of section 4.8 of the SmPC to add the
adverse reactions colitis with a frequency
uncommon. The Package leaflet is updated
accordingly.

The Icelandic and the Norwegian CHMP
members agree with the above-mentioned
recommendation of the CHMP.

EMA/H/C/PSUSA/00010655/202009

(niraparib)

CAPS:

Zejula (EMA/H/C/004249) (niraparib),
GlaxoSmithKline (Ireland) Limited, Rapporteur:
Bjorg Bolstad, PRAC Rapporteur: Jan Neuhauser,
"27/03/2020 To: 26/09/2020"

The CHMP, having considered in accordance with
Article 28 of Regulation (EC) No 726/2004 the
PSUR on the basis of the PRAC recommendation
and the PRAC assessment report as appended,
recommends by consensus the variation to the
terms of the marketing authorisation for the
above mentioned medicinal product, concerning
the following changes:

Update of section 4.8 of the SmPC to add the
adverse reaction cognitive impairment (e.g.,
memory impairment, concentration impairment)
with a frequency of common. Since loss of
concentration influences the ability to drive,
section 4.7 is updated accordingly. The Package
leaflet is updated accordingly.

The Icelandic and the Norwegian CHMP
members agree with the above-mentioned
recommendation of the CHMP.

EMA/H/C/PSUSA/00010733/202009

(galcanezumab)

CAPS:

Emgality (EMA/H/C/004648) (galcanezumab),
Eli Lilly Nederland B.V., Rapporteur: Armando
Genazzani, PRAC Rapporteur: Kirsti Villikka,
"28/03/2020 To: 27/09/2020"

The CHMP, having considered in accordance with
Article 28 of Regulation (EC) No 726/2004 the
PSUR on the basis of the PRAC recommendation
and the PRAC assessment report as appended
recommends by consensus the variation to the
terms of the marketing authorisation(s) for the
above mentioned medicinal product(s),
concerning the following change(s):

Update of section 4.4 of the SmPC to add
information that serious hypersensitivity
reactions occur mainly within 1 day after
galcanezumab administration, however, several
cases have occurred also within days or within
several weeks. The Package leaflet is updated
accordingly.

The Icelandic and the Norwegian CHMP members agree with the above-mentioned recommendation of the CHMP.

B.4. EPARs / WPARs

Abiraterone Krka - abiraterone acetate - EMEA/H/C/005649

KRKA, d.d., Novo mesto, treatment of prostate cancer in adult men, Generic, Generic of Zytiga, Generic application (Article 10(1) of Directive No 2001/83/EC)

For information only. Comments can be sent to the PL in case necessary.

Adtralza - tralokinumab - EMEA/H/C/005255

LEO Pharma A/S, treatment of moderate-to-severe atopic dermatitis in adult patients who are candidates for systemic therapy, New active substance (Article 8(3) of Directive No 2001/83/EC)

For information only. Comments can be sent to the PL in case necessary.

Celsunax - ioflupane (123I) - EMEA/H/C/005135

Pinax Pharma GmbH, is indicated for detecting loss of functional dopaminergic neuron terminals in the striatum, Generic, Generic of DaTSCAN, Generic application (Article 10(1) of Directive No 2001/83/EC)

For information only. Comments can be sent to the PL in case necessary.

Enspryng - satralizumab - EMEA/H/C/004788, Orphan

Roche Registration GmbH, treatment of adult and adolescent patients from 12 years of age with neuromyelitis optica spectrum disorders (NMOSD), New active substance (Article 8(3) of Directive No 2001/83/EC)

For information only. Comments can be sent to the PL in case necessary.

EVKEEZA - evinacumab - EMEA/H/C/005449

Regeneron Ireland Designated Activity Company (DAC), treatment of homozygous familial hypercholesterolemia (HoFH), New active substance (Article 8(3) of Directive No 2001/83/EC)

For information only. Comments can be sent to the PL in case necessary.

Jayempi - azathioprine - EMEA/H/C/005055

Nova Laboratories Ireland Limited, indicated for the prophylaxis of transplant rejection, used as an immunosuppressant antimetabolite, chronic inflammatory bowel disease (IBD) (Crohn's disease or ulcerative colitis), relapsing multiple sclerosis, generalised myasthenia gravis, Hybrid

For information only. Comments can be sent to the PL in case necessary.

application (Article 10(3) of Directive No 2001/83/EC)

Koselugo - selumetinib - EMEA/H/C/005244, Orphan

AstraZeneca AB, treatment of neurofibromatosis type 1 (NF1), New active substance (Article 8(3) of Directive No 2001/83/EC)

For information only. Comments can be sent to the PL in case necessary.

Onureg - azacitidine - EMEA/H/C/004761

Bristol-Myers Squibb Pharma EEIG, treatment for acute myeloid leukaemia, Known active substance (Article 8(3) of Directive No 2001/83/EC)

For information only. Comments can be sent to the PL in case necessary.

B.5. TYPE II VARIATION, WORKSHARING PROCEDURE OUTCOMES

Scopes related to Chemistry, Manufacturing, and Controls cannot be released at the present time as these contain commercially confidential information.

B.5.1. CHMP assessed procedures scope: Pharmaceutical aspects

Adcetris - brentuximab vedotin - EMEA/H/C/002455/II/0088/G, Orphan

Takeda Pharma A/S, Rapporteur: Paula Boudewina van Hennik
Request for Supplementary Information adopted on 20.05.2021.

Request for supplementary information adopted with a specific timetable.

BESPONSA - inotuzumab ozogamicin - EMEA/H/C/004119/II/0020/G, Orphan

Pfizer Europe MA EEIG, Rapporteur: Filip Josephson
Opinion adopted on 06.05.2021.

Positive Opinion adopted by consensus on 06.05.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

Biopoin - epoetin theta - EMEA/H/C/001036/II/0048

TEVA GmbH, Rapporteur: Alexandre Moreau
Request for Supplementary Information adopted on 20.05.2021.

Request for supplementary information adopted with a specific timetable.

COMIRNATY - COVID-19 mRNA vaccine (nucleoside-modified) - EMEA/H/C/005735/II/0027

BioNTech Manufacturing GmbH, Rapporteur: Filip Josephson
Opinion adopted on 27.04.2021.

Positive Opinion adopted by consensus on 27.04.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

COMIRNATY - COVID-19 mRNA vaccine (nucleoside-modified) - EMEA/H/C/005735/II/0028/G

BioNTech Manufacturing GmbH, Rapporteur: Filip Josephson

Positive Opinion adopted by consensus on 07.05.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

Opinion adopted on 07.05.2021.	
Cufence - trientine dihydrochloride - EMEA/H/C/004111/II/0007/G Univar Solutions BV, Rapporteur: Daniela Philadelphia Opinion adopted on 20.05.2021. Request for Supplementary Information adopted on 09.04.2021.	Positive Opinion adopted by consensus on 20.05.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Darunavir Mylan - darunavir - EMEA/H/C/004068/II/0012 Mylan S.A.S, Generic, Generic of Prezista, Rapporteur: John Joseph Borg Opinion adopted on 29.04.2021. Request for Supplementary Information adopted on 25.03.2021, 14.01.2021.	Positive Opinion adopted by consensus on 29.04.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Darzalex - daratumumab - EMEA/H/C/004077/II/0048/G, Orphan Janssen-Cilag International NV, Rapporteur: Sinan B. Sarac Request for Supplementary Information adopted on 20.05.2021.	Request for supplementary information adopted with a specific timetable.
Dupixent - dupilumab - EMEA/H/C/004390/II/0043/G sanofi-aventis groupe, Rapporteur: Jan Mueller-Berghaus Opinion adopted on 20.05.2021.	Positive Opinion adopted by consensus on 20.05.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Efavirenz/Emtricitabine/Tenofovir disoproxil Mylan - efavirenz / emtricitabine / tenofovir disoproxil - EMEA/H/C/004240/II/0015/G Mylan S.A.S, Generic, Generic of Atripla, Rapporteur: Bruno Sepodes Request for Supplementary Information adopted on 20.05.2021.	Request for supplementary information adopted with a specific timetable.
Elonva - corifollitropin alfa - EMEA/H/C/001106/II/0055 Merck Sharp & Dohme B.V., Rapporteur: Paula Boudewina van Hennik Opinion adopted on 06.05.2021. Request for Supplementary Information adopted on 25.03.2021.	Positive Opinion adopted by consensus on 06.05.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Elonva - corifollitropin alfa - EMEA/H/C/001106/II/0057 Merck Sharp & Dohme B.V., Rapporteur: Paula Boudewina van Hennik Opinion adopted on 06.05.2021. Request for Supplementary Information adopted	Positive Opinion adopted by consensus on 06.05.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

on 25.03.2021.	
Eporatio - epoetin theta - EMA/H/C/001033/II/0047 ratiopharm GmbH, Rapporteur: Alexandre Moreau Request for Supplementary Information adopted on 20.05.2021.	Request for supplementary information adopted with a specific timetable.
EVRA - ethinylestradiol / norelgestromin - EMA/H/C/000410/II/0048/G Janssen-Cilag International NV, Rapporteur: Paula Boudewina van Hennik Request for Supplementary Information adopted on 20.05.2021, 14.01.2021.	Request for supplementary information adopted with a specific timetable.
HBVAXPRO - hepatitis B vaccine (rDNA) - EMA/H/C/000373/II/0071/G MSD Vaccins, Rapporteur: Jan Mueller-Berghaus Opinion adopted on 29.04.2021.	Positive Opinion adopted by consensus on 29.04.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Herzuma - trastuzumab - EMA/H/C/002575/II/0038 Celltrion Healthcare Hungary Kft., Rapporteur: Jan Mueller-Berghaus Request for Supplementary Information adopted on 20.05.2021.	Request for supplementary information adopted with a specific timetable.
HyQvia - human normal immunoglobulin - EMA/H/C/002491/II/0068/G Baxalta Innovations GmbH, Rapporteur: Jan Mueller-Berghaus Request for Supplementary Information adopted on 20.05.2021.	Request for supplementary information adopted with a specific timetable.
IMVANEX - smallpox vaccine (live modified vaccinia virus Ankara) - EMA/H/C/002596/II/0064 Bavarian Nordic A/S, Rapporteur: Jan Mueller-Berghaus Request for Supplementary Information adopted on 20.05.2021.	Request for supplementary information adopted with a specific timetable.
Luveris - lutropin alfa - EMA/H/C/000292/II/0089 Merck Europe B.V., Rapporteur: Kirstine Moll Harboe Opinion adopted on 06.05.2021.	Positive Opinion adopted by consensus on 06.05.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
MenQuadfi - meningococcal group a, c, w135 and y conjugate vaccine - EMA/H/C/005084/II/0001/G Sanofi Pasteur, Rapporteur: Andrea Laslop Opinion adopted on 20.05.2021.	Positive Opinion adopted by consensus on 20.05.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

Request for Supplementary Information adopted on 09.04.2021.

**Myalepta - metreleptin -
EMA/H/C/004218/II/0017/G, Orphan**
Amryt Pharmaceuticals DAC, Rapporteur: Karin Janssen van Doorn
Opinion adopted on 06.05.2021.
Request for Supplementary Information adopted on 04.02.2021.

Positive Opinion adopted by consensus on 06.05.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

**Ogivri - trastuzumab -
EMA/H/C/004916/II/0028**
Mylan S.A.S, Rapporteur: Karin Janssen van Doorn
Request for Supplementary Information adopted on 20.05.2021.

Request for supplementary information adopted with a specific timetable.

**Pergoveris - follitropin alfa / lutropin alfa -
EMA/H/C/000714/II/0072**
Merck Europe B.V., Rapporteur: Kirstine Moll Harboe
Opinion adopted on 29.04.2021.

Positive Opinion adopted by consensus on 29.04.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

**Resolor - prucalopride -
EMA/H/C/001012/II/0052**
Shire Pharmaceuticals Ireland Limited, Rapporteur: Kristina Dunder
Request for Supplementary Information adopted on 20.05.2021.

Request for supplementary information adopted with a specific timetable.

**Ruconest - conestat alfa -
EMA/H/C/001223/II/0063**
Pharming Group N.V, Rapporteur: Andrea Laslop
Opinion adopted on 20.05.2021.

Positive Opinion adopted by consensus on 20.05.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

**Vaxelis - diphtheria, tetanus, pertussis (acellular, component), hepatitis B (rDNA), poliomyelitis (inact.) and Haemophilus type b conjugate vaccine (adsorbed) -
EMA/H/C/003982/II/0076/G**
MCM Vaccine B.V., Rapporteur: Christophe Focke
Opinion adopted on 20.05.2021.

Positive Opinion adopted by consensus on 20.05.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

**Vaxzevria - COVID 19 Vaccine (ChAdOx1 S [recombinant]) -
EMA/H/C/005675/II/0016**
AstraZeneca AB, Rapporteur: Sol Ruiz
Request for Supplementary Information adopted on 12.05.2021.

Request for supplementary information adopted with a specific timetable.

Vaxzevria - COVID 19 Vaccine (ChAdOx1 S [recombinant]) -

Positive Opinion adopted by consensus on 12.05.2021. The Icelandic and Norwegian CHMP

EMA/H/C/005675/II/0018 AstraZeneca AB, Rapporteur: Sol Ruiz Opinion adopted on 12.05.2021.	Members were in agreement with the CHMP recommendation.
WS1981 Abseamed-EMA/H/C/000727/WS1981/0093 Binocrit-EMA/H/C/000725/WS1981/0092 Epoetin alfa Hexal-EMA/H/C/000726/WS1981/0092 Sandoz GmbH, Lead Rapporteur: Alexandre Moreau Opinion adopted on 20.05.2021. Request for Supplementary Information adopted on 11.03.2021.	Positive Opinion adopted by consensus on 20.05.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
WS2012/G Infanrix hexa-EMA/H/C/000296/WS2012/0297/G GlaxoSmithkline Biologicals SA, Lead Rapporteur: Christophe Focke Opinion adopted on 20.05.2021.	Positive Opinion adopted by consensus on 20.05.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
WS2018/G Ambirix-EMA/H/C/000426/WS2018/0114/G Twinrix Adult-EMA/H/C/000112/WS2018/0149/G Twinrix Paediatric-EMA/H/C/000129/WS2018/0150/G GlaxoSmithkline Biologicals SA, Lead Rapporteur: Christophe Focke Opinion adopted on 20.05.2021.	Positive Opinion adopted by consensus on 20.05.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

B.5.2. CHMP assessed procedures scope: Non-Clinical and Clinical aspects

Akynzeo - fosnetupitant / netupitant / palonosetron - EMA/H/C/003728/II/0034 Helsinn Birex Pharmaceuticals Limited, Rapporteur: Peter Kiely, "Submission of the results of the in vitro study assessing the ability of fosnetupitant to inhibit all UGTs of interest: UGT1A1, 1A3, 1A4, 1A6, 1A9, and 2B7 following a recommendation from the CHMP. Update of section 4.5 of the SmPC in order to include a warning on the concomitant use of fosnetupitant with oral substrates of UGT2B7/UGT2B15."	Positive Opinion adopted by consensus on 20.05.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	-----------------------------------------------------------------------------------------------------------------------------------------------

Opinion adopted on 20.05.2021.
Request for Supplementary Information adopted
on 25.03.2021.

**Alecensa - alectinib -
EMA/H/C/004164/II/0034**

Roche Registration GmbH, Rapporteur: Filip Josephson, "Update of section 4.8 of the SmPC in order to add haemolytic anaemia to the list of adverse drug reactions (ADRs) with frequency common, based on a report of cumulative safety data (DSR1104210); the Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to bring the PI in line with the latest QRD template version 10.2. Moreover, the MAH took the opportunity to introduce editorial changes in the Greek, Swedish, Dutch, Danish, Latvian, Croatian, Portuguese and Czech PI." Request for Supplementary Information adopted on 20.05.2021.

Request for supplementary information adopted with a specific timetable.

**Brilique - ticagrelor -
EMA/H/C/001241/II/0050**

AstraZeneca AB, Rapporteur: Johann Lodewijk Hillege, "Update of the SmPC in order to add central sleep apnoea including Cheyne-Stokes respiration as a new warning in section 4.4. and in the list of adverse drug reactions (ADRs) section 4.8 with frequency not known, following collection of post-marketing data; the Package Leaflet is updated accordingly." Request for Supplementary Information adopted on 20.05.2021.

Request for supplementary information adopted with a specific timetable.

**Brineura - cerliponase alfa -
EMA/H/C/004065/II/0029, Orphan**

BioMarin International Limited, Rapporteur: Martina Weise, "The postponement of the submission date of the final CSR for Study BMN190-202 ." Opinion adopted on 29.04.2021.

Positive Opinion adopted by consensus on 29.04.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

**Calquence - acalabrutinib -
EMA/H/C/005299/II/0004**

AstraZeneca AB, Rapporteur: Filip Josephson, "Submission of the final report of the nonclinical study 20266648 (5336BV) (Acalabrutinib: Neutral Red Uptake Phototoxicity Assay in BALB/c 3T3 Mouse Fibroblasts), in response to the CHMP recommendation to submit results from a modified 3T3 NRU phototoxicity study with adjusted wavelengths. This variation does not propose amendments to the PI."

Request for supplementary information adopted with a specific timetable.

Request for Supplementary Information adopted on 20.05.2021.

COMIRNATY - COVID-19 mRNA vaccine (nucleoside-modified) - EMEA/H/C/005735/II/0023/G

BioNTech Manufacturing GmbH, Rapporteur: Filip Josephson
Opinion adopted on 20.05.2021.

Positive Opinion adopted by consensus on 20.05.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

Darzalex - daratumumab - EMEA/H/C/004077/II/0047, Orphan

Janssen-Cilag International NV, Rapporteur: Sinan B. Sarac, "C.I.4
Update of section 4.4 of the SmPC in order to include a fatal outcome for IRRs following a systematic cross-programmatic review of fatal cases of Infusion Related Reaction (IRR) with use of daratumumab. In addition, the MAH has taken the opportunity to correct in section 4.8 the reported incidence rate of Grade 3 or 4 treatment-emergent infections from study MMY3003 for DRd from 27% to 28%."
Opinion adopted on 20.05.2021.
Request for Supplementary Information adopted on 09.04.2021.

Positive Opinion adopted by consensus on 20.05.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

Deltyba - delamanid - EMEA/H/C/002552/II/0048, Orphan

Otsuka Novel Products GmbH, Rapporteur: Christophe Focke, "Update of section 5.1 of the SmPC in order to include information on epidemiological cut-off and clinical breakpoint. In addition, the MAH took the opportunity to propose an editorial update in Annex II and Spanish translation of SmPC section 4.8."
Opinion adopted on 29.04.2021.
Request for Supplementary Information adopted on 11.03.2021.

Positive Opinion adopted by consensus on 29.04.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

Dengvaxia - dengue tetravalent vaccine (live, attenuated) - EMEA/H/C/004171/II/0013

Sanofi Pasteur, Rapporteur: Christophe Focke, "To update sections 4.2, 4.8 and 5.1 of the SmPC in order to introduce a new posology regimen from 3 doses to 2 doses for individuals from 9 years of age based on interim results from study CYD65 listed as a category 3 study in the RMP; this is a Phase II, observer-blind, placebo-controlled trial in order to assess Immunogenicity and Safety of Tetravalent Dengue Vaccine Given in 1-, 2-, or 3-Dose

Request for supplementary information adopted with a specific timetable.

See 9.1

Schedules Followed by a Single Booster; section 3 of the Package Leaflet is updated accordingly.”
Request for Supplementary Information adopted on 20.05.2021, 10.12.2020.

Dovato - dolutegravir / lamivudine - EMEA/H/C/004909/II/0019
ViiV Healthcare B.V., Rapporteur: Filip Josephson, “Update of section 5.1 of the SmPC in order to add data on efficacy and safety in treatment experienced, virologically suppressed subjects switching to the Dovato fixed dose combination tablet, based on the week 96 data results from the Phase III study 204862 (TANGO).”
Opinion adopted on 20.05.2021.

Positive Opinion adopted by consensus on 20.05.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

Dovato - dolutegravir / lamivudine - EMEA/H/C/004909/II/0020
ViiV Healthcare B.V., Rapporteur: Filip Josephson, “Update of section 4.8 in order to add new safety information regarding hepatic safety and section 5.1 to include long-term efficacy and safety information, based on studies 204861 (GEMINI-1) and 205543 (GEMINI-2), listed as category 3 studies in the RMP. GEMINI-1 and GEMINI-2 were Phase III, randomised, double-blind, multicentre, parallel group, non-inferiority studies evaluating the efficacy, safety, and tolerability of dolutegravir plus lamivudine compared to dolutegravir plus tenofovir/emtricitabine in HIV-1-infected treatment-naïve adults. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet.”
Opinion adopted on 20.05.2021.

Positive Opinion adopted by consensus on 20.05.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

Dupixent - dupilumab - EMEA/H/C/004390/II/0039
sanofi-aventis groupe, Rapporteur: Jan Mueller-Berghaus, “Update of section 4.8 of the SmPC based on submission of a pooled analysis of 12 safety studies in order to replace the existing adverse drug reactions (ADRs) listed per indication by a consolidated table of ADRs for all dupilumab indications as agreed in the latest PSUR (EMA/H/C/PSUSA/00010645/202003). The Package Leaflet is updated accordingly.”
Opinion adopted on 20.05.2021.
Request for Supplementary Information adopted

Positive Opinion adopted by consensus on 20.05.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

on 28.01.2021.

**Dupixent - dupilumab -
EMA/H/C/004390/II/0044**

sanofi-aventis groupe, Rapporteur: Jan Mueller-Berghaus, "C.I.4 – Update of section 4.8 of the SmPC to include the long-term safety data of dupilumab in adult patients with moderate to severe AD, following interim results from the OLE study (R668-AD-1225) listed as category 3 study in the RMP."

Request for Supplementary Information adopted on 20.05.2021.

Request for supplementary information adopted with a specific timetable.

**Erleada - apalutamide -
EMA/H/C/004452/II/0013**

Janssen-Cilag International N.V., Rapporteur: Blanca Garcia-Ochoa, "Update of sections 4.6 and 5.3 of the SmPC in order to update information on pregnancy and update non-clinical information following results of a developmental toxicity study in rats."

Request for Supplementary Information adopted on 06.05.2021.

Request for supplementary information adopted with a specific timetable.

**Fasenra - benralizumab -
EMA/H/C/004433/II/0031**

AstraZeneca AB, Rapporteur: Fátima Ventura, "C.I.13: Submission of the final report from study D3250C00037 (MELTEMI), listed as a category 3 study in the RMP. This is an open-label safety extension study to evaluate the safety and tolerability of a fixed 30 mg dose of benralizumab s.c. in severe asthma patients." Request for Supplementary Information adopted on 06.05.2021, 11.02.2021.

Request for supplementary information adopted with a specific timetable.

**Genvoya - elvitegravir / cobicistat /
emtricitabine / tenofovir alafenamide -
EMA/H/C/004042/II/0070/G**

Gilead Sciences Ireland UC, Rapporteur: Bruno Sepodes, "- C.I.4 (Type II): Update of section 4.5 of the SmPC to include data on the drug-drug interaction between Genvoya and the thienopyridine anti-platelet drugs clopidogrel and prasugrel, based on a MAH cumulative safety review. The Package Leaflet is updated accordingly.

- C.I.4 (Type II): Update of section 4.5 of the SmPC to include data on the drug-drug interaction between Genvoya and medicinal products or oral supplements containing polyvalent cations, based on a MAH cumulative

Positive Opinion adopted by consensus on 20.05.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

safety review. The Package Leaflet is updated accordingly.

In addition, the Marketing Authorisation Holder (MAH) took the opportunity to correct the amount of lactose stated in section 2 of the SmPC and make minor editorial changes throughout the PI."

Opinion adopted on 20.05.2021.

Request for Supplementary Information adopted on 11.03.2021, 10.12.2020.

**Imfinzi - durvalumab -
EMA/H/C/004771/II/0028**

AstraZeneca AB, Rapporteur: Sinan B. Sarac, "Submission of the final analyses of the CASPIAN study for the Durvalumab (D) + Tremelimumab (T) + etoposide-platinum chemotherapy (EP) vs. EP treatment comparison as recommended by the CHMP in the context of procedure EMA/H/C/004771/II/0014/G. In addition, the MAH submits the results from the China Cohort incorporated in the CASPIAN study. This is an interventional study investigating the efficacy and safety of D ± T in combination with etoposide and either carboplatin or cisplatin for the first-line treatment of patients with extensive-stage small cell lung cancer (ES-SCLC)."

Opinion adopted on 29.04.2021.

Positive Opinion adopted by consensus on 29.04.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

**Kineret - anakinra -
EMA/H/C/000363/II/0080/G**

Swedish Orphan Biovitrum AB (publ), Rapporteur: Kirstine Moll Harboe, "Update of section 4.4 of the SmPC in order to include new safety information about Macrophage activation syndrome (MAS) in the 'serious infections' subsection and to update the 'pulmonary events' and the 'malignancies' subsections with new safety information.

Update of section 4.8 of the SmPC to amend the summary of safety profile, the 'serious infections', the 'neutropenia', 'allergic reactions', 'immunogenicity', 'paediatric population' and the 'injection site reactions' subsections with new safety information.

Update of section 5.1 of the SmPC to update the clinical efficacy and safety information in Still's disease.

The updates proposed are based on the results from study Sobi.ANAKIN-301 (evaluated in

Request for supplementary information adopted with a specific timetable.

procedure no. EMA/H/C/000363/P46/031) and Sobi.ANAKIN-302 (evaluated in procedure no. EMA/H/C/000363/II/0073).

Sobi.ANAKIN-301 was a randomised, double-blind, placebo-controlled, multicenter, phase 3 study to evaluate the efficacy, safety, pharmacokinetics and immunogenicity of anakinra as compared to placebo in newly diagnosed Still's disease patients (including systemic juvenile idiopathic arthritis [SJIA] and adult-onset Still's disease [AOSD]).

Sobi.ANAKIN-302 was a non-interventional, post-authorisation safety study to evaluate long-term safety of anakinra in patients with SJIA."

In addition, the MAH took the opportunity to correct in section 4.8 of the SmPC the frequency of the adverse reaction 'skin and subcutaneous tissue disorder' from 'very common' to 'uncommon'."

Request for Supplementary Information adopted on 06.05.2021.

LEDAGA - chlormethine - EMEA/H/C/002826/II/0027, Orphan
Helsinn Birex Pharmaceuticals Limited,
Rapporteur: Sinan B. Sarac, "Update of section 4.2 of the SmPC in order to allow flexibility in the starting frequency of the treatment based on current clinical practice; the Package Leaflet is updated accordingly."
Request for Supplementary Information adopted on 20.05.2021.

Request for supplementary information adopted with a specific timetable.

See 9.1

Lynparza - olaparib - EMEA/H/C/003726/II/0044
AstraZeneca AB, Rapporteur: Alexandre Moreau, "Update of sections 4.8 and 5.1 of the SmPC of Lynparza tablets based on updated efficacy and safety data from the Phase III PAOLA-1 study. In addition, the MAH took the opportunity to switch the order of the capsule and tablet formulations in Annex I of the PI."
Opinion adopted on 06.05.2021.
Request for Supplementary Information adopted on 11.03.2021.

Positive Opinion adopted by consensus on 06.05.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

Lynparza - olaparib - EMEA/H/C/003726/II/0045
AstraZeneca AB, Rapporteur: Alexandre Moreau, "Update of section 5.1 of the SmPC of Lynparza capsules based on the final report from

Positive Opinion adopted by consensus on 06.05.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

study/D0816C00012 (ORZORA) listed as PAES in the Annex II of the Product Information. This is an Open Label, Single Arm, Multi-centre Study to Assess the Clinical Effectiveness and Safety of Lynparza (Olaparib) Capsules Maintenance Monotherapy in Platinum Sensitive Relapsed somatic or germline BRCA Mutated Ovarian Cancer Patients who are in Complete or Partial Response Following Platinum based Chemotherapy. The Annex II is updated accordingly."

Opinion adopted on 06.05.2021.

Request for Supplementary Information adopted on 18.03.2021.

**Mavenclad - cladribine -
EMA/H/C/004230/II/0016**

Request for supplementary information adopted with a specific timetable.

Merck Europe B.V., Rapporteur: Kirstine Moll Harboe, "C.I.4 Update of section 4.8 of the SmPC in order to add hypersensitivity to the list of adverse drug reactions (ADRs) with frequency "common" based on a review of cumulative clinical and post-marketing data. The Package Leaflet is updated accordingly."

Request for Supplementary Information adopted on 20.05.2021, 14.01.2021.

**Nerlynx - neratinib -
EMA/H/C/004030/II/0021**

Request for supplementary information adopted with a specific timetable.

Pierre Fabre Medicament, Rapporteur: Bruno Sepodes, "Update of sections 5.3 and 6.6 of the SmPC based on an updated environmental risk assessment including ERA studies"

Request for Supplementary Information adopted on 20.05.2021.

**Ondexxya - andexanet alfa -
EMA/H/C/004108/II/0003**

Request for supplementary information adopted with a specific timetable.

Alexion Europe SAS, Rapporteur: Jan Mueller-Berghaus, "Submission of the final report from Population PK and PK/PD Modelling Report (POR-PKPD-ADEX-321) listed as a category 2 study in the RMP/Specific Obligation 004 in Annex II."

See 9.1

Request for Supplementary Information adopted on 20.05.2021, 25.02.2021, 28.05.2020, 12.12.2019.

**Phesgo - pertuzumab / trastuzumab -
EMA/H/C/005386/II/0002**

Request for supplementary information adopted with a specific timetable.

Roche Registration GmbH, Rapporteur: Sinan B. Sarac, "Update of sections 4.2, 4.8 and 5.1 of the SmPC in order to support the safety of

switching from intravenous to subcutaneous route of administration or vice versa, based on results from study MO40628; this is a Phase II, randomised, open-label, cross-over study to assess preference for intravenous or subcutaneous route of administration in patients with HER2-positive early breast cancer.”
Request for Supplementary Information adopted on 29.04.2021.

**Sunosi - solriamfetol -
EMA/H/C/004893/II/0009**

Jazz Pharmaceuticals Ireland Limited,
Rapporteur: Janet Koenig, “Update of section 4.8 of the SmPC in order to add hypersensitivity reactions to the list of adverse drug reactions (ADRs) following confirmation of a post-marketing safety signal for hypersensitivity. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to implement editorial changes and to bring the PI in line with the latest QRD template version 10.2.”
Request for Supplementary Information adopted on 29.04.2021.

Request for supplementary information adopted with a specific timetable.

**Tecentriq - atezolizumab -
EMA/H/C/004143/II/0058**

Roche Registration GmbH, Rapporteur: Sinan B. Sarac, “C.I.4
Update of section 5.1 of the SmPC in order to include the updated efficacy results from study YO40245 (IMbrave150) with a data cut-off of 31 August 2020 as recommended by the CHMP in the context of variation
EMA/H/C/004143/II/0039; IMbrave 150 is a Phase III, open-label, multicenter, randomized, two-arm pivotal study designed to evaluate the efficacy and safety of atezolizumab + bevacizumab versus sorafenib in patients with locally advanced or metastatic hepatocellular carcinoma who had not received prior systemic treatment.
In addition, the MAH took the opportunity to clarify in section 4.4 of the SmPC that the exclusion of patients with hepatitis B or hepatitis C infection only applies to non-HCC patients.”
Opinion adopted on 06.05.2021.

Positive Opinion adopted by consensus on 06.05.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

**Tecentriq - atezolizumab -
EMA/H/C/004143/II/0059**

Roche Registration GmbH, Rapporteur: Sinan B.

Positive Opinion adopted by consensus on 20.05.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP

<p>Sarac, "C.I.13: Submission of the final report from study MO39196 (IMpassion131), a phase III, multicenter, randomized, placebo-controlled study of Tecentriq in combination with paclitaxel in 1L metastatic triple negative breast cancer as recommended by the CHMP during procedure EMEA/H/C/004143/X/0017</p> <p>The requested variation proposed no amendments to the Product Information."</p> <p>Opinion adopted on 20.05.2021.</p>	<p>recommendation.</p>
<p>Tecentriq - atezolizumab - EMEA/H/C/004143/II/0060</p> <p>Roche Registration GmbH, Rapporteur: Sinan B. Sarac, "C.I.4</p> <p>Update of section 4.2 of the SmPC in order to harmonise the atezolizumab posology regimen of 840 mg every 2 weeks, 1200 mg every 3 weeks and 1680 mg every 4 weeks administered as an IV infusion across the currently authorised indications of NSCLC, ES-SCLC, TNBC and HCC, based on PK modelling and simulation data.</p> <p>As a consequence of the harmonised dose schedules, the MAH is applying for a combined SmPC and PL.</p> <p>In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet and to include minor editorial changes to the PI."</p> <p>Request for Supplementary Information adopted on 20.05.2021.</p>	<p>Request for supplementary information adopted with a specific timetable.</p>
<p>Triumeq - dolutegravir / abacavir / lamivudine - EMEA/H/C/002754/II/0091</p> <p>ViiV Healthcare B.V., Rapporteur: Filip Josephson, "Update of sections 4.2, 4.4 and 4.5 of the SmPC to include information on administration of an additional dose of 50 mg dolutegravir when Triumeq is co-administered with strong enzyme inducing drugs, sections 4.4 and 4.5 to include information on co-administration of Triumeq and supplements or multivitamins containing calcium, iron or magnesium when taken with food and section 5.2 to include information on the elimination half-life of lamivudine. The Package Leaflet is updated accordingly. These changes follow the CHMP request to align the Product Information of Triumeq and Dovato, made at the time of recommending the initial marketing authorisation of Dovato. In addition, the MAH</p>	<p>Positive Opinion adopted by consensus on 20.05.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.</p>

took the opportunity to update the details of the Northern Ireland local representative in line with the QRD template v. 10.2.”
Opinion adopted on 20.05.2021.

Vaxzevria - COVID 19 Vaccine (ChAdOx1 S [recombinant]) -

EMA/H/C/005675/II/0017/G

AstraZeneca AB, Rapporteur: Sol Ruiz, “C.I.4 (type II) - Update of section 4.6 of the SmPC in order to add the high-level results from the development and reproductive toxicity (DART) study (study number 490843).

C.I.4 (type II) - Update of section 5.3 of the SmPC in order to add the high-level results from the biodistribution study (study number 514559), listed as an imposed study in Annex II.

The MAH is taking the opportunity to update the wording of section 5.3 of the SmPC to add the results from the already assessed repeat-dose toxicity study. Moreover, the MAH is taking the opportunity to address the nonclinical recommendations adopted during the initial CMA application.”

Request for Supplementary Information adopted on 20.05.2021.

Request for supplementary information adopted with a specific timetable.

See 9.1

Venclyxto - venetoclax -

EMA/H/C/004106/II/0031

AbbVie Deutschland GmbH & Co. KG, Rapporteur: Filip Josephson, “to update venetoclax SmPC wording regarding Tumor lysis syndrome (TLS) prophylaxis and management following an update to the Company Core Data Sheet (CCDS), as well as to amend annex II.D to propose additional risk minimisation measures in the form of Patient Card implementation and Direct Healthcare Professional Communication (DHPC) distribution as result of a medical safety assessment conducted on TLS post-marketing reports. The Package leaflet and RMP have also been updated accordingly.

The proposed changes to the SmPC include section 4.2 and 4.4:

- Section 4.2: A more prescriptive table which replaces the text around the risk assessment, prophylaxis and monitoring measures based on the level of tumor burden. In addition, the text on the recommended dose modifications for toxicities is replaced by a table

Positive Opinion adopted by consensus on 20.05.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

format for clarity.

- Section 4.4: the text is revised to emphasize the fact that TLS occur in all patients and requires adequate risk assessment that considers comorbidities, particularly renal impairment, and other risk factors such as splenomegaly.

Annex A has also been updated at request of EMA.”

Opinion adopted on 20.05.2021.

Request for Supplementary Information adopted on 25.03.2021, 25.02.2021, 12.11.2020.

**Verzenios - abemaciclib -
EMA/H/C/004302/II/0016/G**

Eli Lilly Nederland B.V., Rapporteur: Filip Josephson, “Update of section 5.1 of the SmPC in order to include OS interim results from MONARCH 3 study, a randomised, double blind, placebo controlled phase 3 study in women with HR positive, HER2 negative locally advanced or metastatic breast cancer who had not received prior systemic therapy in this disease setting. In addition, the MAH is updating the ATC code in the SmPC. The MAH is also taking the opportunity to update the list of local representatives in the Package Leaflet in line with the QRD template 10.2.”

Opinion adopted on 20.05.2021.

Positive Opinion adopted by consensus on 20.05.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

**Vfend - voriconazole -
EMA/H/C/000387/II/0142/G**

Pfizer Europe MA EEIG, Rapporteur: Johann Lodewijk Hillege, “Update of sections 4.3, 4.4 and 4.5 of the SmPC in order to add new contraindications to naloxegol and tolvaptan and add a Drug-Drug Interaction with lurasidone, include clarification text regarding adrenal insufficiency and Cushing's syndrome to the warnings and precautions for use, and re-order some of the drug-drug interaction information, respectively. The Package Leaflet is updated accordingly.

In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet and to correct an oversight from a previous procedure in the labelling (addition of the excipient sodium benzoate in section 3 of the outer and inner label for the Powder for oral suspension in line with SmPC section 2 and PL sections 2 and 6).”

Request for Supplementary Information adopted

Request for supplementary information adopted with a specific timetable.

on 20.05.2021.

WS1990

Combivir-EMA/H/C/000190/WS1990/0099

Dovato-EMA/H/C/004909/WS1990/0018

Epivir-EMA/H/C/000107/WS1990/0115

Kivexa-EMA/H/C/000581/WS1990/0088

Triumeq-EMA/H/C/002754/WS1990/0087

Trizivir-EMA/H/C/000338/WS1990/0120

ViiV Healthcare B.V., Lead Rapporteur: Jean-Michel Race, "Update of sections 4.2 and 5.2 of the SmPC to revise the information about use of the products in patients with renal impairment." Request for Supplementary Information adopted on 20.05.2021, 25.03.2021.

Request for supplementary information adopted with a specific timetable.

WS1995

Afinitor-EMA/H/C/001038/WS1995/0069

Votubia-EMA/H/C/002311/WS1995/0068

Novartis Europharm Limited, Lead Rapporteur: Janet Koenig, "Update of the Afinitor and Votubia SmPCs to include radiation recall syndrome as an adverse drug reaction observed in the post-marketing phase with unknown frequency (section 4.8) and a cautionary text regarding radiation therapy complications in 'Special warnings and precautions for use' (section 4.4). Corresponding changes are also made to the package leaflets. Taking the opportunity, the MAH also proposes some editorial changes to harmonise the information in Afinitor and Votubia labels in SmPC (section 4.7) 'Effects on ability to drive and use machines' and Package leaflet '(Afinitor/Votubia) with food and drink.' Afinitor label is further updated in compliance with the QRD template version 10.1, while Votubia label was already updated within the procedure II/061."

Opinion adopted on 20.05.2021.

Request for Supplementary Information adopted on 25.03.2021.

Positive Opinion adopted by consensus on 20.05.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

B.5.3. CHMP-PRAC assessed procedures

Aimovig - erenumab -

Positive Opinion adopted by consensus on

EMA/H/C/004447/II/0013/G

Novartis Europharm Limited, Rapporteur: Kristina Dunder, PRAC Rapporteur: Kirsti Villikka, "Update of section 4.8 of the SmPC in line with revised clinical safety data. Submission of the study report from 5-year open-label study 20120178 with consequential changes to the section 4.8 and section 5.1 of the SmPC as well as an update of the EU RMP. Type IA variation to include the ATC code for erenumab. The Package Leaflet is updated accordingly."

Opinion adopted on 06.05.2021.

Request for Supplementary Information adopted on 09.04.2021, 11.02.2021.

06.05.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

CRYSVITA - burosumab -**EMA/H/C/004275/II/0021, Orphan**

Kyowa Kirin Holdings B.V., Rapporteur: Kristina Dunder, PRAC Rapporteur: Brigitte Keller-Stanislawski, "Update of section 4.2 of the SmPC in order to modify administration instructions to include the option of self/carer-administration based on results from two Phase 3 interventional clinical safety and efficacy studies; study KRN23-003 in paediatric patients (final study report) and study KRN23-004 in adult patients (interim report). The Package Leaflet has been updated accordingly and a new section with instructions for use has been added at the end. In addition, the MAH took the opportunity to implement editorial changes in the SmPC, labelling and Package Leaflet. The updated RMP version 3.1 was agreed during the procedure."

Opinion adopted on 06.05.2021.

Request for Supplementary Information adopted on 11.02.2021.

Positive Opinion adopted by consensus on 06.05.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

Eylea - aflibercept -**EMA/H/C/002392/II/0069**

Bayer AG, Rapporteur: Alexandre Moreau, PRAC Rapporteur: Adrien Inoubli, "This type II variation under category C.1.4 is to update the Posology section 4.2 of the Product Information for the indication DME based on results from the PAES VIOLET (study 17613; EMA/H/C/002392/ANX/011); and to include study data to EU-PI section 5.1. The submission package also contains the AQUA CSR, a phase 4 study which served as run-in study for VIOLET."

Opinion adopted on 20.05.2021.

Positive Opinion adopted by consensus on 20.05.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

Request for Supplementary Information adopted on 25.02.2021.

Lamzede - velmanase alfa -

EMA/H/C/003922/II/0018, Orphan

Chiesi Farmaceutici S.p.A., Rapporteur: Johann

Lodewijk Hillege, PRAC Rapporteur: Jan

Neuhauser, "Type II C.I.4

Update of sections 4.4, 4.8 and 5.1 of the SmPC in order to amend an existing warning on immunogenicity, update the summary of the safety profile, add cyanosis to the list of adverse drug reactions (ADRs) with frequency 'common', add the information that the safety profile observed in children under age 6 is consistent with what was observed in previous studies, and update of the pharmacodynamic properties. These proposed SmPC updates are based on the final results of rhLAMAN-08 study, which is listed as an Annex II study in the RMP, and is a 24-month multi-center, open-label phase II trial investigating the safety and efficacy of repeated velmanase alfa (recombinant human alpha-mannosidase) treatment in paediatric patients <6 years of age with alpha-mannosidosis. The Package Leaflet is being updated accordingly. The RMPv8.1 has also been submitted. In addition, the MAH took the opportunity to bring the PI in line with QRD template v10.1 and v10.2."

Request for Supplementary Information adopted on 20.05.2021.

Request for supplementary information adopted with a specific timetable.

Nplate - romiplostim -

EMA/H/C/000942/II/0079

Amgen Europe B.V., Rapporteur: Maria

Concepcion Prieto Yerro, PRAC Rapporteur: Eva

A. Segovia, "Update of section 4.8 of the SmPC to add Anaphylactic reaction to the list of adverse drug reactions (ADRs) with frequency to be determined in the evaluation of the variation. The package leaflet has been amended accordingly."

Request for Supplementary Information adopted on 06.05.2021.

Request for supplementary information adopted with a specific timetable.

OFEV - nintedanib -

EMA/H/C/003821/II/0040

Boehringer Ingelheim International GmbH,

Rapporteur: Peter Kiely, PRAC Rapporteur:

Nikica Mirošević Skvrce, "Update of sections 4.8 and 4.4 of the SmPC in order to add "nephrotic range proteinuria" as a new adverse drug

Positive Opinion adopted by consensus on 06.05.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

reaction with a frequency of “uncommon” for “Idiopathic pulmonary fibrosis (IPF)” and “Other chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype” and with a frequency of “not known” for “Systemic sclerosis associated interstitial lung disease (SSc-ILD)” and its relevant warning, respectively; the Package Leaflet is updated accordingly.

In addition, the MAH took the opportunity to make minor corrections and editorial changes (correction of frequency category for renal failure in section 4.8 of the SmPC, correction of a typo of non-safety relevant information in section 5.1. of the SmPC and correction of typos in Annex II) in the EN PI.”

Opinion adopted on 06.05.2021.

Request for Supplementary Information adopted on 11.03.2021.

**Ondexxya - andexanet alfa -
EMA/H/C/004108/II/0009/G**

Alexion Europe SAS, Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Menno van der Elst, “C.I.4, C.I.3, C.I.6 (non-EoI)

Update of section 5.2 of the SmPC in order to update pharmacokinetic information based on results from study CSR 19-514 (PK Comparability) and CSR 16-508 (Japanese Ethnicity Study) listed as a specific obligation in the Annex II. Annex II was proposed to be updated accordingly. The RMP version 2.1 has also been submitted.”

Opinion adopted on 20.05.2021.

Request for Supplementary Information adopted on 25.03.2021, 10.12.2020, 30.04.2020.

Positive Opinion adopted by consensus on 20.05.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

See 9.1

**Pyramax - pyronaridine / artesunate -
EMA/H/W/002319/II/0023/G**

Shin Poong Pharmaceutical Co., Ltd.,
Rapporteur: Jean-Michel Race, PRAC
Rapporteur: Adrien Inoubli, “Grouping of variations providing the final clinical study reports (CSR) of two completed studies:

- Study SP-C-021-15: A Phase IIb/IV cohort event monitoring study conducted in Central Africa to evaluate the safety in patients after the local registration of Pyramax (CANTAM study). This study is a Category 3 Required Additional Pharmacovigilance Activity described in the RMP (MEA 013).
- SP-C-026-18: A Randomized Open-Label Exploratory Study to Determine the Efficacy of

Request for supplementary information adopted with a specific timetable.

Different Treatment Regimens of Pyramax (Pyronaridine-Artesunate) In Asymptomatic Carriers of Plasmodium Falciparum Monoinfections. This non-imposed study was conducted in Gambia and Zambia and compared asymptomatic subjects with parasitaemia dosed according to the approved label of 3-day dosing with 2-day and 1-day dosing. There have been no new safety findings from the study but the RMP has been updated to reflect its details. As a result of the additional clinical data, corresponding changes to the Product Information (SmPC and PL) are proposed with the Grouping. RMP version 17 has also been submitted, updated to reflect the results of both above-mentioned CSRs, and converted to the new RMP integrated template format (Rev 2.0.1).” Request for Supplementary Information adopted on 06.05.2021, 14.01.2021.

**Tasigna - nilotinib -
EMA/H/C/000798/II/0109**

Novartis Europharm Limited, Rapporteur: Sinan B. Sarac, PRAC Rapporteur: Anette Kirstine Stark, “Update of SmPC sections 4.4, 4.8 and 5.1 based on the 5-year follow-up data from the study CAMN107A2203 in paediatric patients. Annex II D has been updated to reflect the fulfilment of the obligation to conduct the post-authorisation efficacy study (PAES). The package leaflet is updated accordingly. In addition, the Tasigna EU RMP version 24.0 has been updated to remove the corresponding additional pharmacovigilance activity and the missing information ‘Long-term follow-up in paediatric patients’.” Request for Supplementary Information adopted on 06.05.2021.

Request for supplementary information adopted with a specific timetable.

**TECFIDERA - dimethyl fumarate -
EMA/H/C/002601/II/0069/G**

Biogen Netherlands B.V., Rapporteur: Martina Weise, PRAC Rapporteur: Martin Huber, “C.I.4 type II variation: Update of section 4.8 of the SmPC in order to add rhinorrhoea to the list of adverse drug reactions (ADRs) with frequency unknown based on a systematic review of information from clinical and non-clinical studies, post-marketing data and scientific literature. The Package Leaflet has been updated accordingly.

Request for supplementary information adopted with a specific timetable.

C.I.4 type II variation: Update of sections 4.4, 4.8 and 5.1 of the SmPC in order to update efficacy and safety information based on final results from study 109MS303 (ENDORSE) listed as a category 3 study in the RMP. This is a dose-blind, multicenter, extension study to determine the long-term safety and efficacy of two doses of BG00012 monotherapy in subjects with Relapsing-Remitting Multiple Sclerosis. The RMP version 11.1 has also been submitted.” Request for Supplementary Information adopted on 06.05.2021, 14.01.2021.

Trumenba - meningococcal group B vaccine (recombinant, adsorbed) - EMEA/H/C/004051/II/0032

Pfizer Europe MA EEIG, Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Jean-Michel Dogné, “C.I.4 To update sections 4.8 and 5.1 of the SmPC following the interim data from the primary vaccination phase (Stage 1) of study B1971057; this is a Phase 3, randomised, active-controlled, observer-blinded study to assess the immunogenicity, safety, and tolerability of bivalent rLP2086 when administered as a 2-dose regimen and a first-in-human study to describe the immunogenicity, safety, and tolerability of a bivalent rLP2086 containing pentavalent vaccine (MenABCWY) in healthy subjects ≥10 to <26 years of age. The RMP version 5 has also been submitted. The MAH took the opportunity to implement some editorial changes in section 4.4 of the SmPC and sections 2, 3 and 6 of the Package Leaflet in order to comply with the excipients guideline for Sodium Chloride” Opinion adopted on 06.05.2021. Request for Supplementary Information adopted on 14.01.2021.

Positive Opinion adopted by consensus on 06.05.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

Xeljanz - tofacitinib - EMEA/H/C/004214/II/0038

Pfizer Europe MA EEIG, Rapporteur: Armando Genazzani, PRAC Rapporteur: Liana Gross-Martirosyan, “Submission of an updated RMP version 17.1 in order to incorporate the category 3 US-based drug utilisation study A3921348 into the category 3 protocol of the US-based active surveillance study A3921347.” Opinion adopted on 06.05.2021.

Positive Opinion adopted by consensus on 06.05.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

Zercepac - trastuzumab -

Positive Opinion adopted by consensus on

<p>EMA/H/C/005209/II/0008</p> <p>Accord Healthcare S.L.U., Rapporteur: Sol Ruiz, PRAC Rapporteur: Brigitte Keller-Stanislawski</p> <p>Opinion adopted on 20.05.2021.</p> <p>Request for Supplementary Information adopted on 11.03.2021.</p>	<p>20.05.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.</p>
-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	-------------------------------------------------------------------------------------------------------------

B.5.4. PRAC assessed procedures

<p>PRAC Led</p> <p>Adasuve - loxapine -</p> <p>EMA/H/C/002400/II/0032</p> <p>Ferrer Internacional s.a., Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Liana Gross-Martirosyan, PRAC-CHMP liaison: Johann Lodewijk Hillege, "To submit the final clinical study report (CSR) for study AMDC- 204-401 EU PASS: Post-authorisation Observational Study to Evaluate the Safety of ADASUVE -Staccato loxapine for inhalation- in Agitated Persons in Routine Clinical Care. An updated RMP version 9.5 has also been submitted."</p> <p>Opinion adopted on 06.05.2021.</p> <p>Request for Supplementary Information adopted on 14.01.2021.</p>	<p>Positive Opinion adopted by consensus on 06.05.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.</p>
<p>PRAC Led</p> <p>Alecensa - alectinib -</p> <p>EMA/H/C/004164/II/0033</p> <p>Roche Registration GmbH, Rapporteur: Filip Josephson, PRAC Rapporteur: Jana Lukacisinova, PRAC-CHMP liaison: Ondřej Slanař, "Submission of an updated RMP version 3.1 in order to remove the safety concern of missing information - long term safety, based on a report of the cumulative safety data from the pivotal Phase III clinical trial ALEX (BO28984). In addition, the MAH has taken the opportunity to update the RMP to remove study BO40643 from the pharmacovigilance plan, following assessment in procedure EMA/H/C/004164/II/0030."</p> <p>Request for Supplementary Information adopted on 06.05.2021.</p>	<p>Request for supplementary information adopted with a specific timetable.</p>
<p>PRAC Led</p> <p>Benlysta - belimumab -</p> <p>EMA/H/C/002015/II/0092</p> <p>GlaxoSmithKline (Ireland) Limited, Rapporteur: Kristina Dunder, PRAC Rapporteur: Ulla Wändel</p>	<p>Positive Opinion adopted by consensus on 06.05.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.</p>

Liminga, PRAC-CHMP liaison: Kristina Dunder, "Submission of an updated RMP version 40 in order to add an alternative pregnancy exposure study (Study 213928) as a category 3 study for the missing information on limited data in pregnant and lactating patients. The study is to evaluate pregnancy and infant outcomes for pregnancies in women with SLE exposed to belimumab. The RMP includes also completion date and effectiveness for the DHPC in relation to the important identified risk of psychiatric events including depression and suicidality." Opinion adopted on 06.05.2021.

PRAC Led

Conbriza - bazedoxifene - EMEA/H/C/000913/II/0054

Pfizer Europe MA EEIG, Rapporteur: Martina Weise, PRAC Rapporteur: Martin Huber, PRAC-CHMP liaison: Martina Weise, "Update of Risk Management Plan (RMP) to include updated study milestones and to revise the RMP format in line with latest Good Pharmacovigilance Practices Guidance Module V, revision 2 guidelines."

Request for Supplementary Information adopted on 06.05.2021, 14.01.2021.

Request for supplementary information adopted with a specific timetable.

PRAC Led

Lopinavir/Ritonavir Mylan - lopinavir / ritonavir - EMEA/H/C/004025/II/0016

Mylan S.A.S, Generic, Generic of Kaletra, Rapporteur: John Joseph Borg, PRAC Rapporteur: Adrien Inoubli, PRAC-CHMP liaison: Jean-Michel Race, "Submission of an updated RMP v. 4.0 in order to implement the RMP template in accordance with GVP Module V rev. 2 and to align the safety concerns with the reference product."

Opinion adopted on 06.05.2021.

Request for Supplementary Information adopted on 11.03.2021.

Positive Opinion adopted by consensus on 06.05.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

PRAC Led

Mavenclad - cladribine - EMEA/H/C/004230/II/0015

Merck Europe B.V., Rapporteur: Kirstine Moll Harboe, PRAC Rapporteur: Marcia Sofia Sanches de Castro Lopes Silva, PRAC-CHMP liaison: Bruno Sepodes, "Submission of an updated RMP version 1.5 in order to align to the RMP template Rev. 2. In addition, the MAH took the

Request for supplementary information adopted with a specific timetable.

opportunity to include long-term safety data from the completed PREMIERE registry and remove the completed study from the pharmacovigilance plan, update of the status of the post-approval safety studies CLARION and CLEAR and update the RMP with the most recent post-approval safety data from the PBRER.” Request for Supplementary Information adopted on 06.05.2021, 14.01.2021.

PRAC Led
OCALIVA - obeticholic acid - EMEA/H/C/004093/II/0026, Orphan
Intercept Pharma International Limited,
Rapporteur: Blanca Garcia-Ochoa, PRAC
Rapporteur: Liana Gross-Martirosyan, PRAC-
CHMP liaison: Johann Lodewijk Hillege,
“Submission of an updated RMP version 1.2 in order to update the format in accordance with template to EMA/164014/2018 Rev.2.0.1 and to add Specific Obligation clinical studies 747-302 and 747-401 to the pharmacovigilance plan. This change has been agreed by the CHMP in the outcome Ocaliva 2020 Annual Renewal (EMA/H/C/004093/R/0023). Other changes also include an update to the exposure data from clinical studies and addition of data on post-marketing experience up to the DLP (26 May 2020) and addition of some specific relevant SmPC wording in the risk minimisation measures”
Request for Supplementary Information adopted on 06.05.2021.

Request for supplementary information adopted with a specific timetable.

PRAC Led
Ovaleap - follitropin alfa - EMEA/H/C/002608/II/0034
Theramex Ireland Limited, Rapporteur: Paula Boudewina van Hennik, PRAC Rapporteur: Menno van der Elst, PRAC-CHMP liaison: Johann Lodewijk Hillege, “Submission of the final study report for SOFIA (Safety of Ovaleap (Follitropin alfa) in Infertile Women Undergoing Superovulation for Assisted Reproductive Technologies, XM17-WH-5005) listed as a category 3 study in the RMP. This is a multi-national, comparative, prospective, non-interventional, observational cohort study. The RMP version 3.3 has also been submitted.”
Opinion adopted on 06.05.2021.
Request for Supplementary Information adopted

Positive Opinion adopted by consensus on 06.05.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

on 14.01.2021.

PRAC Led

**Retacrit - epoetin zeta -
EMA/H/C/000872/II/0100**

Pfizer Europe MA EEIG, Rapporteur: Martina Weise, PRAC Rapporteur: Martin Huber, PRAC-CHMP liaison: Martina Weise, "Submission of the final study report of a joint post-authorisation safety cohort study of Retacrit/Silapo (epoetin zeta) administered subcutaneously for the treatment of renal anemia (PASCO II) listed as a category 3 study in the RMP. The primary objective of the observational study was to estimate the incidence of pure red cell aplasia (PRCA), neutralising antibodies, lack of efficacy and thromboembolic events under treatment with Retacrit/Silapo (epoetin zeta).

The RMP version 16 has also been submitted."

Opinion adopted on 06.05.2021.

Request for Supplementary Information adopted on 11.03.2021.

Positive Opinion adopted by consensus on 06.05.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

PRAC Led

**Revatio - sildenafil -
EMA/H/C/000638/II/0091**

Upjohn EESV, Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Menno van der Elst, PRAC-CHMP liaison: Johann Lodewijk Hillege, "Submission of an updated RMP version 7.0 in order to update the summary of safety concerns in line with GVP module V rev 2 guidelines. Consequently, the educational programme for the risk of hypotension is proposed to be terminated."

Request for Supplementary Information adopted on 06.05.2021, 14.01.2021.

Request for supplementary information adopted with a specific timetable.

PRAC Led

**RotaTeq - rotavirus vaccine (live, oral) -
EMA/H/C/000669/II/0085**

MSD Vaccins, Rapporteur: Kristina Dunder, PRAC Rapporteur: Ulla Wändel Liminga, PRAC-CHMP liaison: Kristina Dunder, "To update the RMP for RotaTeq to version 7.2 to meet the requirements and updated definitions in the Guideline on good pharmacovigilance practices (GVP) module V (EMA/838713/2011; Rev 2); consequently, the list of safety concerns is updated and a reclassification of important risks is proposed. In addition, the proposed RMP version 7.2 implements the removal of

Positive Opinion adopted by consensus on 06.05.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

hypersensitivity and severe combined immunodeficiency (SCID) from the list of safety concerns as requested by the PRAC in PSUR procedure (PSUSA/00002666/201911).”
Opinion adopted on 06.05.2021.
Request for Supplementary Information adopted on 11.02.2021.

PRAC Led
**Silapo - epoetin zeta -
EMA/H/C/000760/II/0062**
STADA Arzneimittel AG, Rapporteur: Martina Weise, PRAC Rapporteur: Martin Huber, PRAC-CHMP liaison: Martina Weise, “Submission of the final study report of a joint post-authorisation safety cohort study of Retacrit/Silapo (epoetin zeta) administered subcutaneously for the treatment of renal anemia (PASCO II) listed as a category 3 study in the RMP. The primary objective of the observational study was to estimate the incidence of pure red cell aplasia (PRCA), neutralising antibodies, lack of efficacy and thromboembolic events under treatment with Retacrit/Silapo (epoetin zeta).
The RMP version 12 has also been submitted.”
Opinion adopted on 06.05.2021.
Request for Supplementary Information adopted on 11.03.2021.

Positive Opinion adopted by consensus on 06.05.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

PRAC Led
**Vaxzevria - COVID 19 Vaccine (ChAdOx1 S [recombinant]) -
EMA/H/C/005675/II/0014**
AstraZeneca AB, Rapporteur: Sol Ruiz, PRAC Rapporteur: Jean-Michel Dogné, PRAC-CHMP liaison: Christophe Focke, “Update of sections 4.3, 4.4 and 4.8 of the SmPC, following an update to the Company Core Data Sheet in relation to thromboembolism with thrombocytopenia, to contraindicate the vaccine to individuals who have experienced thrombosis with thrombocytopenia syndrome (TTS) following vaccination with Vaxzevria, update the warnings on ‘thrombosis with thrombocytopenia syndrome and coagulation disorders’ and include an explanation on the ADR ‘thrombocytopenia’. The package leaflet is updated accordingly.”
Opinion adopted on 20.05.2021.
Request for Supplementary Information adopted on 07.05.2021.

Positive Opinion adopted by consensus on 20.05.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation. Request for supplementary information adopted with a specific timetable.

See 9.1

<p>PRAC Led</p> <p>Vaxzevria - COVID 19 Vaccine (ChAdOx1 S [recombinant]) - EMEA/H/C/005675/II/0015</p> <p>AstraZeneca AB, Rapporteur: Sol Ruiz, PRAC Rapporteur: Jean-Michel Dogné, PRAC-CHMP liaison: Christophe Focke, "Submission of an updated RMP version 3.1 in order to update the safety concerns to add 'Thrombosis in combination with thrombocytopenia' as an important identified risk and 'Thrombosis' as an important potential risk, with consequential changes in the RMP. Updates to the Pharmacovigilance Plan have also been implemented. These changes were requested by PRAC in the outcome of Signal Assessment Procedure on Embolic and Thrombotic Events with Vaxzevria EPITT no: 196833. The MAH has taken the opportunity to further update the RMP to reclassify "anaphylaxis" as an important identified risk, already reflected in the product information as an adverse reaction."</p> <p>Request for Supplementary Information adopted on 20.05.2021.</p>	<p>Request for supplementary information adopted with a specific timetable.</p> <p>See 9.1</p>
<p>PRAC Led</p> <p>WS1653</p> <p>Enbrel-EMEA/H/C/000262/WS1653/0230 LIFMIOR (EXP)-EMEA/H/C/004167/WS1653/0024</p> <p>Pfizer Europe MA EEIG, Lead Rapporteur: Maria Concepcion Prieto Yerro, Lead PRAC Rapporteur: Eva A. Segovia, PRAC-CHMP liaison: Maria Concepcion Prieto Yerro, "Submission of the second 5-year report from the British Society for Rheumatology Biologics Register (BSRBR, also referred as study B1801309) listed as a category 3 study in the RMP. This is a prospective observational cohort study which investigates the long-term outcomes of patients with rheumatoid arthritis treated with etanercept with particular reference to safety."</p> <p>Opinion adopted on 06.05.2021.</p> <p>Request for Supplementary Information adopted on 26.11.2020, 17.04.2020, 16.01.2020.</p>	<p>Positive Opinion adopted by consensus on 06.05.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.</p>
<p>PRAC Led</p> <p>WS1970</p> <p>Eucreas-EMEA/H/C/000807/WS1970/0081</p> <p>Galvus-EMEA/H/C/000771/WS1970/0067</p> <p>Icandra-EMEA/H/C/001050/WS1970/</p>	<p>Request for supplementary information adopted with a specific timetable.</p>

0084

Jalra-EMA/H/C/001048/WS1970/0069

Xiliarx-EMA/H/C/001051/WS1970/0067

Zomarist-EMA/H/C/001049/WS1970/0083

Novartis Europharm Limited, Lead Rapporteur: Kristina Dunder, Lead PRAC Rapporteur: Annika Folin, PRAC-CHMP liaison: Kristina Dunder, "Submission of an updated RMP (version 15.0) in order to bring it in line with revision 2 of GVP module V on 'Risk management systems' and aligned with the conclusions of the PSUR single assessment (PSUSA) procedure (PSUSA/00003113/201802) adopted in October 2018. Annex II.D of the product information is updated to remove the statement around submission of an RMP update every 3 years." Request for Supplementary Information adopted on 06.05.2021, 14.01.2021.

PRAC Led

WS2013

Abseamed-EMA/H/C/000727/WS2013/0092

Binocrit-EMA/H/C/000725/WS2013/0091

Epoetin alfa Hexal-EMA/H/C/000726/WS2013/0091

Sandoz GmbH, Lead Rapporteur: Alexandre Moreau, Lead PRAC Rapporteur: Tiphaine Vaillant, PRAC-CHMP liaison: Alexandre Moreau, "Update of the RMP v.18 for Abseamed, Binocrit, Epoetin Alfa Hexal in line with the RMP of the originator product Eprex.

The following changes have been introduced:

- Wording of two potential risks was harmonised in line with the originator's RMP: The term "tumor growth potential" was replaced with "disease progression", and "premature death" was replaced with "survival impact".
 - The clinical study data on these two topics were shortened, in line with the originator's RMP.
 - Removal of TRIGONS study proposal (MEA18; HX575-502) as additional pharmacovigilance activity; in alignment with originator RMP, risks of disease progression and survival impact will be monitored by routine pharmacovigilance and continue to be reviewed in PSURs.
 - Statistical output tables were integrated
-

Request for supplementary information adopted with a specific timetable.

into Annex 7 following a PRAC request.”
Request for Supplementary Information adopted
on 06.05.2021.

PRAC Led
WS2040/G

**Aybintio-EMA/H/C/005106/WS2040/
0004/G**

**Onbevzi-EMA/H/C/005640/WS2040/
0001/G**

Samsung Bioepis NL B.V., Lead Rapporteur:
Andrea Laslop, Lead PRAC Rapporteur: Anette
Kirstine Stark, PRAC-CHMP liaison: Sinan B.
Sarac, “C.I.11.z - To provide an updated RMP,
to remove the missing information of “Long
term effects of bevacizumab when used in the
paediatric population” to align the safety
concerns to the reference product Avastin.
C.I.2.a - To update sections 4.4, 5.1 and 6.6 of
the SmPC following assessment of the same
change for the reference product Avastin
(procedure EMA/H/C/000582/IB/0118).
In addition, the marketing authorisation holder
has taken the opportunity to add the Date of
first authorisation in section 9 of the SmPC and
align the PI with the latest QRD template (v.
10.2) for Onbevzi.”
Opinion adopted on 06.05.2021.

Positive Opinion adopted by consensus on
06.05.2021. The Icelandic and Norwegian CHMP
Members were in agreement with the CHMP
recommendation.

B.5.5. CHMP-CAT assessed procedures

**Zynteglo - betibeglogene autotemcel -
EMA/H/C/003691/II/0022, Orphan,
ATMP**

bluebird bio (Netherlands) B.V, Rapporteur:
Carla Herberts, CHMP Coordinator: Paula
Boudewina van Hennik
Opinion adopted on 20.05.2021, 12.05.2021.
Request for Supplementary Information adopted
on 16.04.2021.

Positive Opinion adopted by consensus on
20.05.2021. The Icelandic and Norwegian CHMP
Members were in agreement with the CHMP
recommendation.

B.5.6. CHMP-PRAC-CAT assessed procedures

B.5.7. PRAC assessed ATMP procedures

PRAC Led
Imlygic - talimogene laherparepvec -

Request for supplementary information adopted
with a specific timetable.

EMA/H/C/002771/II/0044, ATMP

Amgen Europe B.V., Rapporteur: Olli Tenhunen,
CHMP Coordinator: Johanna Lähtenvuo, PRAC
Rapporteur: Brigitte Keller-Stanislawski, PRAC-
CHMP liaison: Jan Mueller-Berghaus,
"Submission of the final report from study
20180099 listed as a category 3 study in the
RMP. This is a cross-sectional survey to evaluate
physician knowledge of safety messages
included in the physician education booklet
(PEB) for Imlygic."

Request for Supplementary Information adopted
on 12.05.2021.

B.5.8. Unclassified procedures and worksharing procedures of type I variations

WS2024**Infanrix hexa-EMA/H/C/000296/
WS2024/0296**

GlaxoSmithKline Biologicals SA, Lead
Rapporteur: Christophe Focke
Opinion adopted on 29.04.2021.

Positive Opinion adopted by consensus on
29.04.2021. The Icelandic and Norwegian CHMP
Members were in agreement with the CHMP
recommendation.

WS2030**Biktarvy-EMA/H/C/004449/WS2030/
0037****Descovy-EMA/H/C/004094/WS2030/
0053****Genvoya-EMA/H/C/004042/WS2030/
0075****Odefsey-EMA/H/C/004156/WS2030/
0050**

Gilead Sciences Ireland UC, Lead Rapporteur:
Bruno Sepodes, "To update section 4.4 of the
SmPC and section 2 of the PL with information
regarding nephrotoxicity, in alignment with the
outcome of procedure
EMA/H/C/PSUSA/00010575/201911 already
approved for Vemlidy.
In addition, the marketing authorisation holder
has taken the opportunity to introduce minor
editorial changes for Biktarvy and to align the PI
of all four products to the latest QRD template
(v. 10.2)."
Opinion adopted on 20.05.2021.

Positive Opinion adopted by consensus on
20.05.2021. The Icelandic and Norwegian CHMP
Members were in agreement with the CHMP
recommendation.

WS2033**Hexacima-EMA/H/C/002702/WS2033/
0116****Hexyon-EMA/H/C/002796/WS2033/**

Request for supplementary information adopted
with a specific timetable.

0120

Sanofi Pasteur, Lead Rapporteur: Jan Mueller-Berghaus
Request for Supplementary Information adopted on 29.04.2021.

WS2045/G

OFEV-EMA/H/C/003821/WS2045/0043/G

Vargatef-EMA/H/C/002569/WS2045/0040/G

Boehringer Ingelheim International GmbH, Lead Rapporteur: Peter Kiely,
Opinion adopted on 29.04.2021.

Positive Opinion adopted by consensus on 29.04.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

WS2047

HyQvia-EMA/H/C/002491/WS2047/0069
Kiovig-EMA/H/C/000628/WS2047/0108

Baxalta Innovations GmbH, Lead Rapporteur: Jan Mueller-Berghaus
Opinion adopted on 20.05.2021.

Positive Opinion adopted by consensus on 20.05.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

WS2051/G

Entresto-EMA/H/C/004062/WS2051/0037/G

Neparvis-EMA/H/C/004343/WS2051/0035/G

Novartis Europharm Limited, Lead Rapporteur: Johann Lodewijk Hillege
Opinion adopted on 06.05.2021.

Positive Opinion adopted by consensus on 06.05.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

B.5.9. Information on withdrawn type II variation / WS procedure

Fluad Tetra - influenza vaccine (surface antigen, inactivated, adjuvanted) - EMA/H/C/004993/II/0003

Seqirus Netherlands B.V., Rapporteur: Sol Ruiz,
"Update of section 5.1 of the SmPC in order to introduce effectiveness information of Fluad (trivalent formulation) in the product information of Fluad Tetra based on the results from three retrospective observational studies "CORE 17-18 and 18-19", "HEOR 17-18" and "HEOR 18-19") and a randomised clinical trial "LTCF 16-17". "Request for Supplementary Information adopted on 28.01.2021, 15.10.2020. Withdrawal request submitted on 11.05.2021.

The MAH withdrew the procedure on 11.05.2021.

Maviret - glecaprevir / pibrentasvir - EMA/H/C/004430/II/0040

The MAH withdrew the procedure on

<p>AbbVie Deutschland GmbH & Co. KG, Rapporteur: Jean-Michel Race, "Update of sections 4.8 and 5.1 of the SmPC to include information related to the safety and efficacy of Maviret for people who inject drugs (PWID) and those who are on medication-assisted treatment (MAT) for opioid use disorder based on data from Phase 2 and 3 clinical trials. In addition, the MAH took the opportunity to include an editorial change and corrected the number of subjects stated in Footnote B, Table 8 of the SmPC section 5.1." Request for Supplementary Information adopted on 09.04.2021. Withdrawal request submitted on 05.05.2021.</p>	<p>05.05.2021.</p>
<p>TRIXEO AEROSPHERE - formoterol fumarate dihydrate / glycopyrronium bromide / budesonide - EMEA/H/C/004983/II/0002 AstraZeneca AB, Rapporteur: Peter Kiely, "C.I.4. Update of section 5.1. of the SmPC in order to add information on the effects on all-cause mortality based on the supplement to the study PT010005 Clinical Study Report on all cause-mortality and additional data analyses to address the concerns identified during the evaluation of the MAA." Withdrawal request submitted on 19.05.2021.</p>	<p>The MAH withdrew the procedure on 19.05.2021.</p>
<p>Xenical - orlistat - EMEA/H/C/000154/II/0083 CHEPLAPHARM Arzneimittel GmbH, Rapporteur: Jean-Michel Race Request for Supplementary Information adopted on 18.02.2021, 15.10.2020. Withdrawal request submitted on 19.05.2021.</p>	<p>The MAH withdrew the procedure on 19.05.2021.</p>
<p>B.5.10. Information on type II variation / WS procedure with revised timetable</p>	
<p>Nulojix - belatacept - EMEA/H/C/002098/II/0065/G Bristol-Myers Squibb Pharma EEIG, Rapporteur: Filip Josephson Request for Supplementary Information adopted on 25.03.2021, 12.11.2020, 12.03.2020.</p>	<p>Request by the applicant for an extension of the clock stop to respond to the RSI adopted on 25.03.2021. The CHMP agreed to the request by the applicant.</p>

**Invokana - canagliflozin -
EMA/H/C/002649/II/0055**

Janssen-Cilag International NV, Rapporteur:
Martina Weise, "Update to sections 4.2 and 5.1
of the INVOKANA SmPC to amend posology
information concerning the treatment of
patients with eGFR between ≥ 30 and < 45
mL/min/1.73 m², whether or not albuminuria is
present; the update is based on further analysis
of previously submitted CANVAS data (studies
DIA3008 and DIA4003).

The Applicant has also taken the opportunity to
make minor editorial changes to section 4.5."
Request for Supplementary Information adopted
on 22.04.2021, 28.01.2021.

Request by the applicant for an extension of the
clock stop to respond to the RSI adopted on
22.04.2021.

The CHMP agreed to the request by the
applicant.

B.6. START OF THE PROCEDURES TIMETABLES FOR INFORMATION

B.6.1. Start of procedure for New Applications: timetables for information

amifampridine - EMA/H/C/005839

treatment of Lambert-Eaton Myasthenic
Syndrome

**ciltacabtagene autoleucel -
EMA/H/C/005095, Orphan, ATMP**

Janssen-Cilag International NV, treatment of
multiple myeloma

Accelerated review

**melphalan flufenamide -
EMA/H/C/005681, Orphan**

Oncopeptides AB, treatment of multiple
myeloma

**omburtamab I-131 - EMA/H/C/005499,
Orphan**

Y-Mabs Therapeutics A/S, treatment of
neuroblastoma

pirfenidone - EMA/H/C/005873

Pirfenidone is indicated in adults for the
treatment of mild to moderate idiopathic
pulmonary fibrosis (IPF).

**sitagliptin / metformin hydrochloride -
EMA/H/C/005850**

treatment of type 2 diabetes mellitus

palovarotene - EMA/H/C/004867, Orphan

Ipsen Pharma, Treatment of fibrodysplasia
ossificans progressiva

ranibizumab - EMEA/H/C/005610

treatment of neovascular age-related macular degeneration in adults

capmatinib - EMEA/H/C/004845

treatment of non-small cell lung cancer (NSCLC)

thalidomide - EMEA/H/C/005715

treatment of multiple myeloma

insulin aspart - EMEA/H/C/005635

treatment of diabetes mellitus

B.6.2. Start of procedure for Extension application according to Annex I of Reg. 1234/2008): timetables for information

Mayzent - siponimod -**EMEA/H/C/004712/X/0007**

Novartis Europharm Limited, Rapporteur:
Kirstine Moll Harboe, PRAC Rapporteur: Maria del Pilar Rayon, "Extension application to add a new strength of 1 mg film-coated tablet. The RMP (version 3.0) is updated in accordance."

Nucala - mepolizumab -**EMEA/H/C/003860/X/0042**

GlaxoSmithKline Trading Services Limited, Rapporteur: Peter Kiely, PRAC Rapporteur: Brigitte Keller-Stanislowski, "Extension application to introduce a new strength of 40 mg for Nucala solution for injection in a pre-filled syringe for subcutaneous use to be used in children aged 6 to 11 years."

Xofluza - baloxavir marboxil -**EMEA/H/C/004974/X/0003/G**

Roche Registration GmbH, Rapporteur: Kirstine Moll Harboe, PRAC Rapporteur: Sonja Hrabcik, "Extension application to add a new strength of 80 mg grouped with a type IB variation to add a new pack size for 40 mg strength. The RMP (version 1.2) is updated in accordance. Furthermore, the PI is being brought in line with the QRD template version 10.2 to update the local representatives with "United Kingdom (Northern Ireland) ". "

YUFLYMA - adalimumab -**EMEA/H/C/005188/X/0005**

Celltrion Healthcare Hungary Kft., Rapporteur: Outi Mäki-Ikola, PRAC Rapporteur: Ulla Wändel Liminga, "Extension application to introduce a

new strengths of 80 mg solution for injection.
Version 1.1 of the RMP has also been
submitted.”

B.6.3. Restart of procedure - responses received to Day 120 List of Questions timetables: for information

abrocitinib - EMEA/H/C/005452

Indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy.
List of Questions adopted on 28.01.2021.

Akynzeo - fosnetupitant / netupitant / palonosetron - EMEA/H/C/003728/X/0031

Helsinn Birex Pharmaceuticals Limited,
Rapporteur: Peter Kiely, PRAC Rapporteur:
Ilaria Baldelli, “Extension application to
introduce a new pharmaceutical form
(concentrate for solution for infusion).”
List of Questions adopted on 28.01.2021.

artesanate - EMEA/H/C/005550, Orphan

Amivas Ireland Ltd, treatment of malaria
List of Questions adopted on 28.01.2021.

fingolimod - EMEA/H/C/005661

treatment of multiple sclerosis
List of Questions adopted on 25.03.2021.

lonapegsomatropin - EMEA/H/C/005367, Orphan

Ascendis Pharma Endocrinology Division A/S,
Treatment of growth hormone deficiency
List of Questions adopted on 28.01.2021.

sodium thiosulfate - EMEA/H/C/005130, PUMA

for the prevention of ototoxicity induced by
cisplatin (CIS) chemotherapy in patients 1
month to < 18 years of age with localized, non-
metastatic, solid tumours.
List of Questions adopted on 25.06.2020.

pegcetacoplan - EMEA/H/C/005553, Orphan

Apellis Ireland Limited, paroxysmal nocturnal
haemoglobinuria (PNH)
List of Questions adopted on 28.01.2021.

ripretinib - EMEA/H/C/005614, Orphan

Deciphera Pharmaceuticals (Netherlands) B.V.,
Treatment of patients with advanced
gastrointestinal stromal tumour (GIST)
List of Questions adopted on 28.01.2021.

**autologous glioma tumor cells, inactivated
/ autologous glioma tumor cell lysates,
inactivated / allogeneic glioma tumor cells,
inactivated / allogeneic glioma tumor cell
lysates, inactivated - EMEA/H/C/003693,
Orphan, ATMP**

Epitopoietic Research Corporation-Belgium
(E.R.C.), treatment of glioma
List of Questions adopted on 22.01.2021.

glucarpidase - EMEA/H/C/005467, Orphan

Protherics Medicines Development Europe B.V.,
treatment of patients at risk of methotrexate
toxicity
List of Questions adopted on 10.12.2020.

B.6.4. Annual Re-assessments: timetables for adoption

**Chenodeoxycholic acid Leadiant -
chenodeoxycholic acid -**

EMA/H/C/004061/S/0017, Orphan

Leadiant GmbH, Rapporteur: Konstantinos
Markopoulos, PRAC Rapporteur: Adam
Przybylkowski

**Elaprase - idursulfase -
EMA/H/C/000700/S/0092**

Shire Human Genetic Therapies AB, Rapporteur:
Johann Lodewijk Hillege, PRAC Rapporteur:
Liana Gross-Martirosyan

**Firdapse - amifampridine -
EMA/H/C/001032/S/0071**

SERB SA, Rapporteur: Kristina Dunder, PRAC
Rapporteur: Ulla Wändel Liminga

B.6.5. Renewals of Marketing Authorisations: timetables for adoption provided only if the validation has been completed

**Adakveo - crizanlizumab -
EMA/H/C/004874/R/0003, Orphan**

Novartis Europharm Limited, Rapporteur:
Daniela Philadelphy, PRAC Rapporteur: Laurence
de Fays

Cystadrops - mercaptamine -**EMA/H/C/003769/R/0022, Orphan**

Recordati Rare Diseases, Rapporteur: Kristina
Dunder, Co-Rapporteur: Maria Concepcion
Prieto Yerro, PRAC Rapporteur: Eva A. Segovia

Suliqua - insulin glargine / lixisenatide -**EMA/H/C/004243/R/0022**

sanofi-aventis groupe, Rapporteur: Kristina
Dunder, Co-Rapporteur: Karin Janssen van
Doorn, PRAC Rapporteur: Menno van der Elst

Talmanco - tadalafil -**EMA/H/C/004297/R/0011**

Mylan S.A.S, Generic, Generic of Adcirca, Cialis,
Rapporteur: Tomas Radimersky, PRAC
Rapporteur: Maria del Pilar Rayon

Vemlidy - tenofovir alafenamide -**EMA/H/C/004169/R/0035**

Gilead Sciences Ireland UC, Rapporteur: Janet
Koenig, Co-Rapporteur: Kristina Dunder, PRAC
Rapporteur: Ilaria Baldelli

Vihuma - simoctocog alfa -**EMA/H/C/004459/R/0026**

Octapharma AB, Rapporteur: Jan Mueller-
Berghaus, PRAC Rapporteur: Ulla Wändel
Liminga

Zinplava - bezlotoxumab -**EMA/H/C/004136/R/0029**

Merck Sharp & Dohme B.V., Rapporteur: Jan
Mueller-Berghaus, Co-Rapporteur: Bjorg
Bolstad, PRAC Rapporteur: Adam Przybylkowski

B.6.6. VARIATIONS – START OF THE PROCEDURE

Timetables for adoption provided that the validation has been completed.

B.6.7. Type II Variations scope of the Variations: Extension of indication

**Adjupanrix - pandemic influenza vaccine
(H5N1) (split virion, inactivated,
adjuvanted) - EMA/H/C/001206/II/0074**

GlaxoSmithKline Biologicals SA, Informed
Consent of Pandemrix (EXP), Rapporteur:
Johann Lodewijk Hillege, PRAC Rapporteur:
Menno van der Elst, "Extension of indication to
include use in children from 6 months to <18
years for Adjupanrix based on the results of the
studies: study H5N1-013, a phase II, non-

randomized, open-label study to evaluate the safety and immunogenicity in children aged 6 to 35 months and study H5N1-032, a phase III, randomized, open, active-controlled study to evaluate the safety and immunogenicity in children aged 3 to 17 years. As a consequence, sections 4.1, 4.2, 4.8, 5.1 and 6.6 of the SmPC are updated and the Package Leaflet is updated in accordance. Further, the MAH proposed to update section 4.4 with information on sodium and potassium content in line with the excipient guideline, as well as to add wording on traceability. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet. Furthermore, the PI is brought in line with the latest QRD template version 10.2, the MAH performed minor editorial changes and removed information related to the withdrawn of the Prepandrix marketing authorisation. Version 13 of the RMP has also been submitted.”

**Hizentra - human normal immunoglobulin -
EMA/H/C/002127/II/0129**

CSL Behring GmbH, Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Brigitte Keller-Stanislawski, “Extension of indication for Hizentra in order to expand the approved secondary immunodeficiencies (SID) indications in the Hizentra SmPC to any symptomatic SID in accordance with the Guideline on core SmPC for human normal immunoglobulin for intravenous administration (EMA/CHMP/BPWP/94038/ 2007 Rev 5; CHMP, 2018); as a consequence, sections 4.1 and 4.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 4.6 of the RMP has also been submitted. In addition, the Marketing authorisation holder (MAH) took the opportunity to update the list of local representatives in the Package Leaflet.”

**Jakavi - ruxolitinib -
EMA/H/C/002464/II/0053**

Novartis Europharm Limited, Rapporteur: Filip Josephson, Co-Rapporteur: Paula Boudewina van Hennik, PRAC Rapporteur: Annika Folin, “Extension of indication to include treatment of patients with GvHD aged 12 years and older who have inadequate response to corticosteroids or other systemic therapies for Jakavi; as a consequence, sections 4.1, 4.2,

4.4, 4.5, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 13.0 of the RMP has also been submitted. In addition, the marketing authorisation holder (MAH) took the opportunity to update the list of local representatives for The Netherlands in the Package Leaflet.”

Kalydeco - ivacaftor -

EMA/H/C/002494/II/0096, Orphan

Vertex Pharmaceuticals (Ireland) Limited,
Rapporteur: Maria Concepcion Prieto Yerro,
PRAC Rapporteur: Maria del Pilar Rayon,
“Extension of indication for Kalydeco tablets in combination regimen with Kaftrio to include the treatment of adults, adolescents and children aged 6 years and older with cystic fibrosis who are homozygous for the F508del mutation in the CFTR gene or heterozygous for F508del and have a minimal function (MF) mutation in the CFTR gene. This application is based on the results of study VX18-445-106, a phase 3, open-label, multicentre study in subjects 6 through 11 years of age, with F/MF and F/F genotypes. As a consequence, sections 4.1, 4.2, 5.1 and 5.2 of the SmPC are updated. The Packaged Leaflet is updated in accordance. Version 12.0 of the RMP has also been submitted.”

Nexpovio - selinexor -

EMA/H/C/005127/II/0001/G

Karyopharm Europe GmbH, Rapporteur: Blanca Garcia-Ochoa, PRAC Rapporteur: Menno van der Elst, “Group of variations including an extension of indication for Nexpovio in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy and a quality variation for the addition of a new pack size to align with the dose modification guidance for the new indication. Sections 4.1, 4.2, 4.4, 4.5, 4.8, 5.1 and 6.5 of the SmPC are updated to reflect the new indication and the new pack size. Annex II is updated to reflect the completion of the Specific Obligation. The Labelling and Package Leaflet are amended accordingly. The RMP (v 1.1) is amended consequently.”

Olumiant - baricitinib -

EMA/H/C/004085/II/0028

Eli Lilly Nederland B.V., Rapporteur: Johann Lodewijk Hillege, Co-Rapporteur: Christophe Focke, PRAC Rapporteur: Adam Przybylowski, "C.I.6 - Extension of indication to include treatment of coronavirus disease 2019 (COVID 19) in hospitalised adult and paediatric patients aged 10 years and older who require low-flow oxygen or non-invasive ventilation/high flow oxygen for Olumiant; as a consequence, sections 4.1, 4.2, 4.4, 4.6, 4.8, 5.1, 5.2 and 6.6 of the SmPC are updated. The Annex II and the Package Leaflet are updated in accordance. Version 11.1 of the RMP has also been submitted."

Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

**Rapiscan - regadenoson -
EMA/H/C/001176/II/0038**

GE Healthcare AS, Rapporteur: Maria Concepcion Prieto Yerro, Co-Rapporteur: Jayne Crowe, "Modification of existing indication to allow use in line with new imaging technologies that have evolved since initial approval of Rapiscan; as a consequence, sections 4.1, 4.2 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance."

**Skyrizi - risankizumab -
EMA/H/C/004759/II/0014**

AbbVie Deutschland GmbH & Co. KG, Rapporteur: Peter Kiely, PRAC Rapporteur: Liana Gross-Martirosyan, "Extension of indication for the treatment of active psoriatic arthritis in adults. Consequently sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 to the SmPC have been updated. The Package leaflet is updated accordingly. Additionally, Annex II is also updated."

B.6.8. CHMP assessed procedures scope: Pharmaceutical aspects

**Briviact - brivaracetam -
EMA/H/C/003898/II/0034/G**

UCB Pharma S.A., Rapporteur: Filip Josephson

COMIRNATY - COVID-19 mRNA vaccine (nucleoside-modified) - EMA/H/C/005735/II/0028/G	See B.5.1
---------------------------------------------------------------------------------------------------	-----------

BioNTech Manufacturing GmbH, Rapporteur:
Filip Josephson

**COMIRNATY - COVID-19 mRNA vaccine
(nucleoside-modified) -
EMA/H/C/005735/II/0033/G**

BioNTech Manufacturing GmbH, Rapporteur:
Filip Josephson

**COMIRNATY - COVID-19 mRNA vaccine
(nucleoside-modified) -
EMA/H/C/005735/II/0034**

BioNTech Manufacturing GmbH, Rapporteur:
Filip Josephson

**COMIRNATY - COVID-19 mRNA vaccine
(nucleoside-modified) -
EMA/H/C/005735/II/0035/G**

BioNTech Manufacturing GmbH, Rapporteur:
Filip Josephson

**COVID-19 Vaccine Moderna - COVID-19
mRNA vaccine (nucleoside-modified) -
EMA/H/C/005791/II/0013/G**

Moderna Biotech Spain, S.L., Rapporteur: Jan
Mueller-Berghaus

**COVID-19 Vaccine Moderna - COVID-19
mRNA vaccine (nucleoside-modified) -
EMA/H/C/005791/II/0016/G**

Moderna Biotech Spain, S.L., Rapporteur: Jan
Mueller-Berghaus

**Cyramza - ramucirumab -
EMA/H/C/002829/II/0041**

Eli Lilly Nederland B.V., Rapporteur: Paula
Boudewina van Hennik

**Eylea - aflibercept -
EMA/H/C/002392/II/0071/G**

Bayer AG, Rapporteur: Alexandre Moreau

**Increlex - mecasermin -
EMA/H/C/000704/II/0068/G**

Ipsen Pharma, Rapporteur: Outi Mäki-Ikola

**Kaftrio - ivacaftor / tezacaftor /
elexacaftor -
EMA/H/C/005269/II/0011/G, Orphan**

Vertex Pharmaceuticals (Ireland) Limited,
Rapporteur: Johann Lodewijk Hillege

**Kineret - anakinra -
EMA/H/C/000363/II/0083**

Swedish Orphan Biovitrum AB (publ),

Rapporteur: Kirstine Moll Harboe

Kineret - anakinra -

EMA/H/C/000363/II/0084

Swedish Orphan Biovitrum AB (publ),

Rapporteur: Kirstine Moll Harboe

Lonquex - lipegfilgrastim -

EMA/H/C/002556/II/0064/G

Teva B.V., Rapporteur: Outi Mäki-Ikola

MabThera - rituximab -

EMA/H/C/000165/II/0185/G

Roche Registration GmbH, Rapporteur: Sinan B.

Sarac

Menveo - meningococcal group a, c, w135

and y conjugate vaccine -

EMA/H/C/001095/II/0101

GSK Vaccines S.r.l, Rapporteur: Johann

Lodewijk Hillege

Nucala - mepolizumab -

EMA/H/C/003860/II/0043

GlaxoSmithKline Trading Services Limited,

Rapporteur: Peter Kiely

Nyvepria - pegfilgrastim -

EMA/H/C/005085/II/0002/G

Pfizer Europe MA EEIG, Rapporteur: Ondřej

Slanař

Ondexxys - andexanet alfa -

EMA/H/C/004108/II/0020/G

Alexion Europe SAS, Rapporteur: Jan Mueller-

Berghaus

OPDIVO - nivolumab -

EMA/H/C/003985/II/0103

Bristol-Myers Squibb Pharma EEIG, Rapporteur:

Blanca Garcia-Ochoa

Pemetrexed Sandoz - pemetrexed -

EMA/H/C/004011/II/0011/G

Sandoz GmbH, Generic, Generic of Alimta,

Rapporteur: Bjorg Bolstad

SCENESSE - afamelanotide -

EMA/H/C/002548/II/0037, Orphan

Clinuvel Europe Limited, Rapporteur: Janet

Koenig

Skyrizi - risankizumab -

EMA/H/C/004759/II/0015/G

AbbVie Deutschland GmbH & Co. KG,

Rapporteur: Peter Kiely

TAKHZYRO - lanadelumab -

EMA/H/C/004806/II/0021/G, Orphan

Shire Pharmaceuticals Ireland Limited,

Rapporteur: Kristina Dunder

Tremfya - guselkumab -

EMA/H/C/004271/II/0029/G

Janssen-Cilag International N.V., Rapporteur:

Agnes Gyurasics

Ultomiris - ravulizumab -

EMA/H/C/004954/II/0015/G

Alexion Europe SAS, Rapporteur: Blanca Garcia-Ochoa

Vaxzevria - COVID 19 Vaccine (ChAdOx1 S [recombinant]) -

See B.5.1

EMA/H/C/005675/II/0016

AstraZeneca AB, Rapporteur: Sol Ruiz

Vaxzevria - COVID 19 Vaccine (ChAdOx1 S [recombinant]) -

See B.5.1

EMA/H/C/005675/II/0018

AstraZeneca AB, Rapporteur: Sol Ruiz

YUFLYMA - adalimumab -

EMA/H/C/005188/II/0002

Celltrion Healthcare Hungary Kft., Rapporteur:

Outi Mäki-Ikola

Ziextenzo - pegfilgrastim -

EMA/H/C/004802/II/0014

Sandoz GmbH, Rapporteur: Andrea Laslop

Zubsolv - buprenorphine / naloxone -

EMA/H/C/004407/II/0015

Accord Healthcare S.L.U., Rapporteur: Peter Kiely

WS1964

HyQvia-EMA/H/C/002491/WS1964/0072

Kiovig-EMA/H/C/000628/WS1964/0110

Baxalta Innovations GmbH, Lead Rapporteur:

Jan Mueller-Berghaus

WS2026

AMGEVITA-EMA/H/C/004212/WS2026/0026

Aranesp-EMA/H/C/000332/WS2026/0155

MVASI-EMA/H/C/004728/WS2026/0021

Prolia-EMA/H/C/001120/WS2026/0089

Repatha-EMA/H/C/003766/WS2026/

0052

XGEVA-EMA/H/C/002173/WS2026/0077

Amgen Europe B.V., Lead Rapporteur: Martina
Weise

WS2037

Gardasil-EMA/H/C/000703/WS2037/

0092

Gardasil 9-EMA/H/C/003852/WS2037/

0045

MSD Vaccins, Lead Rapporteur: Kristina Dunder

WS2044

Herceptin-EMA/H/C/000278/WS2044/

0171

MabThera-EMA/H/C/000165/WS2044/

0184

Roche Registration GmbH, Lead Rapporteur: Jan
Mueller-Berghaus

WS2074

Riarify-EMA/H/C/004836/WS2074/0012

Trimbow-EMA/H/C/004257/WS2074/

0017

Trydonis-EMA/H/C/004702/WS2074/

0012

Chiesi Farmaceutici S.p.A., Lead Rapporteur:
Janet Koenig

B.6.9. CHMP assessed procedures scope: Non-Clinical and Clinical aspects

Adcetris - brentuximab vedotin -

EMA/H/C/002455/II/0089, Orphan

Takeda Pharma A/S, Rapporteur: Paula
Boudewina van Hennik, "Submission of long-
term follow-up data for clinical trial Echelon-2
(SGN035-014): A randomized, double-blind,
placebo-controlled, phase 3 study of
brentuximab vedotin and CHP (A+CHP) versus
CHOP in the frontline treatment of patients with
CD30-positive mature T-cell lymphoma. The
study is submitted to fulfil the post-approval-
measure MEA 015.1."

Calquence - acalabrutinib -

EMA/H/C/005299/II/0005

AstraZeneca AB, Rapporteur: Filip Josephson,
"Submission of the final report from study XS-
1468 to further characterise the plasma protein
binding of acalabrutinib and its metabolite ACP-

5862 in different species.”

Cosentyx - secukinumab -

EMA/H/C/003729/II/0073

Novartis Europharm Limited, Rapporteur: Outi Mäki-Ikola, “C.I.4 - Update of section 5.1 of the SmPC in order to include the 52 weeks results from study A2311; a multicenter, randomized, open-label study in paediatric patients aged 6 years to less than 18 years with moderate to severe chronic plaque psoriasis.”

Dupilumab - dupilumab -

EMA/H/C/004390/II/0046

sanofi-aventis groupe, Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Kimmo Jaakkola, “Update of section 4.8 of the SmPC to introduce a new ADR (facial rash) with uncommon frequency. The package leaflet will be updated accordingly.”

Erleada - apalutamide -

EMA/H/C/004452/II/0015

Janssen-Cilag International N.V., Rapporteur: Blanca Garcia-Ochoa, “Update of section 5.1 of the SmPC in order to update the efficacy and safety information based on final results from study 56021927PCR3002 (TITAN) listed as Letter of Recommendations (11 December 2019, EMA/H/C/004452/II/0001); this is a double-blind, placebo-controlled, multinational, multicenter Phase 3 study in metastatic castration-sensitive prostate cancer (mCSPC) patients.”

Fasenra - benralizumab -

EMA/H/C/004433/II/0036

AstraZeneca AB, Rapporteur: Fátima Ventura, PRAC Rapporteur: David Olsen, “Update of the RMP to remove long-term use of benralizumab, serious hypersensitivity, loss of/reduction of long-term efficacy as safety concern and to change categorisation of helminth infection from important identified risk to important potential risk.
RMP version 4.0 is submitted”

**Genvoya - elvitegravir / cobicistat /
emtricitabine / tenofovir alafenamide -**

EMA/H/C/004042/II/0077

Gilead Sciences Ireland UC, Rapporteur: Bruno Sepodes, “Update of sections 4.8 and 5.1 of the SmPC to include long-term safety and efficacy

data from study GS-US-292-0106. This was a phase 2/3, open-label study of pharmacokinetics, safety and antiviral activity in HIV-1 infected antiretroviral treatment-naïve adolescents and virologically suppressed children.”

Imfinzi - durvalumab -

EMA/H/C/004771/II/0030/G

AstraZeneca AB, Rapporteur: Sinan B. Sarac, “Update of sections 4.2. and 4.4 the SmPC in order to change posology recommendations for management of immune-mediated adverse reactions and amend an existing warning on Immune-mediated type 1 diabetes mellitus to include diabetic ketoacidosis; these changes are based on case studies reports, updated guidelines.

The Package Leaflet is updated accordingly.

In addition, the MAH took the opportunity to make some minor corrections to section 4.8 of the SmPC.”

INREBIC - fedratinib -

EMA/H/C/005026/II/0003/G, Orphan

Celgene Europe BV, Rapporteur: Paula Boudewina van Hennik, “Update of sections 4.4 and 4.5 of the SmPC in order to updated drug-drug interaction information regarding medicinal products renally excreted via organic cation transporter

(OCT)2 and multidrug and toxin extrusion (MATE)1/2-K (e.g. metformin) based on data from study FEDR-CP-003 (drug transporter DDI Study) listed as a recommendation during initial assessment. The Package Leaflet is updated accordingly. In addition, the MAH is updating the recently revised ATC code in section 5.1 of the SmPC.”

Revestive - teduglutide -

EMA/H/C/002345/II/0053, Orphan

Shire Pharmaceuticals Ireland Limited, Rapporteur: Kirstine Moll Harboe, “Update of sections 4.2, 4.8, 5.1 and 5.2 of the SmPC in order to update the product information with results from two studies included in the paediatric investigation plan (PIP). Study SHP633-1 was performed to evaluate the safety, efficacy/pharmacodynamics (PD), and pharmacokinetics (PK) of teduglutide in infants 4 to 12 months gestational age with SBS and

who are dependent on parenteral support. The second study is a paediatric population PK model including data from study SHP633-301. The Package Leaflet was updated accordingly. In addition, the MAH took the opportunity to make editorial changes to section 4.5 of the SmPC."

SIRTURO - bedaquiline -

EMA/H/C/002614/II/0043, Orphan

Janssen-Cilag International NV, Rapporteur: Filip Josephson, "Update of section 4.2 of the SmPC to include reference on the use of bedaquiline as specified in the product information of other medicines used for the treatment of pulmonary tuberculosis (TB) caused by multidrug-resistant Mycobacterium tuberculosis (MDR-TB), based on recent information regarding EU approval of pretomanid, as part of a combination regimen with bedaquiline and linezolid. In addition, the MAH took the opportunity to include an editorial correction in section 5.1 of the SmPC and to update the contact details for the local representative for UK in the package leaflet, in line with QRD version 10.2."

Tecentriq - atezolizumab -

EMA/H/C/004143/II/0061

Roche Registration GmbH, Rapporteur: Sinan B. Sarac, PRAC Rapporteur: Marcia Sofia Sanches de Castro Lopes Silva, "Submission of an updated RMP version 20.0 in order to add severe cutaneous adverse reactions (SCARs) as an important identified risk and its associated risk minimisation measures, a DHPC, following the addition of SCARs to the tecentriq PI with procedure EMA/H/C/004143/II/0054. In addition, the MAH has also taken the opportunity to update the due dates of final CSR of two Post-authorisation efficacy studies."

Tysabri - natalizumab -

EMA/H/C/000603/II/0127

Biogen Netherlands B.V., Rapporteur: Jan Mueller-Berghaus, "Update of section 4.6 of the SmPC in order to update information on pregnancy following a safety signal assessment of cases of neonatal thrombocytopenia that may be associated with natalizumab treatment."

Vaxzevria - COVID 19 Vaccine (ChAdOx1 S [recombinant]) - See B.5.2

EMA/H/C/005675/II/0017/G

AstraZeneca AB, Rapporteur: Sol Ruiz, "C.I.4 (type II) - Update of section 4.6 of the SmPC in order to add the high-level results from the development and reproductive toxicity (DART) study (study number 490843).

C.I.4 (type II) - Update of section 5.3 of the SmPC in order to add the high-level results from the biodistribution study (study number 514559), listed as an imposed study in Annex II.

The MAH is taking the opportunity to update the wording of section 5.3 of the SmPC to add the results from the already assessed repeat-dose toxicity study. Moreover, the MAH is taking the opportunity to address the nonclinical recommendations adopted during the initial CMA application."

**Vazkepa - icosapent ethyl -
EMA/H/C/005398/II/0001**

Amarin Pharmaceuticals Ireland Limited, Rapporteur: Martina Weise, "C.I.13: Submission of the final report from study assessing the in vitro effects of Eicosapentaenoic acid (EPA) on Cloned hERG Potassium Channels Expressed in Human Embryonic Kidney Cells."

**Vfend - voriconazole -
EMA/H/C/000387/II/0143**

Pfizer Europe MA EEIG, Rapporteur: Johann Lodewijk Hillege, Co-Rapporteur: Alexandre Moreau, "Update of sections 4.4 and 4.5 of the SmPC in order to add a new warning on co-administration with glasdegib and add drug-drug interaction information with eszopiclone, glasdegib, tretinoin and tyrosine kinase inhibitors metabolised by CYP3A4; the Package Leaflet is updated accordingly."

**Viramune - nevirapine -
EMA/H/C/000183/II/0147**

Boehringer Ingelheim International GmbH, Rapporteur: Bruno Sepodes, Co-Rapporteur: Christophe Focke, "Update of sections 4.4 and 5.2 of the SmPC in order to remove wording on precautionary measures related to reassuring that tablet remnants in faeces have no impact on the therapeutic response of Viramune, based on additional clinical and pharmacovigilance data that have become available; the Package Leaflet is updated accordingly."

In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet and to bring the PI in line with the latest QRD template version 10.2.”

**Viread - tenofovir disoproxil -
EMA/H/C/000419/II/0204**

Gilead Sciences Ireland UC, Rapporteur: Jean-Michel Race, Co-Rapporteur: Maria Concepcion Prieto Yerro, PRAC Rapporteur: Adrien Inoubli, “Submission of final study report for study GS-US-174-0144, listed as category 3 study in the RMP for Viread. This is a randomized, double-blind evaluation of the antiviral efficacy, safety and tolerability of Tenofovir disoproxil fumarate. This application fulfils the Article 46 commitment to provide the final Week 192 study results for clinical measure 'Study 5' (Study GS_US_174-0144) listed in the PIP. Section 5.1 of the SmPC is being amended accordingly. Additionally, the risk minimisation measures for paediatrics are being removed from the RMP and Annex II of the PI. The Package Leaflet has been updated accordingly. The MAH took the opportunity to implement minor linguistic amendments throughout the PI. In addition, the expression of lactose content in Annex I for the tablets was changed, to refer to lactose base (not as monohydrate), in line with current practice. The RMP version 25.1 has been submitted.”

**Yondelis - trabectedin -
EMA/H/C/000773/II/0063**

Pharma Mar, S.A., Rapporteur: Sinan B. Sarac, “Update of section 4.8 of the SmPC in order to revise the frequency of ADRs based on a pooled safety analysis. the Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to bring the PI in line with the latest QRD template version 10.2 Rev. 1”

**Zavesca - miglustat -
EMA/H/C/000435/II/0072/G**

Janssen-Cilag International N.V., Rapporteur: Kristina Dunder, “Update of sections 4.4, 4.6 and 5.3 of the SmPC in order to improve clarity and to implement linguistic changes following an update of the non-clinical information in the MAH's Company Core Data Sheet. In addition, the MAH took the opportunity to make editorial

changes in the Annexes, and to update the list of local representatives in the Package Leaflet. The application also includes a type IA variation .”

WS2048

Kalydeco-EMA/H/C/002494/WS2048/0101

Symkevi-EMA/H/C/004682/WS2048/0030

Vertex Pharmaceuticals (Ireland) Limited, Lead Rapporteur: Johann Lodewijk Hillege, Lead PRAC Rapporteur: Rhea Fitzgerald, “Update of the Product information to provide the final clinical study report (CSR) Part A of Study VX17-661-116 (A Phase 3, Open-label, Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With Tezacaftor in Combination With Ivacaftor in Subjects With Cystic Fibrosis Aged 6 Years and Older, Homozygous or Heterozygous for the F508del-CFTR Mutation). Consequently, the SmPC sections 4.2, 4.5, 4.8 and 5.1 and the package leaflet are updated accordingly. The RMP is also updated.”

WS2083/G

Nilemdo-EMA/H/C/004958/WS2083/

0013/G

Nustendi-EMA/H/C/004959/WS2083/0014/G

Daiichi Sankyo Europe GmbH, Lead Rapporteur: Johann Lodewijk Hillege, “C.I.13: Submission of the final reports of non-clinical (in vitro) studies evaluating drug interactions of bempedoic acid with substrates of OAT2 (MEA 004.2, MEA 005.1 and MEA 006.2).”

WS2085

Kaftrio-EMA/H/C/005269/WS2085/0014

Kalydeco-EMA/H/C/002494/WS2085/0099

Vertex Pharmaceuticals (Ireland) Limited, Lead Rapporteur: Johann Lodewijk Hillege, Lead PRAC Rapporteur: Martin Huber, “Update of SmPC sections 4.4 and 4.8 following cases of liver failure in the post marketing setting. The PL is updated accordingly. The RMP version 3.1 is submitted for Kaftrio.”

B.6.10. CHMP-PRAC assessed procedures

Adenuric - febuxostat -

EMA/H/C/000777/II/0061

Menarini International Operations Luxembourg S.A., Rapporteur: Andrea Laslop, PRAC Rapporteur: Jan Neuhauser, "C.I.4 - Update of sections 4.4, 4.8 and 5.1 of the SmPC based on the final results from study FAST (Febuxostat versus Allopurinol Streamlined Trial) listed as a category 3 study in the RMP; this is an interventional study investigating the cardiovascular safety of febuxostat in comparison with allopurinol in patients with chronic symptomatic hyperuricaemia. The Package Leaflet is updated accordingly. The RMP version 8.0 has also been submitted. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet and to update the warning relevant to the content of sodium according to the Annex to the European Commission guideline on 'Excipients in the labelling and package leaflet of medicinal products for human use'."

Cometriq - cabozantinib -

EMA/H/C/002640/II/0044, Orphan

Ipsen Pharma, Rapporteur: Paula Boudewina van Hennik, PRAC Rapporteur: Menno van der Elst, "Update of the annex IIE and SmPC section 5.1 to remove the specific obligation (SOB 001) and the reference to the conditional approval based on the final results from the study XL184-401 (EXAMINER), a randomised, double-blind study to evaluate the efficacy and safety of cabozantinib (XL184) at 60 mg/day compared to a 140 mg/day in progressive, metastatic medullary thyroid cancer patients. The package leaflet is updated accordingly. The updated RMP version 5.4 has also been submitted. With this submission, the MAH is proposing to revert from conditional marketing authorisation to full marketing authorisation. Additionally, the MAH took the opportunity to bring the Product Information in line with the latest QRD template version 10.2 Rev 1, to add the sodium content in the Summary of product Characteristics and Package Information Leaflet in line with the guideline on 'Excipients in the labelling and package leaflet of medicinal products for human use' and update details of

local representatives.”

Cosentyx - secukinumab -

EMA/H/C/003729/II/0076

Novartis Europharm Limited, Rapporteur: Outi Mäki-Ikola, PRAC Rapporteur: Eva A. Segovia, “C.I.4 - Update of sections 4.2 and 5.1 of the SmPC in order to introduce a new posology regimen for adult plaque psoriasis patients and psoriatic arthritis patients with concomitant moderate to severe plaque psoriasis based on the final results from study CAIN457A2324 and exposure-response modelling; this is a randomized, double-blind, multicenter study assessing short (16 weeks) and long-term efficacy (up to 1 year), safety, and tolerability of sub-cutaneous secukinumab in subjects of body weight 90 kg or higher with moderate to severe chronic plaque-type psoriasis; the Package Leaflet is updated accordingly. The RMP version 9.0 has also been submitted.”

Defitelio - defibrotide -

EMA/H/C/002393/II/0056, Orphan

Gentium S.r.l., Rapporteur: Kristina Dunder, PRAC Rapporteur: Ulla Wändel Liminga, “Submission of the final report from study 15-007 listed as a specific obligation in the Annex II of the Product Information. This is a phase 3, randomised, adaptive study (15-007) of Defibrotide vs. best supportive care in the prevention of hepatic venoocclusive disease in adult and paediatric patients undergoing hematopoietic stem cell transplant (HSCT). The RMP version 9 has also been submitted. The MAH has also taken the opportunity to align the PI to the latest QRD template 10.2 which replaces the United Kingdom with United Kingdom (Northern Ireland) in the PIL. In addition, the MAH is correcting the following errata during the linguistic review of the PI: correction of the paragraph number for Regulation (EC) No 726.2004 which was cited incorrectly in Annex II of the French PI and formatting updates to Norwegian and Swedish language PIs.”

Gazyvaro - obinutuzumab -

EMA/H/C/002799/II/0044/G, Orphan

Roche Registration GmbH, Rapporteur: Sinan B. Sarac, PRAC Rapporteur: Annika Folin, “C.I.4 Update of sections 4.2, 4.8 and 5.1 of the SmPC

in order to include the administration of obinutuzumab as a short duration infusion (SDI) of approximately 90 minutes in patients with Follicular Lymphoma (FL), based on the end of induction safety and efficacy data from the ongoing Phase IV study MO40597 (GAZELLE); the Package Leaflet is updated accordingly. The RMP version 8.0 has also been submitted. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet.

C.I.11.z

Update of RMP version 8.0 to:

- change the due date for the submission of the final CSR for category 3 study BO21223 (GALLIUM);
- remove important identified risks as per the PRAC Assessment Report for the PSUR covering period 01Nov2018 to 30Oct2019 (Procedure no. EMEA/H/C/PSUSA/00010279/201910);
- correction of clinical cut-off dates and trial exposure data from previously conducted studies"

Kisplyx - lenvatinib -

EMA/H/C/004224/II/0048

Eisai GmbH, Rapporteur: Karin Janssen van Doorn, PRAC Rapporteur: David Olsen, "Submission of the final report from study E7080-G000-211 listed as a category 3 study in the RMP. This is a Multicenter, Randomized, Double-Blind Phase 2 Trial of Lenvatinib (E7080) in subjects with 131 I-Refractory Differentiated Thyroid Cancer to evaluate whether an oral starting dose of 18 mg daily will provide comparable efficacy to a 24 mg starting dose with a better safety profile. The RMP version 12.3 has also been submitted."

Lenvima - lenvatinib -

EMA/H/C/003727/II/0045

Eisai GmbH, Rapporteur: Karin Janssen van Doorn, PRAC Rapporteur: Annika Folin, "Update of the SmPC section 5.1 with additional efficacy and safety data from the Phase 2 multicentre, randomized, double-blind, non-inferiority trial in Subjects with 131I-Refractory Differentiated Thyroid Cancer to evaluate whether an oral starting dose of 18 mg daily will provide comparable efficacy to a 24 mg starting dose with an improved safety profile (study E7080-G000-211). The RMP version 12.3 is updated

accordingly to remove the commitment, MEA 005.5. In addition, the MAH took the opportunity to update the details of local representatives of Bulgaria, Croatia, Estonia, Hungary, Lithuania, Latvia, Malta, Poland, Romania, Slovenia.”

**Natpar - parathyroid hormone -
EMA/H/C/003861/II/0029, Orphan**

Shire Pharmaceuticals Ireland Limited,
Rapporteur: Karin Janssen van Doorn, PRAC
Rapporteur: Rhea Fitzgerald, “Submission of the final results of study SHP634-101: An Open-Label, Randomized, Crossover Study to Assess the Pharmacokinetic and Pharmacodynamic Profiles of Once-Daily and Twice-Daily Dose Regimens of recombinant human Parathyroid Hormone (rhPTH[1-84]) Administered Subcutaneously to Subjects with Hypoparathyroidism. Further clinical evaluation of an alternative dosing regimen is no longer warranted, as outlined in the current specific obligation (study SHP634-403). The conditional marketing authorisation can therefore be converted into a standard marketing authorisation (no longer subject to a specific obligation) valid for 5 years.”

**Rydapt - midostaurin -
EMA/H/C/004095/II/0018/G, Orphan**

Novartis Europharm Limited, Rapporteur: Paula Boudewina van Hennik, PRAC Rapporteur: Marcia Sofia Sanches de Castro Lopes Silva, “A.6 - Administrative change - Change in ATC Code/ATC Vet Code
C.I.4, Update of SmPC in section 4.5 in order to add drug-drug interaction information with P-gp, BCRP, CYP2D6, substrates (digoxin, rosuvastatin, and dextromethorphan), based on final results from study CPKC412A2121, a Phase 1, open-label, drug-drug interaction study, listed as category 3 study in the RMP; section 5.2 of the SmPC and the Package Leaflet is updated accordingly. (MEA 005.3)
C.I.4, Update of SmPC in section 4.5 in order to add drug-drug interaction information with CYP2B6, CYP2C8, CYP3A4 substrates, based on final results from study CPKC412A2122, a Phase 1, open-label, drug-drug interaction study, listed as category 3 study in the RMP; section 5.2 of the SmPC and the Package Leaflet is updated accordingly. (MEA 007.2)

C.I.4 Update of SmPC in section 4.5 in order to add drug-drug interaction information with oral contraceptives, and section 4.6 to update information on pregnancy and contraception based on final results from study CPKC412A2123, a Phase 1, open-label, drug-drug interaction study, listed as category 3 study in the RMP; the Package Leaflet is updated accordingly. (MEA 008.2)

C.I.4 Update of SmPC in section 5.2 in order to update pharmacokinetic information on OATP1B1 transporters based on final results from PBPK modelling study DMPK R2000528 listed as category 3 studies in the RMP (MEA 009);

C.I.4 Update of SmPC in section 4.2 in order to amend posology instructions, section 4.4 to amend an existing warning and section 5.2 to update pharmacokinetic information for patients with severe hepatic impairment, based on final results from study CPKC412A2116 listed as category 3 study in the RMP. This is an open label, multiple dose study to evaluate the PK of midostaurin in subjects with mild, moderate and severe hepatic impairment compared to matched healthy subjects; (MEA010)

The RMP version 6.0 has also been submitted.

In addition, MAH takes this opportunity to introduce minor changes to edit the wording related to the ethanol excipient in the Package Leaflet, according to the Annex to the European Commission guideline on 'Excipients in the labelling and package leaflet of medicinal products for human use' (SANTE-2017-11668), by rounding the volume of alcohol to the next integer number, i.e. from 16.9 to 17 ml."

Ultomiris - ravulizumab -

EMA/H/C/004954/II/0016

Alexion Europe SAS, Rapporteur: Blanca Garcia-Ochoa, PRAC Rapporteur: Kimmo Jaakkola, "to update section 4.4 Special warnings and precautions for use and section 4.8 Undesirable effects of the SmPC, with consequential updates to sections 2 and 4 of the Patient Information Leaflet regarding anaphylactic reaction, hypersensitivity, and infusion-related reactions."

B.6.11. PRAC assessed procedures

PRAC Led

Abilify Maintena - aripiprazole -

EMA/H/C/002755/II/0040

Otsuka Pharmaceutical Netherlands B.V.,
Rapporteur: Bruno Sepodes, PRAC Rapporteur:
Ulla Wändel Liminga, PRAC-CHMP liaison:
Kristina Dunder, "Submission of the final report
from study 15893N listed as a category 3 study
in the RMP, requested by PRAC
(EMA/PRAC/209497/2014, dated from 10 April
2014, EMA/H/C/MEA/002). This is a non-
interventional post-authorisation safety study
(PASS) related to extrapyramidal symptoms:
cohort study with a 2-year follow-up using
European longitudinal electronic medical records
or claims databases."

PRAC Led

Azarga - brinzolamide / timolol -

EMA/H/C/000960/II/0045

Novartis Europharm Limited, Rapporteur:
Kirstine Moll Harboe, PRAC Rapporteur: Anette
Kirstine Stark, PRAC-CHMP liaison: Kirstine Moll
Harboe, "Update to the current Risk
management plan (Version 3.0) to remove
important identified risks (Respiratory disorders,
Cardiovascular disorders, Corneal
decompensation and Metabolic acidosis),
Important potential risk (Long-term use of
preserved eye drops) and Missing information
(Use in paediatric patients)."

PRAC Led

Cresemba - isavuconazole -

EMA/H/C/002734/II/0035/G, Orphan

Basilea Pharmaceutica Deutschland GmbH,
Rapporteur: Johann Lodewijk Hillege, PRAC
Rapporteur: Adam Przybylowski, PRAC-CHMP
liaison: Ewa Balkowiec Iskra, "Grouping of
variations to
- submit the final report from study (WSA-REG-
001) listed as a category 3 study in the RMP.
This is a retrospective case-collection study, in
which cases of invasive mucormycosis treated
with isavuconazole were compared to cases
treated with other systemic antifungals. The
RMP version 8.2 has also been submitted.
- remove Japanese study AK1820-301 as a
category 3 study from the Cresemba RMP."

PRAC Led

**Duavive - estrogens conjugated /
bazedoxifene -**

EMA/H/C/002314/II/0030

Pfizer Europe MA EEIG, Rapporteur: Martina Weise, PRAC Rapporteur: Martin Huber, PRAC-CHMP liaison: Martina Weise, "Submission of the final report from study B2311060 listed as a category 3 study in the RMP. This is a non-interventional, post-authorisation safety study of conjugated estrogens/bazedoxifene (CE/BZA) in the US, with the aim to monitor the safety profile of Duavee (CE/BZA) in comparison to estrogen and progestin combination hormone therapy (E+P HT)."

PRAC Led

Fampyra - fampridine -

EMA/H/C/002097/II/0049

Biogen Netherlands B.V., Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Liana Gross-Martirosyan, PRAC-CHMP liaison: Johann Lodewijk Hillege, "Following a PSUR 10 assessment, update to the section 4.8 of the SmPC to include new symptoms of trigeminal neuralgia. The package leaflet to be updated accordingly. The Marketing authorisation holder (MAH) introduced further editorial updates including bringing the SmPC template to version 10.2 and updating contact details of the local representatives."

PRAC Led

Gilenya - fingolimod -

EMA/H/C/002202/II/0070/G

Novartis Europharm Limited, Rapporteur: Alexandre Moreau, PRAC Rapporteur: Tiphaine Vaillant, PRAC-CHMP liaison: Alexandre Moreau, "Submission of the non-interventional final study report D2403 (long-term, prospective, multinational, parallel-cohort study monitoring safety in patients with multiple sclerosis newly started on fingolimod once daily or treated with another approved disease-modifying therapy). Submission of the non-interventional final study report D2406/D2409 (long-term, prospective, non-interventional, multinational, parallel-cohort study monitoring safety in patients with MS newly initiated on fingolimod once daily or treated with another approved disease-modifying therapy (including cardiac sub-study D2409)). Consequently, the Annex IID is

updated to remove the obligation to perform the PASS D2409. The RMP v 19.0 has been submitted accordingly. In addition, the MAH took the opportunity to implement some minor editorial changes.”

PRAC Led

See B.5.4

Vaxzevria - COVID 19 Vaccine (ChAdOx1 S [recombinant]) - EMEA/H/C/005675/II/0015

AstraZeneca AB, Rapporteur: Sol Ruiz, PRAC Rapporteur: Jean-Michel Dogné, PRAC-CHMP liaison: Christophe Focke, “Submission of an updated RMP version 3.1 in order to update the safety concerns to add 'Thrombosis in combination with thrombocytopenia' as an important identified risk and 'Thrombosis' as an important potential risk, with consequential changes in the RMP. Updates to the Pharmacovigilance Plan have also been implemented. These changes were requested by PRAC in the outcome of Signal Assessment Procedure on Embolic and Thrombotic Events with Vaxzevria EPITT no: 196833. The MAH has taken the opportunity to further update the RMP to reclassify "anaphylaxis" as an important identified risk, already reflected in the product information as an adverse reaction.”

PRAC Led

WS2086

Epclusa-EMEA/H/C/004210/WS2086/0059

Harvoni-EMEA/H/C/003850/WS2086/0097

Sovaldi-EMEA/H/C/002798/WS2086/0071

Gilead Sciences Ireland UC, Lead Rapporteur: Filip Josephson, Lead PRAC Rapporteur: Ana Sofia Diniz Martins, PRAC-CHMP liaison: Bruno Sepodes, “To provide an updated Annex II to revise the study milestone , for the hepatocellular carcinoma (HCC) recurrence post authorisation safety study (PASS) following PRAC recommendation received on 11 June 2020 (EMA procedure no.: EMEA/H/C/PSA/J/0055) for the approval of protocol amendment 1 (version 4.2). In addition, the marketing authorisation holder has taken the opportunity to update the list of local representatives and align the PI to the latest QRD template (v. 10.2).”

B.6.12. CHMP-CAT assessed procedures

Zynteglo - betibeglogene autotemcel - EMA/H/C/003691/II/0025, Orphan, ATMP

bluebird bio (Netherlands) B.V, Rapporteur:
Carla Herberts, CHMP Coordinator: Paula
Boudewina van Hennik

B.6.13. CHMP-PRAC-CAT assessed procedures

B.6.14. PRAC assessed ATMP procedures

B.6.15. Unclassified procedures and worksharing procedures of type I variations

WS2053

Infanrix hexa-

EMA/H/C/000296/WS2053/0300

GlaxoSmithkline Biologicals SA, Lead
Rapporteur: Christophe Focke

WS2072

Abseamed-EMA/H/C/000727/WS2072/ 0094

Binocrit-EMA/H/C/000725/WS2072/ 0093

Epoetin alfa Hexal-EMA/H/C/000726/ WS2072/0093

Sandoz GmbH, Lead Rapporteur: Alexandre
Moreau

WS2075

Riarify-EMA/H/C/004836/WS2075/0014

Trimbow-EMA/H/C/004257/WS2075/ 0019

Trydonis-EMA/H/C/004702/WS2075/ 0014

Chiesi Farmaceutici S.p.A., Lead Rapporteur:
Janet Koenig

WS2077

Kinzalkomb-EMA/H/C/000415/WS2077/ 0116

MicardisPlus-EMA/H/C/000413/ WS2077/0119

PritorPlus-EMA/H/C/000414/WS2077/ 0126

Boehringer Ingelheim International GmbH, Lead Rapporteur: Armando Genazzani, "To update sections 2 and 4.4 of the SmPC and sections 2 and 6 of the PL to align the wording for the excipients lactose, sodium and sorbitol to the "Annex to the European Commission guideline on 'Excipients in the labelling and package leaflet of medicinal products for human use' (SANTE-2017-11668)".

In addition, the marketing authorisation holder has taken the opportunity to:

- implement minor editorial changes;
- update the list of local representatives and align the PI for Kinzalkomb and PritorPlus to the QRD template v.10.1;
- update the list of local representatives and align the PI for MicardiPlus to the latest QRD template v. 10.2;
- "

WS2079/G

Fluenz Tetra-EMA/H/C/002617/

WS2079/0108/G

Pandemic influenza vaccine H5N1

AstraZeneca-EMA/H/C/003963/

WS2079/0041/G

AstraZeneca AB, Lead Rapporteur: Christophe Focke

B.7. DOCUMENTS TABLED IN MMD AFTER THE CHMP PLENARY

B.7.1. Yearly Line listing for Type I and II variations

B.7.2. Monthly Line listing for Type I variations

B.7.3. Opinion on Marketing Authorisation transfer (MMD only)

B.7.4. Notifications in accordance with Article 61(3) of Council Directive 2001/83/EC (MMD only)

B.7.5. Request for supplementary information relating to Notification of Type I variation (MMD only)

B.7.6. Notifications of Type I Variations (MMD only)

C. Annex C - Post-Authorisation Measures (PAMs), (Line listing of Post authorisation measures with a description of the PAM. Procedures starting in that given month with assessment timetabled)

D. Annex D - Post-Authorisation Measures (PAMs), (Details on PAMs including description and conclusion, for adoption by CHMP in that given month, or finalised ones with PRAC recommendation and no adoption by CHMP needed)

E. Annex E - EMA CERTIFICATION OF PLASMA MASTER FILES

Information related to plasma master files cannot be released at the present time as these contain commercially confidential information.

E.1. PMF Certification Dossiers:

E.1.1. Annual Update

E.1.2. Variations:

E.1.3. Initial PMF Certification:

E.2. Timetables – starting & ongoing procedures: For information

F. ANNEX F - Decision of the Granting of a Fee Reduction/Fee Waiver

G. ANNEX G

G.1. Final Scientific Advice (Reports and Scientific Advice letters):

G.2. PRIME

Some information related to PRIME cannot be released at the present time as these contain commercially confidential information.

G.2.1. List of procedures concluding at 17-20 May 2021 CHMP plenary:

<i>Neurology</i>	
CTI-1601	
Treatment of Friedreich's Ataxia(SME)	The CHMP granted eligibility to PRIME (early entry) and adopted the critical summary report.
<i>Oncology</i>	
Treatment of BCG unresponsive non-muscle invasive bladder cancer	The CAT and the CHMP denied eligibility to PRIME and adopted the critical summary report.

G.2.2. List of procedures starting in May 2021 for June 2021 CHMP adoption of outcomes

H. ANNEX H - Product Shared Mailboxes – e-mail address